

INVENTOR SEARCH

=> fil hcapl; d que nos 147; fil uspatf; d que nos 190; fil ifipat; d que nos 1157
 FILE 'HCAPLUS' ENTERED AT 12:36:48 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Sep 2008 VOL 149 ISS 10
 FILE LAST UPDATED: 1 Sep 2008 (20080901/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.
 'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

L3	1	SEA FILE=REGISTRY ABB=ON	1404-26-8
L4		STR	
L7	1933	SEA FILE=REGISTRY SSS FUL L4	
L11	1845	SEA FILE=HCAPLUS ABB=ON	WHITE E7/AU
L12	1355	SEA FILE=HCAPLUS ABB=ON	REYNOLDS R7/AU
L13	50	SEA FILE=HCAPLUS ABB=ON	SULING W7/AU
L14	1	SEA FILE=HCAPLUS ABB=ON	US2005-519731/APPS
L15	985	SEA FILE=HCAPLUS ABB=ON	L7
L16	2755	SEA FILE=HCAPLUS ABB=ON	L3
L17	3190	SEA FILE=HCAPLUS ABB=ON	GRAM-POSITIVE BACTERIA/CT
L18	433	SEA FILE=HCAPLUS ABB=ON	ACTINOBACTERIA+NT/CT
L19	4108	SEA FILE=HCAPLUS ABB=ON	ACTINOMYCETES/CT
L20	3910	SEA FILE=HCAPLUS ABB=ON	ACTINOMYCETALES+NT/CT
L21	678	SEA FILE=HCAPLUS ABB=ON	ACTINOPLANETES+NT/CT
L22	17	SEA FILE=HCAPLUS ABB=ON	ACTINOSYNMEMATACEAE+NT/CT
L23	5	SEA FILE=HCAPLUS ABB=ON	ARSENICOCOCCUS+NT/CT
L24	898	SEA FILE=HCAPLUS ABB=ON	CORYNEFORM BACTERIA+NT/CT
L25	5800	SEA FILE=HCAPLUS ABB=ON	MICROCOCCACEAE+NT/CT
L26	1189	SEA FILE=HCAPLUS ABB=ON	MICROMONOSPORACEAE+NT/CT
L27	175	SEA FILE=HCAPLUS ABB=ON	MICROTHRUX/CW
L28	7309	SEA FILE=HCAPLUS ABB=ON	NOCARDIOFORM ACTINOMYCETES+NT/CT
L29	1455	SEA FILE=HCAPLUS ABB=ON	PSEUDONOCARDIACEAE+NT/CT
L30	324	SEA FILE=HCAPLUS ABB=ON	STREPTOSPORANGIACEAE+NT/CT
L31	112336	SEA FILE=HCAPLUS ABB=ON	BACILLALES+NT/CT
L32	14	SEA FILE=HCAPLUS ABB=ON	ACIDAMINOCOCCACEAE/CT
L33	4	SEA FILE=HCAPLUS ABB=ON	AEROCOCCACEAE/CT
L34	23025	SEA FILE=HCAPLUS ABB=ON	CLOSTRIDIACEAE+NT/CT
L35	134	SEA FILE=HCAPLUS ABB=ON	CLOSTRIDIALES+NT/CT

L36 16 SEA FILE=HCAPLUS ABB=ON EUBACTERIACEAE/CT
 L37 48 SEA FILE=HCAPLUS ABB=ON HALANAEROBIACEAE+NT/CT
 L38 1062 SEA FILE=HCAPLUS ABB=ON LACHNOSPIRACEAE+NT/CT
 L39 22915 SEA FILE=HCAPLUS ABB=ON LACTOBACILLACEAE+NT/CT
 L40 6759 SEA FILE=HCAPLUS ABB=ON MYCOPLASMATAACEAE+NT/CT
 L41 1 SEA FILE=HCAPLUS ABB=ON PARASPOROBACTERIUM/CW
 L42 7 SEA FILE=HCAPLUS ABB=ON PEPTOSTREPTOCOCCACEAE/CT
 L43 41508 SEA FILE=HCAPLUS ABB=ON STREPTOCOCCACEAE+NT/CT
 L44 36336 SEA FILE=HCAPLUS ABB=ON MYCOBACTER?/OBI
 L45 15 SEA FILE=HCAPLUS ABB=ON "LOW G+C GRAM-POSITIVE BACTERIA"/CT
 L47 5 SEA FILE=HCAPLUS ABB=ON (L11 OR L12 OR L13 OR L14) AND L15
 AND (L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR
 L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR
 L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR
 L42 OR L43 OR L44 OR L45)

FILE 'USPATFULL' ENTERED AT 12:36:48 ON 02 SEP 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 26 Aug 2008 (20080826/PD)
 FILE LAST UPDATED: 2 Sep 2008 (20080902/ED)
 HIGHEST GRANTED PATENT NUMBER: US7421742
 HIGHEST APPLICATION PUBLICATION NUMBER: US20080209606
 CA INDEXING IS CURRENT THROUGH 2 Sep 2008 (20080902/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 26 Aug 2008 (20080826/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2008
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2008

USPATFULL now includes complete International Patent Classification (IPC)
 reclassification data for the second quarter of 2008.

L4 STR
 L7 1933 SEA FILE=REGISTRY SSS FUL L4
 L55 767 SEA FILE=REGISTRY ABB=ON L7 AND (IFIPAT/LC OR USPATFULL/LC OR
 SCISEARCH/LC)
 L56 206 SEA FILE=USPATFULL ABB=ON WHITE E?/AU
 L57 400 SEA FILE=USPATFULL ABB=ON REYNOLDS R?/AU
 L58 3 SEA FILE=USPATFULL ABB=ON SULING W?/AU
 L86 588 SEA FILE=USPATFULL ABB=ON L55
 L90 1 SEA FILE=USPATFULL ABB=ON (L56 OR L57 OR L58) AND L86

FILE 'IFIPAT' ENTERED AT 12:36:48 ON 02 SEP 2008
 COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE COVERS 1950 TO PATENT PUBLICATION DATE: 28 Aug 2008 (20080828/PD)
 FILE LAST UPDATED: 29 Aug 2008 (20080829/ED)
 HIGHEST GRANTED PATENT NUMBER: US7418737
 HIGHEST APPLICATION PUBLICATION NUMBER: US20080209606
 UNITERM INDEXING IS AVAILABLE IN THE IFIUIDB FILE
 UNITERM INDEXING LAST UPDATED: 15 Aug 2008 (20080815/UP)
 INDEXING CURRENT THROUGH PAT PUB DATE: 29 Jul 2008 (20080729/PD)

IFIPAT reloaded on 7/27/08. Enter HELP RLOAD for details.

```

L4          STR
L7          1933 SEA FILE=REGISTRY SSS FUL L4
L55         767 SEA FILE=REGISTRY ABB=ON L7 AND (IFIPAT/LC OR USPATFULL/LC OR
           SCISEARCH/LC)
L124        311 SEA FILE=IFIPAT ABB=ON WHITE E?/AU
L125        551 SEA FILE=IFIPAT ABB=ON REYNOLDS R?/AU
L126        3 SEA FILE=IFIPAT ABB=ON SULING W?/AU
L156        8 SEA FILE=IFIPAT ABB=ON L55
L157        0 SEA FILE=IFIPAT ABB=ON (L124 OR L125 OR L126) AND L156

```

```
=> dup rem 147,190
```

FILE 'HCAPLUS' ENTERED AT 12:36:49 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:36:49 ON 02 SEP 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
 PROCESSING COMPLETED FOR L47
 PROCESSING COMPLETED FOR L90
 L191 6 DUP REM L47 L90 (0 DUPLICATES REMOVED)
 ANSWERS '1-5' FROM FILE HCAPLUS
 ANSWER '6' FROM FILE USPATFULL

```
=> d ibib abs hitind hitstr 1-6
```

L191 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:41604 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:105238
 TITLE: Antibacterial inhibitors of Ftsz protein
 INVENTOR(S): White, Lucile E.; Reynolds, Robert C.;
 Suling, William
 PATENT ASSIGNEE(S): Southern Research Institute, USA
 SOURCE: PCT Int. Appl., 117 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005472	A2	20040115	WO 2003-US20984	20030702
WO 2004005472	A3	20040923		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2491680	A1	20040115	CA 2003-2491680	20030702
AU 2003281340	A1	20040123	AU 2003-281340	20030702
EP 1538907	A2	20050615	EP 2003-756780	20030702
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
JP	2005535662	T	20051124
JP	2004-519843		20030702
US	20060241103	A1	20061026
US	2005-519731		20050705 <--
PRIORITY APPLN. INFO.:	US 2002-393680P	P	20020702
	WO 2003-US20984	W	20030702

OTHER SOURCE(S): MARPAT 140:105238

AB The invention relates to inhibitors of FtsZ polymerization and uses thereof.

IC ICM C12N

CC 1-5 (Pharmacology)

IT *Actinobacillus pleuropneumoniae**Actinomyces**Actinomyces israelii*

Antibacterial agents

*Bacillus anthracis**Bacillus subtilis*

Bactericide resistance

*Bacteroides fragilis**Brucella**Brucella melitensis**Burkholderia cepacia**Burkholderia pseudomallei**Campylobacter*

Chelating agents

*Chlamydia trachomatis**Chlamydomydia psittaci**Clostridium**Clostridium botulinum**Clostridium perfringens**Clostridium tetani**Coxiella burnetii**Ehrlichia**Ehrlichia ruminantium**Enterobacter hirae*

Enterobacteriaceae

*Escherichia**Escherichia coli**Francisella tularensis**Fusobacterium nucleatum*

Gram-negative bacteria

Gram-positive bacteria

*Granulicatella adiacens**Haemophilus**Haemophilus ducreyi**Haemophilus influenzae**Legionella**Legionella pneumophila**Listeria ivanovii**Listeria monocytogenes**Mannheimia haemolytica**Mycobacterium africanum**Mycobacterium avium**Mycobacterium bovis**Mycobacterium intracellulare**Mycobacterium kansasii**Mycobacterium marinum**Mycobacterium tuberculosis**Mycobacterium ulcerans**Neisseria gonorrhoeae**Neisseria meningitidis**Nocardia*

Nocardia asteroides
Pasteurella
Pasteurella multocida
Peptococcus
Peptostreptococcus
Prevotella
Propionibacterium acnes
Pseudomonas
Pseudomonas aeruginosa
Salmonella
Salmonella typhi
Shigella
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus agalactiae
Streptococcus pyogenes
 Surfactants
 Tuberculostatics
Vibrio cholerae
Yersinia
Yersinia enterocolitica
Yersinia pestis
 (inhibitors of ftsz and uses thereof)

IT *Mycobacterium*

(typhimurium; inhibitors of ftsz and uses thereof)

IT 5255-67-4 6497-83-2 6497-84-3 6497-85-4

6502-02-9 6502-03-0 6502-04-1

6506-38-3 6506-96-1 6603-68-5

15223-96-8 15223-97-9 15223-98-0

15223-99-1 16335-92-5 16335-94-7

16335-96-9 16335-98-1 16336-03-1

16336-05-3 16336-06-4 19254-73-0

19270-28-1 19270-29-2 19270-36-1

19270-37-2 19270-38-3 19270-40-7

19270-41-8 19270-42-9 19270-44-1

19270-46-3 21271-60-3 21271-61-4

21271-65-8 21271-66-9 21271-70-5

21271-76-1 21271-80-7 21271-82-9

21271-88-5 21271-89-6 21271-91-0

21271-93-2 21271-98-7 21395-43-7

21395-44-8 21395-46-0 28642-73-1

28642-74-2 28642-75-3 28642-77-5

28642-81-1 28642-83-3 28642-87-7

28642-88-8 28642-95-7 28648-99-9

28649-01-6 28649-04-9 28649-06-1

28649-08-3 30768-44-6 30768-45-7

30768-46-8 30768-50-4 30826-44-9

31541-76-1 37437-06-2 39359-68-1

39359-73-8 39359-79-4 40497-61-8

40497-62-9 40525-21-1 53995-21-4

63708-78-1 80434-77-1 82585-57-7

82585-58-8 82585-59-9 82585-60-2

82585-64-6 82585-65-7 82585-67-9

82585-68-0 82585-70-4 82585-71-5

82585-73-7 82585-77-1 82585-81-7

82585-83-9 82585-84-0 82585-86-2

82585-87-3 82585-88-4 82585-90-8

82585-91-9 82585-94-2 82585-95-3

83269-04-9 83269-09-4 83269-10-7

83269-13-0 83269-14-1 83269-15-2

83269-17-4 83269-20-9 83269-23-1 83269-25-4

86970-41-4 86970-43-6 86970-47-0
 86970-49-2 86970-50-5 86970-51-6
 86970-52-7 86970-53-8 86970-54-9
 86970-55-0 86970-58-3 86970-59-4
 86970-60-7 86970-61-8 86970-62-9
 86970-63-0 87077-29-2 91599-70-1
 97235-86-4 109182-31-2 109182-32-3
 109182-33-4 109182-34-5 109182-36-7
 109182-37-8 109182-39-9 109182-43-6
 109182-47-0 109182-48-1 109182-53-8
 109182-54-9 109182-55-0 109182-68-5
 109182-69-6 109182-70-9 109182-71-0
 109182-73-2 109217-57-4 116403-17-9
 116659-54-2 121572-30-3 121572-32-5
 121572-34-7 121572-37-0 121572-46-1
 121572-53-0 121596-28-9 122293-96-3
 122293-97-4 122293-99-6 122332-17-6
 122332-18-7 123753-52-6 123753-54-8
 123753-55-9 123753-56-0 123753-57-1
 123753-59-3 123753-60-6 123753-62-8
 123753-63-9 123753-64-0 123753-66-2
 123753-68-4 123753-70-8 123753-72-0
 123775-16-6 130145-52-7 130145-54-9
 130145-56-1 130145-61-8 130145-65-2
 135696-25-2 135696-27-4 135696-30-9
 135696-31-0 135696-32-1 135696-33-2
 135696-35-4 135696-36-5 135696-37-6
 135696-39-8 135696-40-1 135696-42-3
 135696-46-7 135696-47-8 135696-48-9
 135696-50-3 135696-51-4 135696-52-5
 135696-54-7 139016-58-3 139016-59-4
 139016-61-8 139068-49-8 139068-54-5
 139068-55-6 139068-56-7 143858-90-6
 144694-16-6 144694-17-7 144694-18-8
 144694-20-2 144694-26-8 144694-29-1
 496816-53-6, SRI 3072 496816-54-7 500309-46-6
 500312-15-2 500363-91-7 500540-83-0
 501017-34-1 502485-83-8 646072-86-8
 646072-87-9 646072-88-0 646072-89-1
 646072-90-4 646072-91-5 646072-92-6
 646072-93-7 646072-94-8 646072-95-9
 646072-96-0 646072-97-1 646072-98-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (biological study); USES (Uses)
 (inhibitors of ftsz and uses thereof)

IT 646072-99-3 646073-00-9 646073-01-0
 646073-02-1 646073-03-2 646073-04-3
 646073-05-4 646073-06-5 646073-07-6
 646073-08-7 646073-09-8 646073-10-1
 646073-11-2 646073-12-3 646073-13-4
 646073-14-5 646073-15-6 646073-16-7
 646073-17-8 646073-18-9 646073-19-0
 646073-20-3 646073-21-4 646073-22-5
 646073-23-6 646073-24-7 646073-25-8
 646073-26-9 646073-27-0 646073-28-1
 646073-29-2 646073-30-5 646073-31-6
 646073-32-7 646073-33-8 646073-34-9
 646073-35-0 646073-36-1 646073-37-2
 646073-38-3 646073-39-4 646073-40-7

646073-41-8 646073-42-9 646073-43-0
 646073-44-1 646073-45-2 646073-46-3 646073-47-4
 646073-48-5 646073-49-6 646073-50-9 646073-51-0
 646073-52-1 646073-53-2 646073-54-3
 646073-55-4 646073-56-5 646073-57-6
 646073-58-7 646073-59-8 646073-60-1
 646073-61-2 646073-62-3 646073-63-4
 646073-64-5 646073-65-6 646073-66-7
 646073-67-8 646073-68-9 646073-69-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitors of ftsz and uses thereof)

IT 1494-26-8, Polymyxin B 103220-14-0, Defensin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors of ftsz and uses thereof)


IT 6497-83-2 6497-84-3 6497-85-4
 6502-02-9 6502-03-0 6502-04-1
 6506-38-3 6506-86-1 6603-68-5
 15223-96-8 15223-97-9 15223-98-0
 15223-99-1 16335-92-5 16335-94-7
 16335-96-9 16335-98-1 16336-03-1
 16336-05-3 16336-06-4 19254-73-0
 19270-28-1 19270-29-2 19270-36-1
 19270-37-2 19270-38-3 19270-40-7
 19270-41-8 19270-42-9 19270-44-1
 19270-46-3 21271-60-3 21271-61-4
 21271-65-8 21271-66-9 21271-70-5
 21271-76-1 21271-80-7 21271-82-9
 21271-88-5 21271-89-6 21271-91-0
 21271-93-2 21271-98-7 21395-43-7
 21395-44-8 21395-46-0 28642-73-1
 28642-74-2 28642-75-3 28642-77-5
 28642-81-1 28642-83-3 28642-87-7
 28642-88-8 28642-95-7 28648-99-9
 28649-01-6 28649-04-9 28649-06-1
 28649-08-3 30768-44-6 30768-45-7
 30768-46-8 30768-50-4 30826-44-9
 31541-76-1 37437-06-2 39359-68-1
 39359-73-8 39359-79-4 40497-61-8
 40497-62-9 40525-21-1 53995-21-4
 63708-78-1 80434-77-1 82585-57-7
 82585-58-8 82585-59-9 82585-60-2
 82585-64-6 82585-65-7 82585-67-9
 82585-68-0 82585-70-4 82585-71-5
 82585-73-7 82585-77-1 82585-81-7
 82585-83-9 82585-84-0 82585-86-2
 82585-87-3 82585-88-4 82585-90-8
 82585-91-9 82585-94-2 82585-95-3
 83269-04-9 83269-09-4 83269-10-7
 83269-13-0 83269-14-1 83269-15-2
 83269-17-4 83269-20-9 83269-23-2
 86970-41-4 86970-43-6 86970-47-0
 86970-49-2 86970-50-5 86970-51-6
 86970-52-7 86970-53-8 86970-54-9
 86970-55-0 86970-58-3 86970-59-4
 86970-60-7 86970-61-8 86970-62-9
 86970-63-0 87607-29-2 91899-70-1
 97235-86-4 109182-31-2 109182-32-3
 109182-33-4 109182-34-5 109182-36-7
 109182-37-8 109182-38-9 109182-43-6

109182-47-0 109182-48-1 109182-53-8
 109182-54-9 109182-55-0 109182-68-5
 109182-69-6 109182-70-9 109182-71-0
 109182-72-2 109217-57-4 116659-54-2
 121572-30-3 121572-32-5 121572-34-7
 121572-37-0 121572-46-1 121572-53-0
 121596-28-9 122293-96-3 122293-97-4
 122293-99-6 122332-17-6 122332-18-7
 123753-52-6 123753-54-8 123753-55-9
 123753-56-0 123753-57-1 123753-59-3
 123753-60-6 123753-62-8 123753-64-0
 123753-66-2 123753-68-4 123753-70-8
 123753-72-0 123775-16-6 130145-52-7
 130145-54-9 130145-56-1 130145-61-8
 130145-65-2 135696-25-2 135696-27-4
 135696-30-9 135696-31-0 135696-32-1
 135696-33-2 135696-35-4 135696-36-5
 135696-37-6 135696-39-8 135696-40-1
 135696-42-3 135696-46-7 135696-47-8
 135696-48-9 135696-50-3 135696-51-4
 135696-52-5 135696-54-7 139016-58-3
 139016-59-4 139016-61-8 139068-49-8
 139068-54-5 139068-55-6 139068-56-7
 143858-90-6 144694-16-6 144694-17-7
 144694-20-2 144694-26-8 144694-29-1
 496816-53-6, SRI 3072 496816-54-7 500309-46-6
 500312-15-2 500363-91-7 500540-83-0
 501017-34-1 502485-83-8 646072-86-8
 646072-87-9 646072-88-0 646072-89-1
 646072-90-4 646072-91-5 646072-92-6
 646072-93-7 646072-94-8 646072-95-9
 646072-96-0 646072-97-1 646072-98-2
 646072-99-3 646073-00-9 646073-01-0
 646073-02-1 646073-03-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibitors of ftsz and uses thereof)

RN 6497-83-2 HCAPLUS


CN Carbamic acid, [4-amino-5-nitro-6-[(2-oxopropyl)amino]-2-pyridinyl]-,
 ethyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 6497-84-3 HCAPLUS

CN Carbamic acid, (8-amino-2-methylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester
 (9CI) (CA INDEX NAME)




RN 6497-85-4 HCAPLUS

CN Carbamic acid, [6-chloro-4-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 6502-02-9 HCAPLUS

CN Carbamic acid, (4,6-diamino-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6502-03-0 HCAPLUS

CN Carbamic acid, [4-[(diphenylmethyl)amino]-1,6-dihydro-5-nitro-6-oxo-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 6502-04-1 HCAPLUS

CN Carbamic acid, (4-amino-6-chloro-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6506-38-3 HCAPLUS

CN Carbamic acid, (8-amino-3,4-dihydro-2-methylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6506-86-1 HCAPLUS

CN Carbamic acid, (6-amino-4-chloro-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6603-68-5 HCAPLUS

CN Carbamic acid, [7-[(diphenylmethyl)amino]-2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 15223-96-8 HCAPLUS

CN Carbamic acid, [3-amino-4-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 15223-97-9 HCAPLUS

CN Carbamic acid, [4-[[3-(methylphenylamino)-2-oxopropyl]amino]-3-nitro-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 15223-98-0 HCAPLUS

CN Carbamic acid, [2,3-dihydro-7-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-2-oxo-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 15223-99-1 HCAPLUS

CN Carbamic acid, [4-amino-6-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 16335-92-5 HCAPLUS

CN Carbamic acid, (4-amino-3-nitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 16335-94-7 HCAPLUS

CN Carbamic acid, (2-methylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 16335-96-9 HCAPLUS

CN Carbamic acid, (2,3-diphenylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 16335-98-1 HCAPLUS

CN Carbamic acid, [8-[(diphenylmethyl)amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 16336-03-1 HCAPLUS

CN Carbamic acid, (5-amino-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 16336-05-3 HCAPLUS

CN Carbamic acid, (8-ethoxy-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 16336-06-4 HCAPLUS

CN Carbamic acid, (5-ethoxy-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 19254-73-0 HCAPLUS


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 19270-28-1 HCAPLUS

CN Carbamic acid, [6-amino-4-[[4-(diethylamino)-1-methylbutyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-29-2 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 19270-36-1 HCAPLUS


CN Carbamic acid, [6-amino-4-[[4-(diethylamino)-1-methylbutyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 19270-37-2 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-38-3 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[(4-chlorophenyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-40-7 HCAPLUS

CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-41-8 HCAPLUS

CN Carbamic acid, [3-(4-chlorophenyl)-8-[[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-42-9 HCAPLUS

CN Carbamic acid, [8-[(4-chlorophenyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-44-1 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 19270-46-3 HCAPLUS


CN Carbamic acid, [3-(4-chlorophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 21271-60-3 HCAPLUS

CN Carbamic acid, [6-amino-4-[(4-chlorophenyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-61-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-65-8 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-66-9 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-70-5 HCAPLUS

CN Carbamic acid, [8-[[[4-(diethylamino)-1-methylbutyl]amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-76-1 HCAPLUS

CN Carbamic acid, [2,3-bis(4-chlorophenyl)-8-[[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-80-7 HCAPLUS

CN Carbamic acid, [8-[(4-chlorophenyl)amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-82-9 HCAPLUS

CN Carbamic acid, [8-[(4-chlorophenyl)amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-88-5 HCAPLUS

CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-89-6 HCAPLUS

CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 21271-91-0 HCAPLUS


CN Carbamic acid, [8-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 21271-93-2 HCAPLUS


CN Carbamic acid, [8-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-3-

methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-98-7 HCAPLUS

CN Carbamic acid, [8-[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21395-43-7 HCAPLUS

CN Carbamic acid, [3-(4-chlorophenyl)-8-[(4-chlorophenyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21395-44-8 HCAPLUS

CN Carbamic acid, [2,3-bis(4-chlorophenyl)-8-[(4-chlorophenyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21395-46-0 HCAPLUS

CN Carbamic acid, [8-[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-73-1 HCAPLUS

CN Carbamic acid, [8-[(diphenylmethyl)amino]-3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-74-2 HCAPLUS

CN Carbamic acid, [8-[(diphenylmethyl)amino]-1,2-dihydro-2-oxopyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-75-3 HCAPLUS

CN Carbamic acid, [8-amino-3-(4-chlorophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-77-5 HCAPLUS

CN Carbamic acid, [8-amino-3-(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 28642-81-1 HCAPLUS


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 28642-83-3 HCAPLUS


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-phenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 28642-87-7 HCAPLUS


CN Carbamic acid, [3-(3,4-dichlorophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 28642-88-8 HCAPLUS


CN Carbamic acid, [3-(4-bromophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 28642-95-7 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-[4-(trifluoromethyl)phenyl]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




RN 28648-99-9 HCAPLUS

CN Carbamic acid, [8-chloro-3-(4-chlorophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-01-6 HCAPLUS

CN Carbamic acid, [8-chloro-2,3-bis(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-04-9 HCAPLUS


CN Carbamic acid, [2-(4-chlorophenyl)-8-[(diphenylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-06-1 HCAPLUS
 CN Carbamic acid, [8-[(diphenylmethyl)amino]-2-(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-08-3 HCAPLUS
 CN Carbamic acid, [8-[(diphenylmethyl)amino]-2,3-bis(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 30768-44-6 HCAPLUS
 CN Benzoic acid, 4-[[3-[[2-amino-6-[(ethoxycarbonyl)amino]-3-nitro-4-pyridinyl]amino]-2-(hydroxyimino)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 30768-45-7 HCAPLUS
 CN Benzoic acid, 4-[[3-[[2-amino-6-[(ethoxycarbonyl)amino]-3-nitro-4-pyridinyl]amino]-2-oxopropyl]amino]-, ethyl ester (CA INDEX NAME)




RN 30768-46-8 HCAPLUS

CN Benzoic acid, 4-[[[5-amino-7-[(ethoxycarbonyl)amino]-1,2-dihydropyrido[3,4-b]pyrazin-3-yl)methyl]amino]-, ethyl ester (CA INDEX NAME)




RN 30768-50-4 HCAPLUS

CN Benzoic acid, 4-[[[3-[[[5-amino-7-[(ethoxycarbonyl)amino]-1,2-dihydropyrido[3,4-b]pyrazin-3-yl)methyl]methylamino]-, methyl ester (CA INDEX NAME)



RN 30826-44-9 HCAPLUS


CN Benzoic acid, 4-[[[3-[[[2-amino-6-[(ethoxycarbonyl)amino]-3-nitro-4-pyridinyl]amino]-2-oxopropyl]methylamino]-, methyl ester (CA INDEX NAME)



RN 31541-76-1 HCAPLUS


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride

(9CI) (CA INDEX NAME)




RN 37437-06-2 HCAPLUS

CN Carbamic acid, (5,6-diamino-4-chloro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 38359-68-1 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[(diphenylmethyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 38359-73-8 HCAPLUS

CN Carbamic acid, (7-chloro-1H-1,2,3-triazolo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 38359-79-4 HCAPLUS

CN Carbamic acid, [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40497-61-8 HCAPLUS

CN Carbamic acid, [6-amino-4-(dimethylamino)-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40497-62-9 HCAPLUS

CN Carbamic acid, [6-amino-4-[[bis(4-chlorophenyl)methyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40525-21-1 HCAPLUS

CN Carbamic acid, (7-amino-1H-imidazo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 53995-21-4 HCAPLUS

CN Carbamic acid, (4-chloro-3-nitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 63708-78-1 HCAPLUS

CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 80434-77-1 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-[(methylphenylamino)methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-57-7 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-3-(methylphenylamino)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-58-8 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-3-[(4-methoxyphenyl)methylamino]propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-59-9 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-60-2 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-methylphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-64-6 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(4-chlorophenyl)-2-(hydroxyimino)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-65-7 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(2,4-dichlorophenyl)-2-(hydroxyimino)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-67-9 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(3-methoxyphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-68-0 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-methoxyphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-70-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-nitrophenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-71-5 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-73-7 HCAPLUS

CN Carbamic acid, [6-amino-4-[[3-(methylphenylamino)-2-oxopropyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-77-1 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(4-fluorophenyl)-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-81-7 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(4-methoxyphenyl)-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-83-9 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[[2-(4-nitrophenyl)-2-oxoethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-84-0 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-86-2 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-87-3 HCAPLUS

CN Carbamic acid, [6-amino-4-[[3-[(4-chlorophenyl)methylamino]-2-hydroxypropyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-88-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-hydroxy-3-[(4-methoxyphenyl)methylamino]propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-90-8 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-[[4-methoxyphenyl)methylamino]methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-91-9 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-94-2 HCAPLUS

CN Carbamic acid, [5-amino-3-(3,4-dimethylphenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-95-3 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-fluorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-04-9 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[(2-oxo-4-phenylbutyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-09-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[(1-methyl-2-oxo-2-phenylethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-10-7 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-13-0 HCAPLUS

CN Carbamic acid, [5-amino-3-[(methylphenylamino)methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-14-1 HCAPLUS

CN Carbamic acid, [5-amino-3-[(methylphenylamino)carbonyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-15-2 HCAPLUS

CN Carbamic acid, (5-amino-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-17-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-4-phenylbutyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-20-9 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-23-2 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-2-phenylethyl)methylamino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-41-4 HCAPLUS

CN Carbamic acid, [6-amino-4-hydroxy-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-43-6 HCAPLUS

CN Carbamic acid, [dithiobis(6-amino-5-nitro-4,2-pyridinediyl)]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 86970-47-0 HCAPLUS

RN Carbamic acid, (5-amino-2,3-diphenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-,
ethyl ester (9CI) (CA INDEX NAME)




RN 86970-49-2 HCAPLUS

CN Carbamic acid, (5-amino-2-oxo-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-,
ethyl ester (9CI) (CA INDEX NAME)




RN 86970-50-5 HCAPLUS

CN Carbamic acid, [5-amino-3-(3-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-51-6 HCAPLUS

CN Carbamic acid, [5-amino-3-(3,5-dimethoxyphenyl)-2-methyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-52-7 HCAPLUS

CN Carbamic acid, [5-amino-3-(3,4,5-trimethoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-53-8 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-chlorophenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-54-9 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-nitrophenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-55-0 HCAPLUS

CN Carbamic acid, (5-amino-3-phenyl-2H-pyrido[4,3-b]-1,4-thiazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 86970-58-3 HCAPLUS


CN Carbamic acid, (5-amino-2,2-dimethyl-3-phenyl-2H-pyrido[4,3-b]-1,4-thiazin-7-yl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 86970-59-4 HCAPLUS

CN Carbamic acid, [5-amino-3-(3-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-thiazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-60-7 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-thiazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-61-8 HCAPLUS

CN Carbamic acid, [5-amino-3-(2-naphthalenyl)-2H-pyrido[4,3-b]-1,4-thiazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-62-9 HCAPLUS

CN Carbamic acid, [5-[(dimethylamino)methylene]amino]-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-63-0 HCAPLUS

CN Carbamic acid, [5-[(bromoacetyl)amino]-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 87607-29-2 HCAPLUS

CN Carbamic acid, (5-amino-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 91599-70-1 HCAPLUS

CN Carbamic acid, (5-amino-2-methyl-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 97235-86-4 HCAPLUS

CN Carbamic acid, (3-methylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 109182-31-2 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-(phenylamino)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-32-3 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[(phenylmethyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-33-4 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[(2-phenylethyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-34-5 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[(4-phenylbutyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 109182-36-7 HCAPLUS


CN Carbamic acid, [5,6-diamino-4-[(phenylmethyl)amino]-2-pyridinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 109182-37-8 HCAPLUS


CN Carbamic acid, [5,6-diamino-4-[(2-phenylethyl)amino]-2-pyridinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 109182-38-9 HCAPLUS


CN Carbamic acid, [5,6-diamino-4-[(4-phenylbutyl)amino]-2-pyridinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 109182-43-6 HCAPLUS

CN Carbamic acid, (7-chloro-2-phenyl-1H-imidazo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-47-0 HCAPLUS

CN Carbamic acid, (4-chloro-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-48-1 HCAPLUS

CN Carbamic acid, [4-chloro-1-(diphenylmethyl)-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-53-8 HCAPLUS

CN Carbamic acid, [4-[(diphenylmethyl)amino]-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-54-9 HCAPLUS

CN Carbamic acid, [4-[(diphenylmethyl)amino]-2-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-55-0 HCAPLUS

CN Carbamic acid, [2-(1,3-benzodioxol-5-yl)-4-[(diphenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-68-5 HCAPLUS

CN Carbamic acid, [7-[(phenylmethyl)amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-69-6 HCAPLUS

CN Carbamic acid, (4-amino-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-70-9 HCAPLUS

CN Carbamic acid, [7-[(2-phenylethyl)amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-71-0 HCAPLUS

CN Carbamic acid, [7-[(4-phenylbutyl)amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-73-2 HCAPLUS

CN Carbamic acid, [4-amino-2-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109217-57-4 HCAPLUS

CN Carbamic acid, [4-amino-2-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 116659-54-2 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-(2-propenylamino)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 121572-30-3 HCAPLUS

CN Carbamic acid, [5-(acetylamino)-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 121572-32-5 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, 1-methylpropyl ester (9CI) (CA INDEX NAME)




RN 121572-34-7 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 121572-37-0 HCAPLUS

CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 121572-46-1 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 121572-53-0 HCAPLUS

CN Carbamic acid, (4-chloro-3,5-dinitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 121596-28-9 HCAPLUS


CN Carbamic acid, (8-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 122293-96-3 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 122293-97-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

(NAME)


Absolute stereochemistry.



RN 122293-99-6 HCAPLUS

CN Carbamic acid, [6-amino-4-[(1S)-1-methyl-2-oxo-2-phenylethyl]amino]-5-nitro-2-pyridinyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 122332-17-6 HCAPLUS

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 122332-18-7 HCAPLUS


CN Carbamic acid, N-[(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 123753-52-6 HCAPLUS

CN Carbamic acid, (4,5,6-triamino-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-54-8 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[(phenylmethylene)hydrazino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-55-9 HCAPLUS

CN Carbamic acid, [4-amino-1-[(phenylmethylene)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 123753-56-0 HCAPLUS


CN Carbamic acid, [7-[(phenylmethylene)hydrazino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 123753-57-1 HCAPLUS


CN Carbamic acid, [7-[(phenylmethylene)hydrazino]-2-[(phenylmethyl)thio]-1H-

imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-59-3 HCAPLUS

CN Carbamic acid, [4-amino-2,3-dihydro-1-[(phenylmethylene)amino]-2-thioxo-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-60-6 HCAPLUS

CN Carbamic acid, [2,3-dihydro-7-[(phenylmethylene)hydrazino]-2-thioxo-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-62-8 HCAPLUS

CN Carbamic acid, (1,4-diamino-2,3-dihydro-2-thioxo-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-64-0 HCAPLUS

CN Carbamic acid, [4-amino-1-[(phenylmethylene)amino]-2-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-66-2 HCAPLUS

CN Carbamic acid, [4-amino-1-[(4-methoxyphenyl)methylene]amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-68-4 HCAPLUS

CN Carbamic acid, [1,4-diamino-2-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-70-8 HCAPLUS

CN Carbamic acid, [1,4-diamino-2-[(1,3-benzodioxol-5-ylmethyl)thio]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-72-0 HCAPLUS

CN Carbamic acid, [6-amino-4-[methyl(phenylmethylene)hydrazino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123775-16-6 HCAPLUS

CN Carbamic acid, [4-amino-1-[(1,3-benzodioxol-5-ylmethylene)amino]-2,3-dihydro-2-thioxo-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-52-7 HCAPLUS

CN Carbamic acid, [5-[(diphenylmethyl)amino]-1,2-dihydro-2-oxo-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-54-9 HCAPLUS

CN Carbamic acid, [6-[(diphenylmethyl)amino]-4-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-56-1 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-2-oxo-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-61-8 HCAPLUS

CN Carbamic acid, (3,8-diamino-2-phenylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-65-2 HCAPLUS

CN Carbamic acid, [6-amino-4-(2-formylhydrazino)-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-25-2 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-1-methyl-2-(3-nitrophenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-27-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(2,3,4-trimethoxyphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-30-9 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-tricyclo[3.3.1.3⁰.3⁰.1.3⁰.7⁰]dec-1-ylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-31-0 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(1,3-benzodioxol-5-yl)-1-methyl-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-32-1 HCAPLUS

CN Carbamic acid, [4-[(1-benzoylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-33-2 HCAPLUS

CN Carbamic acid, [4-[(1-acetylpropyl)amino]-6-amino-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-35-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[(1-methyl-2-oxohexyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-36-5 HCAPLUS

CN Carbamic acid, [6-amino-4-[(1-methyl-2-oxo-3-phenylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-37-6 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(1,3-benzodioxol-5-yl)-2-hydroxy-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-39-8 HCAPLUS

CN Carbamic acid, [6-amino-4-[[1-(1-hydroxyethyl)pentyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-40-1 HCAPLUS

CN Carbamic acid, [6-amino-4-[(2-hydroxy-1-methyl-3-phenoxypropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-42-3 HCAPLUS

CN Carbamic acid, [6-amino-4-[(2-hydroxy-1-methyl-3-phenylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-46-7 HCAPLUS

CN Carbamic acid, [5-amino-3-(1,3-benzodioxol-5-yl)-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-47-8 HCAPLUS

CN Carbamic acid, (5-amino-2-ethyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-48-9 HCAPLUS

CN Carbamic acid, (5-amino-2-butyl-1,2-dihydro-3-methylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-50-3 HCAPLUS

CN Carbamic acid, (5-amino-3-butyl-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-51-4 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-2-methyl-3-(phenylmethyl)pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-52-5 HCAPLUS

CN Carbamic acid, [5-amino-3-(3-aminophenyl)-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-54-7 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-(4-methoxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 139016-58-3 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-methoxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 139016-59-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 139016-61-8 HCAPLUS


CN Carbamic acid, [5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 139068-49-8 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139068-54-5 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[(1R)-2-(4-hydroxyphenyl)-1-methyl-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139068-55-6 HCAPLUS

CN Carbamic acid, [(2S)-5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 139068-56-7 HCAPLUS

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143858-90-6 HCAPLUS


CN Carbamic acid, [5,6-diamino-4-[[1(1S,2R)-2-hydroxy-1-methyl-2-phenylethylamino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 144694-16-6 HCAPLUS

CN Carbamic acid, [6-amino-4-[(3-hydroxy-3-phenylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 144694-17-7 HCAPLUS

CN Carbamic acid, [6-amino-5-nitro-4-[(3-oxo-3-phenylpropyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 144694-20-2 HCAPLUS


CN Carbamic acid, (6-amino-2,3-dihydro-4-phenyl-1H-pyrido[3,4-b][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 144694-26-8 HCAPLUS

CN Carbamic acid, [4-amino-6-[(1S)-1-methyl-2-oxo-2-phenylethylamino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 144694-29-1 HCAPLUS


CN Carbamic acid, [(3S)-8-amino-3,4-dihydro-3-methyl-2-phenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496816-53-6 HCAPLUS


CN Carbamic acid, [8-[[4-(diethylamino)-1,3-dimethylbutylamino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 496816-54-7 HCAPLUS


CN Carbamic acid, [(2S)-5-amino-3-[4-[[(butylamino)carbonyl]oxy]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500309-46-6 HCAPLUS

CN Carbamic acid, (4-chloro-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 500312-15-2 HCAPLUS

CN Carbamic acid, (4-chloro-1H-1,2,3-triazolo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 500363-91-7 HCAPLUS

CN Carbamic acid, [3-nitro-4-(2-propenylamino)-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 500540-83-0 HCAPLUS

CN Carbamic acid, [6-[[2-(4-chlorophenyl)-2-oxoethyl]amino]-4-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 501017-34-1 HCAPLUS

CN Carbamic acid, (7-amino[1,2,3]thiadiazolo[5,4-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 502485-83-8 HCAPLUS

CN Carbamic acid, (4-hydrazino-3-nitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 646072-86-8 HCAPLUS

CN Carbamic acid, [4-[methyl(phenylmethyl)amino]-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646072-87-9 HCAPLUS


CN Carbamic acid, [2-(4-chlorophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646072-88-0 HCAPLUS

CN Carbamic acid, [(2S)-5-amino-1,2-dihydro-2-methyl-3-[4-(phenylmethoxy)phenyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 646072-89-1 HCAPLUS

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-2-methyl-3-[4-(phenylmethoxy)phenyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 646072-90-4 HCAPLUS


CN Carbamic acid, [4-(diethylamino)-2-(4-methylphenyl)-1H-imidazo[4,5-

c[pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-91-5 HCAPLUS

CN Carbamic acid, [2-(4-nitrophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-92-6 HCAPLUS

CN Carbamic acid, [2-(4-phenoxyphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-93-7 HCAPLUS

CN Carbamic acid, [2-(4-methoxyphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-94-8 HCAPLUS

CN Carbamic acid, [2-(4-ethylphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-95-9 HCAPLUS

CN Carbamic acid, [2-(1-naphthalenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-96-0 HCAPLUS

CN Carbamic acid, [2-(2-phenylethyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-97-1 HCAPLUS

CN Carbamic acid, [2-(2-fluorophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-98-2 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




RN 646072-99-3 HCAPLUS

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-00-9 HCAPLUS

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-(2,4,5-trimethoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-01-0 HCAPLUS

CN Carbamic acid, [2-(2,5-dimethoxyphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)




RN 646073-02-1 HCAPLUS

CN Carbamic acid, [2-phenyl-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-03-2 HCAPLUS

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 646073-04-3 646073-05-4 646073-06-5
 646073-07-6 646073-08-7 646073-09-8
 646073-10-1 646073-11-2 646073-12-3
 646073-13-4 646073-14-5 646073-15-6
 646073-16-7 646073-17-8 646073-18-9
 646073-19-0 646073-20-3 646073-21-4
 646073-22-5 646073-23-6 646073-24-7
 646073-25-8 646073-26-9 646073-27-0
 646073-28-1 646073-29-2 646073-30-5
 646073-31-6 646073-32-7 646073-33-8
 646073-34-9 646073-35-0 646073-36-1
 646073-37-2 646073-38-3 646073-39-4
 646073-40-7 646073-41-8 646073-42-9
 646073-43-0 646073-44-1 646073-46-3
 646073-49-6 646073-50-9 646073-52-1
 646073-53-2 646073-54-3 646073-55-4
 646073-56-5 646073-57-6 646073-58-7
 646073-59-8 646073-60-1 646073-61-2
 646073-62-3 646073-63-4 646073-64-5
 646073-65-6 646073-66-7 646073-67-8
 646073-68-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors of ftsz and uses thereof)

RN 646073-04-3 HCAPLUS


CN Carbamic acid, [2-(4-chlorophenyl)-8-[[4-(diethylamino)-1-methylbutyl]aminopyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 646073-05-4 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-1-methyl-3-phenoxypropyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-06-5 HCAPLUS

CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, diphenyl ester (9CI) (CA INDEX NAME)



RN 646073-07-6 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2-(4-nitrophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 646073-08-7 HCAPLUS

CN Carbamic acid, [7-(phenylamino)-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl


ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 646073-09-8 HCAPLUS

CN Carbamic acid, [2-methyl-4-[(2-phenylethyl)(phenylmethyl)amino]oxazolo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-10-1 HCAPLUS

CN Carbamic acid, (2,3-dihydro-2-phenyl-1H-1,2,3-triazolo[4,5-c]pyridine-4,6-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 646073-11-2 HCAPLUS

CN Carbamic acid, [5-amino-3-[[4-methoxyphenyl)methylamino]methyl]-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-12-3 HCAPLUS


CN Carbamic acid, [6-amino-4-[(aminoiminomethyl)thio]-5-nitro-2-pyridinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 646073-13-4 HCAPLUS


CN Carbamic acid, (11-amino-6,6a-dihydro-5H-naphtho[2,1-b]pyrido[3,4-e][1,4]oxazin-9-yl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 646073-14-5 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-2-methyl-3-[3-[[4-(2-triazenyl)benzoyl]aminophenyl]pyrido[3,4-b]pyrazin-7-yl]]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-15-6 HCAPLUS

CN Carbamic acid, [7-[[bis(4-chlorophenyl)methyl]amino]-1H-imidazo[4,5-b]pyridin-5-yl]]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-16-7 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-[4-(trifluoromethyl)phenyl]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 646073-17-8 HCAPLUS

CN Carbamic acid, (7-amino-3-phenyl-3H-imidazo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-18-9 HCAPLUS

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-(3,4,5-trimethoxyphenyl)oxazolo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-19-0 HCAPLUS

CN Carbamic acid, [4-amino-6-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-20-3 HCAPLUS

CN Carbamic acid, [6-[[2-(4-chlorophenyl)-2-(hydroxyimino)ethyl]amino]-4-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-21-4 HCAPLUS

CN Carbamic acid, [5-amino-3-(2-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-22-5 HCAPLUS


CN Carbamic acid, [6-amino-4-[[1-methyl-2-oxo-3-(phenylmethoxy)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-23-6 HCAPLUS


CN Carbamic acid, [2-(4-chlorophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]o

xazolo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-24-7 HCAPLUS

CN Carbamic acid, [2-(4-methylphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-25-8 HCAPLUS

CN Carbamic acid, [6-[(ethoxycarbonyl)amino]-4-[[2-(hydroxyimino)-1-methyl-2-phenylethyl]amino]-3,5-dinitro-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-26-9 HCAPLUS

CN Carbamic acid, [2-(1,3-benzodioxol-5-yl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-27-0 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[(1R)-2-(hydroxyimino)-1-methyl-2-phenylethyl]amino]-3,5-dinitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 646073-28-1 HCAPLUS


CN Carbamic acid, [(2R)-5-amino-3-[4-[[[(butylamino)carbonyl]oxy]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 646073-29-2 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[[[1-(1-hydroxyethyl)pentyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-30-5 HCAPLUS

CN Carbamic acid, [6-[(diphenylmethyl)amino]-5-nitro-2,4-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 646073-31-6 HCAPLUS


CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-1-methylhexyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-32-7 HCAPLUS


CN Carbamic acid, [6-amino-4-[(1S)-2-(hydroxyimino)-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 646073-33-8 HCAPLUS


CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, bis(phenylmethyl) ester
(9CI) (CA INDEX NAME)



RN 646073-34-9 HCAPLUS


CN Carbamic acid, [5-amino-3-[4-(2-triazenyl)phenyl]-2H-pyrido[4,3-b]-1,4-

oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-35-0 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-36-1 HCAPLUS

CN Carbamic acid, [5-amino-3-(3,4-dimethoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-37-2 HCAPLUS

CN Carbamic acid, [6-amino-4-[[[(3,4-dimethylphenyl)methyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-38-3 HCAPLUS

CN Carbamic acid, [7-[(diphenylmethyl)amino]-1H-1,2,3-triazolo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-39-4 HCAPLUS

CN Carbamic acid, [6-amino-4-[[3-(dimethylamino)-2-hydroxypropyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-40-7 HCAPLUS


CN Carbamic acid, (5,6-diamino-2-pyridinyl)-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 646073-41-8 HCAPLUS

CN Carbamic acid, [3-(4-chlorophenyl)-8-(diphenylamino)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-42-9 HCAPLUS

CN Carbamic acid, [2-[[[(2,4-dichlorophenyl)methylene]amino]-8-[(diphenylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-43-0 HCAPLUS

CN Carbamic acid, [3-amino-8-[(diphenylmethyl)amino]-2-nitropyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-44-1 HCAPLUS

CN Carbamic acid, [4-[(3-amino-2-hydroxypropyl)amino]-3-nitro-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 646073-46-3 HCAPLUS


CN Carbamic acid, 1H-imidazo[4,5-c]pyridine-4,6-diylbis-, diethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 646073-49-6 HCAPLUS

CN Carbamic acid, [2-(3-methylphenyl)-4-[[3-phenyl-1-(phenylmethyl)propyl]amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-50-9 HCAPLUS


CN Carbamic acid, [6-amino-4-[(2-[1,1'-biphenyl]-4-yl-2-oxoethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 646073-52-1 HCAPLUS


CN Carbamic acid, [6-amino-4-[[2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-53-2 HCAPLUS

CN Carbamic acid, [4-[[2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 646073-54-3 HCAPLUS


CN Carbamic acid, [4-[[2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 646073-55-4 HCAPLUS

CN Carbamic acid, [7-(2-triazenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-56-5 HCAPLUS

CN Carbamic acid, (1,2-dihydropyrido[3,4-e]-1,2,4-triazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 646073-57-6 HCAPLUS

CN Carbamic acid, [6-amino-4-(methylamino)-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-58-7 HCAPLUS

CN Carbamic acid, [6-amino-4-[[2-[(aminocarbonyl)hydrazono]propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-59-8 HCAPLUS

CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-1-methyl-3-phenoxypropyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 646073-60-1 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 646073-61-2 HCAPLUS

CN Carbamic acid, (9-amino-4,5-dihydro-2-phenyl-3H-pyrido[2,3-b][1,4]diazepin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-62-3 HCAPLUS


CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-63-4 HCAPLUS


CN Carbamic acid, [(2S)-5-amino-3-butyl-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 646073-64-5 HCAPLUS

CN Carbamic acid, (5-amino-2,3-diphenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-65-6 HCAPLUS


CN Carbamic acid, (5-ethoxy-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-66-7 HCAPLUS


CN Carbamic acid, (5-amino-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, methyl

ester (9CI) (CA INDEX NAME)



RN 646073-67-8 HCAPLUS


CN Carbamic acid, [5-amino-1,2-dihydro-3-[[4-methoxyphenyl)methylamino]methyl]pyrido[3,4-b]pyrazin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-68-9 HCAPLUS

CN Carbamic acid, [(2S)-5-amino-3-[4-[(butylamino)carbonyloxy]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 1404-26-8, Polymyxin B

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors of ftsz and uses thereof)

RN 1404-26-8 HCAPLUS

CN Polymyxin B (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


L191 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:403825 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:157094

TITLE: A new 2-carbamoyl pteridine that inhibits
mycobacterial FtsZAUTHOR(S): Reynolds, R. C.; Srivastava, S.; Ross, L.
J.; Saling, W. J.; White, E. L.CORPORATE SOURCE: Drug Discovery Division, Southern Research Institute,
Birmingham, AL, 35205, USA


SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
14(12), 3161-3164
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:157094
GI



- AB The preparation of a new 2-carbamoyl pteridine (I), its activity data against FtsZ from *M. tuberculosis* (Mtb), and in vitro antibacterial data against Mtb strain H37Ra are presented.
- CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 10
- ST carbamoyl pteridine deriv prepn inhibitor mycobacterium tuberculosis FtsZ
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ftsZ; preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)
- IT Antibacterial agents
Mycobacterium tuberculosis
Tuberculosis
(preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)
- IT 727729-07-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)
- IT 56-05-3, 2-Amino-4,6-dichloropyrimidine 79-37-8, Oxalyl chloride 134-81-6, Benzil 140-80-7, 2-Amino-5-diethylaminopentane
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)
- IT 496769-48-3P 727729-08-0P 727729-09-1P
727729-10-4P 727729-11-5P 727729-12-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)
- IT 727729-07-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)

RN 727729-07-9 HCAPLUS

CN Carbamic acid, [4-[[4-(diethylamino)-1-methylbutyl]amino]-6,7-diphenyl-2-pteridiny]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 496769-48-3P 727729-06-8P 727729-09-1E


727729-10-4P 727729-11-5P 727729-12-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-carbamoyl pteridine derivative as inhibitor of mycobacterium tuberculosis FtsZ)


RN 496769-48-3 HCAPLUS

CN Carbamic acid, (4,6-dichloro-2-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 727729-08-0 HCAPLUS

CN Carbamic acid, (4-azido-6-chloro-2-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 727729-09-1 HCAPLUS


CN Carbamic acid, (4-amino-6-chloro-2-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 727729-10-4 HCAPLUS
 CN Carbamic acid, (4-amino-6-chloro-5-nitro-2-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 727729-11-5 HCAPLUS
 CN Carbamic acid, [4-amino-6-[[4-(diethylamino)-1-methylbutyl]amino]-5-nitro-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 727729-12-6 HCAPLUS
 CN Carbamic acid, [4,5-diamino-6-[[4-(diethylamino)-1-methylbutyl]amino]-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L191 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2002:555109 HCAPLUS Full-text
 DOCUMENT NUMBER: 138:150120
 TITLE: 2-Alkoxy-carbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ
 AUTHOR(S): White, E. Lucile; Suling, William J.
 ; Ross, Larry J.; Seitz, Laine E.; Reynolds, Robert C.
 CORPORATE SOURCE: Drug Discovery Division, Southern Research Institute, Birmingham, AL, 35205, USA
 SOURCE: Journal of Antimicrobial Chemotherapy (2002), 50(1), 111-114
 CODEN: JACHDX; ISSN: 0305-7453

PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

- AB Compds. originally designed as putative tubulin inhibitors were tested as antitubercular agents for inhibition of the *Mycobacterium tuberculosis* analog of tubulin, FtsZ. Initial screening of 2002-alkoxycarbonylpyridines found several that inhibited *M. tuberculosis* growth. Two compds., SRI-3072 and SRI-7614, inhibited FtsZ polymerization and were equipotent against susceptible and single-drug-resistant strains of *M. tuberculosis*. In addition, SRI-3072 reduced the growth of *M. tuberculosis* in mouse bone marrow macrophages. Our results suggest that these types of compound might be developed into antitubercular drugs effective against the current multidrug-resistant strains of *M. tuberculosis*.
- CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
Section cross-reference(s): 1
- ST alkoxycarbonylaminopyridine antibacterial *Mycobacterium* FtsZ
- IT Antibacterial agents
Mycobacterium tuberculosis
(efficacy of 2-alkoxycarbonylaminopyridines as inhibitors of *Mycobacterium tuberculosis* FtsZ)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (ftsZ; efficacy of 2-alkoxycarbonylaminopyridines as inhibitors of *Mycobacterium tuberculosis* FtsZ)
- IT 496816-53-6, SRI 3072
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of 2-alkoxycarbonylaminopyridines as inhibitors of *Mycobacterium tuberculosis* FtsZ)
- IT 82585-90-8, SRI 5713 144694-20-2, SRI-7614
496816-54-7, SRI 20158
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of 2-alkoxycarbonylaminopyridines as inhibitors of *Mycobacterium tuberculosis* FtsZ)
- IT 496816-53-6, SRI 3072
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of 2-alkoxycarbonylaminopyridines as inhibitors of *Mycobacterium tuberculosis* FtsZ)
- RN 496816-53-6 HCAPLUS
- CN Carbamic acid, [8-[[4-(diethylamino)-1,3-dimethylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




- IT 82585-90-8, SRI 5713 144694-20-2, SRI-7614
496816-54-7, SRI 20158
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of 2-alkoxycarbonylaminopyridines as inhibitors of

Mycobacterium tuberculosis FtsZ)


RN 82585-90-8 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-[[[4-methoxyphenyl)methylamino]methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 144694-20-2 HCAPLUS


CN Carbamic acid, (6-amino-2,3-dihydro-4-phenyl-1H-pyrido[3,4-b][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 496816-54-7 HCAPLUS

CN Carbamic acid, [(2S)-5-amino-3-[4-[[[butylamino)carbonyl]oxy]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L191 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2001:302582 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 135:43367

TITLE: Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro


AUTHOR(S): Suling, William J.; Maddry, Joseph A.

CORPORATE SOURCE: Drug Discovery Division, Southern Research Institute, Birmingham, AL, 35205, USA

SOURCE: Journal of Antimicrobial Chemotherapy (2001), 47(4), 451-454


PUBLISHER: CODEN: JACHDX; ISSN: 0305-7453
 DOCUMENT TYPE: Oxford University Press
 LANGUAGE: Journal
 English

- AB Twenty-five 1-deaza-7,8-dihydropteridine derivs. were screened for antimycobacterial activity against *Mycobacterium tuberculosis* strain H37Ra and three *Mycobacterium avium* clin. isolates (serovar 1, 4 or 6). Antibacterial activity was determined with a colorimetric microdilution broth assay. Seventeen of the compds. inhibited growth in the range >1.28 to ≤ 12.8 mg/L against one or more of the test strains. The presence of an alkoxycarbonyl group on the amino nitrogen at position 2 was not required for activity. Activity was dependent upon the type and location of group substitutions on the 6-Ph ring and, in some cases, the presence of a 7-alkyl group.
- CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
- ST antibacterial deazadihydropteridine deriv *Mycobacterium*
- IT *Mycobacterium avium*
Mycobacterium tuberculosis
 (antibacterial activity of 1-deaza-7,8-dihydropteridine derivs. against *Mycobacterium*)
- IT Structure-activity relationship
 (bactericidal; antibacterial activity of 1-deaza-7,8-dihydropteridine derivs. against *Mycobacterium*)
- IT 82585-91-9 82585-93-1 82585-95-3
 82585-96-4 82585-97-5 82585-98-6
 82585-99-7 82586-01-4 82586-02-5
 82586-03-6 83269-10-7 83269-12-9
 121572-32-5 121572-34-7 121572-46-1
 121572-50-7 122332-17-6 122332-18-7
 135696-47-8 135696-52-5 135696-54-7
 139016-61-8 139068-55-6 345270-06-6
 345270-07-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (antibacterial activity of 1-deaza-7,8-dihydropteridine derivs. against *Mycobacterium*)
- IT 82585-91-9 82585-93-1 82585-95-3
 82585-96-4 82585-97-5 82585-98-6
 82585-99-7 82586-01-4 82586-02-5
 82586-03-6 83269-10-7 83269-12-9
 121572-32-5 121572-34-7 121572-46-1
 122332-17-6 122332-18-7 135696-47-8
 135696-52-5 135696-54-7 139016-61-8
 139068-55-6 345270-06-6 345270-07-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (antibacterial activity of 1-deaza-7,8-dihydropteridine derivs. against *Mycobacterium*)
- RN 82585-91-9 HCAPLUS
- CN Carbamic acid, (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-93-1 HCAPLUS

CN Carbamic acid, [5-amino-3-(2,4-dimethylphenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-95-3 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-fluorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-96-4 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-chlorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-97-5 HCAPLUS

CN Carbamic acid, [5-amino-3-(2,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-98-6 HCAPLUS

CN Carbamic acid, [5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-99-7 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-(3-methoxyphenyl)pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82586-01-4 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-(3,4,5-trimethoxyphenyl)pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82586-02-5 HCAPLUS

CN Carbamic acid, [5-amino-3-(4-aminophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82586-03-6 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-[4-(trifluoromethyl)phenyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-10-7 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-12-9 HCAPLUS

CN Carbamic acid, (5-amino-1,2-dihydro-1-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 121572-32-5 HCAPLUS


CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, 1-methylpropyl ester (9CI) (CA INDEX NAME)



RN 121572-34-7 HCAPLUS


CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-

7-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 121572-46-1 HCAPLUS


CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 122332-17-6 HCAPLUS

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 122332-18-7 HCAPLUS

CN Carbamic acid, N-[(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 135696-47-8 HCAPLUS


CN Carbamic acid, (5-amino-2-ethyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-

yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-52-5 HCAPLUS

CN Carbamic acid, [5-amino-3-(3-aminophenyl)-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-54-7 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-(4-methoxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 139016-61-8 HCAPLUS


CN Carbamic acid, [5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 139068-55-6 HCAPLUS

CN Carbamic acid, [(2S)-5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 345270-06-6 HCAPLUS


CN Carbamic acid, [(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, 2-chloroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 345270-07-7 HCAPLUS

CN Carbamic acid, [5-amino-1,2-dihydro-3-(2,3,4-trimethylphenyl)pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L191 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2000:847727 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 134:174446

TITLE: Crystallization of the Mycobacterium

tuberculosis cell-division protein FtsZ

Leung, Adelaine K. W.; White, E. Lucie;

Ross, Larry J.; Borhani, David W.

CORPORATE SOURCE: Drug Discovery Division, Southern Research Institute, Birmingham, AL, 35205, USA

SOURCE: Acta Crystallographica, Section D: Biological

Crystallography (2000), D56(12), 1634-1637


CODEN: ABCRE6; ISSN: 0907-4449

PUBLISHER: Munksgaard International Publishers Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

- AB M. tuberculosis FtsZ (MtbFtsZ), an essential protein in bacterial cell division, was crystallized in the presence of a new inhibitor of MtbFtsZ polymerization and GTPase activity, Et (6-amino-2,3-dihydro-4-phenyl-1H-pyrido[4,3-b][1,4]diazepin-8-yl)carbamate (SRI-7614). Crystals of the MtbFtsZ-SRI-7614 complex (form I, 30% polyethylene glycol 4000, 0.1 M sodium citrate pH 5.6, 0.2 M NH₄OAc, 293 K) belong to space group P6₁ or P6₅, with unit-cell parameters a = 88.78, c = 178.02 Å, and diffract to 2.3 Å resolution A 2nd crystal form, of the GDP complex, grows in the presence or absence of Mg²⁺ from PEG 4000 at 277 K or from (NH₄)₂SO₄ at 293 K, resp. (form II, space group P6₂22 or P6₄22, with unit-cell parameters a = 135.02, c = 328.97 Å or a = 129.30, c = 327.97 Å, resp.). Complete data sets to .apprx.7 Å resolution were collected from both. Exceptional form II crystals diffract to ≤4.5 Å resolution Determination of the MtbFtsZ structure may advance the design of improved inhibitors of FtsZ polymerization
- CC 6-3 (General Biochemistry)
- ST Mycobacterium protein FtsZ crystal structure
- IT Crystal structure
Mycobacterium tuberculosis
(crystallization of the Mycobacterium tuberculosis cell-division protein FtsZ)
- IT Proteins, specific or class
RL: PRP (Properties)
(gene ftsZ; crystallization of the Mycobacterium tuberculosis cell-division protein FtsZ)
- IT 144694-20-2, SRI 7614
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(crystallization of the Mycobacterium tuberculosis cell-division protein FtsZ)
- IT 144694-20-2, SRI 7614
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(crystallization of the Mycobacterium tuberculosis cell-division protein FtsZ)
- RN 144694-20-2 HCAPLUS
- CN Carbamic acid, (6-amino-2,3-dihydro-4-phenyl-1H-pyrido[3,4-b][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L191 ANSWER 6 OF 6 USPATTFULL on STN

ACCESSION NUMBER: 2006:282160 USPATTFULL Full-text

TITLE: Inhibitors of ftsz and uses thereof

INVENTOR(S): White, E Lucile, Birmingham, AL, UNITED STATES

STATES

Keynolds, Robert C., Birmingham, AL, UNITED STATES

STATES

Seiling, William J., Pelham, AL, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 20060241103 A1 20061026
 APPLICATION INFO.: US 2003-519731 A1 20030702 (10)
 WO 2003-US20984 20030702
 20050705 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393680P	20020702 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915, US	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2970	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to inhibitors of FtsZ polymerization and uses thereof.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 6497-83-2 6497-84-3 6497-85-4


6502-02-9 6502-03-0 6502-04-1
 6506-38-3 6506-86-1 6603-68-5
 15223-96-8 15223-97-9 15223-98-0
 15223-99-1 16335-92-5 16335-94-7
 16335-96-9 16335-98-1 16336-02-1
 16336-05-3 16336-06-4 19254-72-0
 19270-28-1 19270-29-2 19270-36-1
 19270-37-2 19270-38-3 19270-40-7
 19270-41-8 19270-42-9 19270-44-1
 19270-46-3 21271-60-3 21271-61-4
 21271-65-8 21271-66-9 21271-76-5
 21271-76-1 21271-80-7 21271-82-9
 21271-88-5 21271-89-6 21271-91-0
 21271-93-2 21271-98-7 21395-43-7
 21395-44-8 21395-46-0 28642-73-1
 28642-74-2 28642-75-3 28642-77-5
 28642-81-1 28642-83-3 28642-87-7
 28642-88-8 28642-95-7 28648-99-9
 28649-01-6 28649-04-9 28649-06-1
 28649-08-3 30768-44-6 30768-45-7
 30768-46-8 30768-50-4 30826-44-9
 31541-76-1 37437-06-2 38359-68-1
 38359-73-8 38359-79-4 40497-61-8
 40497-62-9 40525-21-1 53995-21-4
 63708-78-1 80434-77-1 92585-57-7
 92585-58-8 92585-59-9 92585-60-2
 92585-64-6 92585-65-7 92585-67-9
 92585-68-0 92585-70-4 92585-71-5
 92585-73-7 92585-77-1 92585-81-7
 92585-83-9 92585-84-0 92585-86-2
 92585-87-3 92585-88-4 92585-90-8
 92585-91-9 92585-94-2 92585-95-3
 93269-04-9 93269-09-4 93269-10-7
 93269-13-0 93269-14-1 93269-15-2
 93269-17-4 93269-20-5 93269-23-2
 96970-41-4 96970-43-6 96970-47-0
 96970-49-2 96970-50-5 96970-51-6
 96970-52-7 96970-53-8 96970-54-9

86970-55-0 86970-58-3 86970-59-4
 86970-60-7 86970-61-8 86970-62-9
 86970-63-0 87607-29-2 91599-76-1
 97235-86-1 109182-31-2 109182-32-3
 109182-33-4 109182-34-5 109182-36-7
 109182-37-8 109182-38-9 109182-43-6
 109182-47-0 109182-48-1 109182-53-8
 109182-54-9 109182-55-0 109182-66-5
 109182-69-6 109182-70-9 109182-71-0
 109182-73-2 109182-75-4 116659-54-2
 121572-30-3 121572-32-5 121572-34-7
 121572-37-0 121572-46-1 121572-53-0
 121596-28-9 122293-96-3 122293-97-4
 122293-99-6 122332-17-6 122332-18-7
 123753-52-6 123753-54-8 123753-55-9
 123753-56-0 123753-57-1 123753-59-3
 123753-60-6 123753-62-8 123753-64-0
 123753-66-2 123753-68-4 123753-70-8
 123753-72-0 123775-16-6 130145-52-7
 130145-54-9 130145-56-1 130145-61-8
 130145-65-2 135696-25-2 135696-27-4
 135696-30-9 135696-31-0 135696-32-1
 135696-33-2 135696-35-4 135696-36-5
 135696-37-6 135696-39-8 135696-40-1
 135696-42-3 135696-46-7 135696-47-8
 135696-48-9 135696-50-3 135696-51-4
 135696-52-5 135696-54-7 139016-58-3
 139016-59-4 139016-61-8 139068-49-8
 139068-54-5 139068-55-6 139068-56-7
 143858-90-6 144694-16-6 144694-17-7
 144694-20-2 144694-26-8 144694-29-1
 496816-53-6, **SRI 3072** 496816-54-7 500309-46-6
 500312-15-2 500363-91-7 500546-83-0
 501017-34-1 502485-83-8 646072-86-8
 646072-87-9 646072-88-0 646072-89-1
 646072-90-4 646072-91-5 646072-92-6
 646072-93-7 646072-94-8 646072-95-9
 646072-96-0 646072-97-1 646072-98-2
 646072-99-3 646073-00-9 646073-01-0
 646073-02-1

(inhibitors of ftsz and uses thereof)

RN 6497-83-2 USPATFULL


CN Carbamic acid, [4-amino-5-nitro-6-[(2-oxopropyl)amino]-2-pyridinyl]-, ethyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 6497-84-3 USPATFULL

CN Carbamic acid, (8-amino-2-methylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6497-85-4 USPATFULL

CN Carbamic acid, [6-chloro-4-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 6502-02-9 USPATFULL

CN Carbamic acid, (4,6-diamino-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6502-03-0 USPATFULL

CN Carbamic acid, [4-[(diphenylmethyl)amino]-1,6-dihydro-5-nitro-6-oxo-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 6502-04-1 USPATFULL

CN Carbamic acid, (4-amino-6-chloro-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6506-38-3 USPATFULL

CN Carbamic acid, (8-amino-3,4-dihydro-2-methylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6506-86-1 USPATFULL

CN Carbamic acid, (6-amino-4-chloro-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 6603-68-5 USPATFULL

CN Carbamic acid, [7-[(diphenylmethyl)amino]-2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 15223-96-8 USPATFULL

CN Carbamic acid, [3-amino-4-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 15223-97-9 USPATFULL

CN Carbamic acid, [4-[[3-(methylphenylamino)-2-oxopropyl]amino]-3-nitro-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 15223-98-0 USPATFULL

CN Carbamic acid, [2,3-dihydro-7-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-2-oxo-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 15223-99-1 USPATFULL

CN Carbamic acid, [4-amino-6-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 16335-92-5 USPATFULL

CN Carbamic acid, (4-amino-3-nitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 16335-94-7 USPATFULL

CN Carbamic acid, (2-methylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 16335-96-9 USPATFULL

CN Carbamic acid, (2,3-diphenylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 16335-98-1 USPATFULL

CN Carbamic acid, [8-[(diphenylmethyl)amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 16336-03-1 USPATFULL

CN Carbamic acid, (5-amino-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 16336-05-3 USPATFULL

CN Carbamic acid, (8-ethoxy-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 16336-06-4 USPATFULL

CN Carbamic acid, (5-ethoxy-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 19254-73-0 USPATFULL


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 19270-28-1 USPATFULL

CN Carbamic acid, [6-amino-4-[[4-(diethylamino)-1-methylbutyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-29-2 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 19270-36-1 USPATFULL


CN Carbamic acid, [6-amino-4-[[4-(diethylamino)-1-methylbutyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 19270-37-2 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-38-3 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[(4-chlorophenyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-40-7 USPATFULL

CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-41-8 USPATFULL

CN Carbamic acid, [3-(4-chlorophenyl)-8-[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-42-9 USPATFULL

CN Carbamic acid, [8-[(4-chlorophenyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 19270-44-1 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 19270-46-3 USPATFULL


CN Carbamic acid, [3-(4-chlorophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 21271-60-3 USPATFULL

CN Carbamic acid, [6-amino-4-[(4-chlorophenyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-61-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-65-8 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-66-9 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-70-5 USPATFULL

CN Carbamic acid, [8-[[[4-(diethylamino)-1-methylbutyl]amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-76-1 USPATFULL

CN Carbamic acid, [2,3-bis(4-chlorophenyl)-8-[[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-80-7 USPATFULL

CN Carbamic acid, [8-[(4-chlorophenyl)amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-82-9 USPATFULL

CN Carbamic acid, [8-[(4-chlorophenyl)amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-88-5 USPATFULL

CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-89-6 USPATFULL

CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 21271-91-0 USPATFULL


CN Carbamic acid, [8-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 21271-93-2 USPATFULL


CN Carbamic acid, [8-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-3-

methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21271-98-7 USPATFULL

CN Carbamic acid, [8-[[2-[[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]-3-methylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21395-43-7 USPATFULL

CN Carbamic acid, [3-(4-chlorophenyl)-8-[(4-chlorophenyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21395-44-8 USPATFULL

CN Carbamic acid, [2,3-bis(4-chlorophenyl)-8-[(4-chlorophenyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 21395-46-0 USPATFULL

CN Carbamic acid, [8-[[2-[4-[(diethylamino)sulfonyl]phenyl]ethyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-73-1 USPATFULL

CN Carbamic acid, [8-[(diphenylmethyl)amino]-3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-74-2 USPATFULL

CN Carbamic acid, [8-[(diphenylmethyl)amino]-1,2-dihydro-2-oxopyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-75-3 USPATFULL

CN Carbamic acid, [8-amino-3-(4-chlorophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-77-5 USPATFULL

CN Carbamic acid, [8-amino-3-(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28642-81-1 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 28642-83-3 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-phenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI)
(CA INDEX NAME)

●2 HCl

RN 28642-87-7 USPATFULL


CN Carbamic acid, [3-(3,4-dichlorophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 28642-88-8 USPATFULL


CN Carbamic acid, [3-(4-bromophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 28642-95-7 USPATFULL


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-[4-(trifluoromethyl)phenyl]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 28648-99-9 USPATFULL

CN Carbamic acid, [8-chloro-3-(4-chlorophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-01-6 USPATFULL

CN Carbamic acid, [8-chloro-2,3-bis(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-04-9 USPATFULL

CN Carbamic acid, [2-(4-chlorophenyl)-8-[(diphenylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-06-1 USPATFULL

CN Carbamic acid, [8-[(diphenylmethyl)amino]-2-(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 28649-08-3 USPATFULL

CN Carbamic acid, [8-[(diphenylmethyl)amino]-2,3-bis(3,4,5-trimethoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 30768-44-6 USPATFULL

CN Benzoic acid, 4-[[3-[[2-amino-6-[(ethoxycarbonyl)amino]-3-nitro-4-pyridinyl]amino]-2-(hydroxyimino)propyl]amino]-, ethyl ester (CA INDEX NAME)




RN 30768-45-7 USPATFULL

CN Benzoic acid, 4-[[3-[[2-amino-6-[(ethoxycarbonyl)amino]-3-nitro-4-pyridinyl]amino]-2-oxopropyl]amino]-, ethyl ester (CA INDEX NAME)




RN 30768-46-8 USPATFULL

CN Benzoic acid, 4-[[[5-amino-7-[(ethoxycarbonyl)amino]-1,2-dihydropyrido[3,4-b]pyrazin-3-yl)methyl]amino]-, ethyl ester (CA INDEX NAME)




RN 30768-50-4 USPATFULL

CN Benzoic acid, 4-[[[3-[[2-amino-6-[(ethoxycarbonyl)amino]-1,2-dihydropyrido[3,4-b]pyrazin-3-yl)methyl]methylamino]-, methyl ester (CA INDEX NAME)



RN 30826-44-9 USPATFULL


CN Benzoic acid, 4-[[[3-[[2-amino-6-[(ethoxycarbonyl)amino]-3-nitro-4-pyridinyl]amino]-2-oxopropyl]methylamino]-, methyl ester (CA INDEX NAME)



RN 31541-76-1 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-(4-


methoxyphenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 37437-06-2 USPATFULL

CN Carbamic acid, (5,6-diamino-4-chloro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 38359-68-1 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[(diphenylmethyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 38359-73-8 USPATFULL

CN Carbamic acid, (7-chloro-1H-1,2,3-triazolo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 38359-79-4 USPATFULL

CN Carbamic acid, [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40497-61-8 USPATFULL

CN Carbamic acid, [6-amino-4-(dimethylamino)-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40497-62-9 USPATFULL

CN Carbamic acid, [6-amino-4-[[bis(4-chlorophenyl)methyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40525-21-1 USPATFULL

CN Carbamic acid, (7-amino-1H-imidazo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 53995-21-4 USPATFULL

CN Carbamic acid, (4-chloro-3-nitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 63708-78-1 USPATFULL

CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 80434-77-1 USPATFULL

CN Carbamic acid, [5-amino-1,2-dihydro-3-[(methylphenylamino)methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-57-7 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-3-(methylphenylamino)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-58-8 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-3-[(4-methoxyphenyl)methylamino]propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-59-9 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-60-2 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-methylphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-64-6 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(4-chlorophenyl)-2-(hydroxyimino)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-65-7 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(2,4-dichlorophenyl)-2-(hydroxyimino)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-67-9 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(3-methoxyphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-68-0 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-methoxyphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-70-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-nitrophenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-71-5 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-73-7 USPATFULL

CN Carbamic acid, [6-amino-4-[[3-(methylphenylamino)-2-oxopropyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-77-1 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(4-fluorophenyl)-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-81-7 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(4-methoxyphenyl)-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-83-9 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[[2-(4-nitrophenyl)-2-oxoethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-84-0 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[[2-oxo-2-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-86-2 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-hydroxy-3-(methylphenylamino)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-87-3 USPATFULL

CN Carbamic acid, [6-amino-4-[[3-[(4-chlorophenyl)methylamino]-2-hydroxypropyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-88-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-hydroxy-3-[(4-methoxyphenyl)methylamino]propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-90-8 USPATFULL

CN Carbamic acid, [5-amino-1,2-dihydro-3-[[4-methoxyphenyl)methylamino]methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-91-9 USPATFULL

CN Carbamic acid, (5-amino-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-94-2 USPATFULL

CN Carbamic acid, [5-amino-3-(3,4-dimethylphenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 82585-95-3 USPATFULL

CN Carbamic acid, [5-amino-3-(4-fluorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-04-9 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[(2-oxo-4-phenylbutyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-09-4 USPATFULL

CN Carbamic acid, [6-amino-4-[(1-methyl-2-oxo-2-phenylethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-10-7 USPATFULL

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-13-0 USPATFULL

CN Carbamic acid, [5-amino-3-[(methylphenylamino)methyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-14-1 USPATFULL

CN Carbamic acid, [5-amino-3-[(methylphenylamino)carbonyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-15-2 USPATFULL

CN Carbamic acid, (5-amino-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-17-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-4-phenylbutyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-20-9 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 83269-23-2 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-2-phenylethyl)methylamino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-41-4 USPATFULL

CN Carbamic acid, (6-amino-4-hydroxy-5-nitro-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-43-6 USPATFULL

CN Carbamic acid, [dithiobis(6-amino-5-nitro-4,2-pyridinediyl)]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 86970-47-0 USPATFULL

RN Carbamic acid, (5-amino-2,3-diphenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-,
ethyl ester (9CI) (CA INDEX NAME)




RN 86970-49-2 USPATFULL

CN Carbamic acid, (5-amino-2-oxo-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-,
ethyl ester (9CI) (CA INDEX NAME)




RN 86970-50-5 USPATFULL

CN Carbamic acid, [5-amino-3-(3-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-51-6 USPATFULL

CN Carbamic acid, [5-amino-3-(3,5-dimethoxyphenyl)-2-methyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-52-7 USPATFULL

CN Carbamic acid, [5-amino-3-(3,4,5-trimethoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-53-8 USPATFULL

CN Carbamic acid, [5-amino-3-(4-chlorophenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-54-9 USPATFULL

CN Carbamic acid, [5-amino-3-(4-nitrophenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-55-0 USPATFULL

CN Carbamic acid, (5-amino-3-phenyl-2H-pyrido[4,3-b]-1,4-thiazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 86970-58-3 USPATFULL


CN Carbamic acid, (5-amino-2,2-dimethyl-3-phenyl-2H-pyrido[4,3-b]-1,4-thiazin-7-yl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 86970-59-4 USPATFULL

CN Carbamic acid, [5-amino-3-(3-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-thiazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-60-7 USPATFULL

CN Carbamic acid, [5-amino-3-(4-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-thiazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-61-8 USPATFULL

CN Carbamic acid, [5-amino-3-(2-naphthalenyl)-2H-pyrido[4,3-b]-1,4-thiazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-62-9 USPATFULL

CN Carbamic acid, [5-[(dimethylamino)methylene]amino]-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 86970-63-0 USPATFULL

CN Carbamic acid, [5-[(bromoacetyl)amino]-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 87607-29-2 USPATFULL

CN Carbamic acid, (5-amino-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 91599-70-1 USPATFULL

CN Carbamic acid, (5-amino-2-methyl-3-phenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 97235-86-4 USPATFULL

CN Carbamic acid, (3-methylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 109182-31-2 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-(phenylamino)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-32-3 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[(phenylmethyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-33-4 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[(2-phenylethyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-34-5 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[(4-phenylbutyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 109182-36-7 USPATFULL


CN Carbamic acid, [5,6-diamino-4-[(phenylmethyl)amino]-2-pyridinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 109182-37-8 USPATFULL


CN Carbamic acid, [5,6-diamino-4-[(2-phenylethyl)amino]-2-pyridinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 109182-38-9 USPATFULL


CN Carbamic acid, [5,6-diamino-4-[(4-phenylbutyl)amino]-2-pyridinyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 109182-43-6 USPATFULL

CN Carbamic acid, (7-chloro-2-phenyl-1H-imidazo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-47-0 USPATFULL

CN Carbamic acid, (4-chloro-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-48-1 USPATFULL

CN Carbamic acid, [4-chloro-1-(diphenylmethyl)-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-53-8 USPATFULL

CN Carbamic acid, [4-[(diphenylmethyl)amino]-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-54-9 USPATFULL

CN Carbamic acid, [4-[(diphenylmethyl)amino]-2-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-55-0 USPATFULL

CN Carbamic acid, [2-(1,3-benzodioxol-5-yl)-4-[(diphenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-68-5 USP/FULL

CN Carbamic acid, [7-[(phenylmethyl)amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-69-6 USP/FULL

CN Carbamic acid, (4-amino-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-70-9 USP/FULL

CN Carbamic acid, [7-[(2-phenylethyl)amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-71-0 USP/FULL

CN Carbamic acid, [7-[(4-phenylbutyl)amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109182-73-2 USPATFULL

CN Carbamic acid, [4-amino-2-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 109217-57-4 USPATFULL

CN Carbamic acid, [4-amino-2-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 116659-54-2 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-(2-propenylamino)-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 121572-30-3 USPATFULL

CN Carbamic acid, [5-(acetylamino)-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 121572-32-5 USPATFULL

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, 1-methylpropyl ester (9CI) (CA INDEX NAME)




RN 121572-34-7 USPATFULL

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 121572-37-0 USPATFULL

CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 121572-46-1 USPATFULL

CN Carbamic acid, (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 121572-53-0 USPATFULL

CN Carbamic acid, (4-chloro-3,5-dinitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 121596-28-9 USPATFULL


CN Carbamic acid, (8-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 122293-96-3 USPATFULL

CN Carbamic acid, [6-amino-4-[[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 122293-97-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

(NAME)


Absolute stereochemistry.



RN 122293-99-6 USPATFULL

CN Carbamic acid, [6-amino-4-[(1S)-1-methyl-2-oxo-2-phenylethylamino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 122332-17-6 USPATFULL

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 122332-18-7 USPATFULL


CN Carbamic acid, N-[(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 123753-52-6 USPATFULL

CN Carbamic acid, (4,5,6-triamino-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-54-8 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[(phenylmethylene)hydrazino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-55-9 USPATFULL

CN Carbamic acid, [4-amino-1-[(phenylmethylene)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-56-0 USPATFULL

CN Carbamic acid, [7-[(phenylmethylene)hydrazino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-57-1 USPATFULL

CN Carbamic acid, [7-[(phenylmethylene)hydrazino]-2-[(phenylmethyl)thio]-1H-




RN 123753-66-2 USPATFULL

CN Carbamic acid, [4-amino-1-[(4-methoxyphenyl)methylene]amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-68-4 USPATFULL

CN Carbamic acid, [1,4-diamino-2-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-70-8 USPATFULL

CN Carbamic acid, [1,4-diamino-2-[(1,3-benzodioxol-5-ylmethyl)thio]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123753-72-0 USPATFULL

CN Carbamic acid, [6-amino-4-[methyl(phenylmethylene)hydrazino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 123775-16-6 USPATFULL

CN Carbamic acid, [4-amino-1-[(1,3-benzodioxol-5-ylmethylene)amino]-2,3-dihydro-2-thioxo-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-52-7 USPATFULL

CN Carbamic acid, [5-[(diphenylmethyl)amino]-1,2-dihydro-2-oxo-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-54-9 USPATFULL

CN Carbamic acid, [6-[(diphenylmethyl)amino]-4-phenylpyrido[3,4-e]tetrazolo[1,5-a]pyrazin-8-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-56-1 USPATFULL

CN Carbamic acid, [5-amino-1,2-dihydro-2-oxo-3-phenylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-61-8 USPATFULL

CN Carbamic acid, (3,8-diamino-2-phenylpyrido[2,3-b]pyrazin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 130145-65-2 USPATFULL

CN Carbamic acid, [6-amino-4-(2-formylhydrazino)-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-25-2 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-1-methyl-2-(3-nitrophenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-27-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(2,3,4-trimethoxyphenyl)ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-30-9 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-tricyclo[3.3.1.1,3,7]dec-1-ylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-31-0 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(1,3-benzodioxol-5-yl)-1-methyl-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-32-1 USPATFULL

CN Carbamic acid, [6-amino-4-[(1-benzoylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-33-2 USPATFULL

CN Carbamic acid, [4-[(1-acetylpentyl)amino]-6-amino-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-35-4 USPATFULL

CN Carbamic acid, [6-amino-4-[(1-methyl-2-oxohexyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-36-5 USPATFULL

CN Carbamic acid, [6-amino-4-[(1-methyl-2-oxo-3-phenylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-37-6 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(1,3-benzodioxol-5-yl)-2-hydroxy-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-39-8 USPATFULL

CN Carbamic acid, [6-amino-4-[[1-(1-hydroxyethyl)pentyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-40-1 USPATFULL

CN Carbamic acid, [6-amino-4-[(2-hydroxy-1-methyl-3-phenoxypropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-42-3 USPATFULL

CN Carbamic acid, [6-amino-4-[(2-hydroxy-1-methyl-3-phenylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-46-7 USPATFULL

CN Carbamic acid, [5-amino-3-(1,3-benzodioxol-5-yl)-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-47-8 USPATFULL

CN Carbamic acid, (5-amino-2-ethyl-1,2-dihydro-3-phenylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-48-9 USPATFULL

CN Carbamic acid, (5-amino-2-butyl-1,2-dihydro-3-methylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-50-3 USPATFULL

CN Carbamic acid, (5-amino-3-butyl-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-51-4 USPATFULL

CN Carbamic acid, [5-amino-3-(3-aminophenyl)-1,2-dihydro-2-methyl-3-(phenylmethyl)pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-52-5 USPATFULL

CN Carbamic acid, [5-amino-3-(3-aminophenyl)-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 135696-54-7 USPATFULL

CN Carbamic acid, [5-amino-1,2-dihydro-3-(4-methoxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 139016-58-3 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-methoxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 139016-59-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-(hydroxyimino)-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 139016-61-8 USPATFULL


CN Carbamic acid, [5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 139068-49-8 USPATFULL

CN Carbamic acid, [6-amino-4-[[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139068-54-5 USPATFULL

CN Carbamic acid, [6-amino-4-[[[(1R)-2-(4-hydroxyphenyl)-1-methyl-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 139068-55-6 USPATFULL

CN Carbamic acid, [(2S)-5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 139068-56-7 USPATFULL

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143858-90-6 USPATFULL


CN Carbamic acid, [5,6-diamino-4-[[[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 144694-16-6 USPATFULL

CN Carbamic acid, [6-amino-4-[(3-hydroxy-3-phenylpropyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 144694-17-7 USPATFULL

CN Carbamic acid, [6-amino-5-nitro-4-[(3-oxo-3-phenylpropyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 144694-20-2 USPATFULL


CN Carbamic acid, (6-amino-2,3-dihydro-4-phenyl-1H-pyrido[3,4-b][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 144694-26-8 USPATFULL

CN Carbamic acid, [4-amino-6-[[[(1S)-1-methyl-2-oxo-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 144694-29-1 USPATFULL


CN Carbamic acid, [(3S)-8-amino-3,4-dihydro-3-methyl-2-phenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496816-53-6 USPATFULL


CN Carbamic acid, [8-[[4-(diethylamino)-1,3-dimethylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 496816-54-7 USPATFULL


CN Carbamic acid, [(2S)-5-amino-3-[4-[[butylamino]carbonyl]oxy]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500309-46-6 USPATFULL

CN Carbamic acid, (4-chloro-1H-imidazo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 500312-15-2 USPATFULL

CN Carbamic acid, (4-chloro-1H-1,2,3-triazolo[4,5-c]pyridin-6-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 500363-91-7 USPATFULL

CN Carbamic acid, [3-nitro-4-(2-propenylamino)-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 500540-83-0 USPATFULL

CN Carbamic acid, [6-[[2-(4-chlorophenyl)-2-oxoethyl]amino]-4-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 501017-34-1 USPATFULL

CN Carbamic acid, (7-amino[1,2,3]thiadiazolo[5,4-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 502485-83-8 USPATFULL

CN Carbamic acid, (4-hydrazino-3-nitro-2,6-pyridinediyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 646072-86-8 USPATFULL

CN Carbamic acid, [4-[methyl(phenylmethyl)amino]-2-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646072-87-9 USPATFULL


CN Carbamic acid, [2-(4-chlorophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646072-88-0 USPATFULL

CN Carbamic acid, [(2S)-5-amino-1,2-dihydro-2-methyl-3-[4-(phenylmethoxy)phenyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 646072-89-1 USPATFULL

CN Carbamic acid, [(2R)-5-amino-1,2-dihydro-2-methyl-3-[4-(phenylmethoxy)phenyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 646072-90-4 USPATFULL


CN Carbamic acid, [4-(diethylamino)-2-(4-methylphenyl)-1H-imidazo[4,5-

c[pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-91-5 USPATFULL

CN Carbamic acid, [2-(4-nitrophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-92-6 USPATFULL

CN Carbamic acid, [2-(4-phenoxyphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-93-7 USPATFULL

CN Carbamic acid, [2-(4-ethylphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-94-8 USPATFULL

CN Carbamic acid, [2-(4-ethylphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-95-9 USPATFULL

CN Carbamic acid, [2-(1-naphthalenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-96-0 USPATFULL

CN Carbamic acid, [2-(2-phenylethyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646072-97-1 USPATFULL

CN Carbamic acid, [2-(2-fluorophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646072-98-2 USPATFULL


CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 646072-99-3 USPATFULL

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-(3,4,5-trimethoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 646073-00-9 USPATFULL

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-(2,4,5-trimethoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 646073-01-0 USPATFULL

CN Carbamic acid, [2-(2,5-dimethoxyphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]- (9CI)
(CA INDEX NAME)



RN 646073-02-1 USPATFULL


CN Carbamic acid, [2-phenyl-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 646073-03-2 646073-04-3 646073-05-4
 646073-06-5 646073-07-6 646073-08-7
 646073-09-8 646073-10-1 646073-11-2
 646073-12-3 646073-13-4 646073-14-5
 646073-15-6 646073-16-7 646073-17-8
 646073-18-9 646073-19-0 646073-20-3
 646073-21-4 646073-22-5 646073-23-6
 646073-24-7 646073-25-8 646073-26-9
 646073-27-0 646073-28-1 646073-29-2
 646073-30-5 646073-31-6 646073-32-7
 646073-33-8 646073-34-9 646073-35-0
 646073-36-1 646073-37-2 646073-38-3
 646073-39-4 646073-40-7 646073-41-8
 646073-42-9 646073-43-0 646073-44-1
 646073-45-3 646073-46-6 646073-49-9
 646073-52-1 646073-53-2 646073-54-3
 646073-55-4 646073-56-5 646073-57-6
 646073-58-7 646073-59-8 646073-60-1
 646073-61-2 646073-62-3 646073-63-4
 646073-64-5 646073-65-6 646073-66-7
 646073-67-8 646073-68-9
 (inhibitors of ftsz and uses thereof)


RN 646073-03-2 USPATFULL

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-04-3 USPATFULL


CN Carbamic acid, [2-(4-chlorophenyl)-8-[[4-(diethylamino)-1-methylbutyl]amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 646073-05-4 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-1-methyl-3-phenoxypropyl)amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-06-5 USPATFULL

CN Carbamic acid, (4-chloro-2,6-pyridinediyl)bis-, diphenyl ester (9CI) (CA INDEX NAME)



RN 646073-07-6 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2-(4-nitrophenyl)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 646073-08-7 USPATFULL

CN Carbamic acid, [7-(phenylamino)-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl


ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 646073-09-8 USPATFULL

CN Carbamic acid, [2-methyl-4-[(2-phenylethyl)(phenylmethyl)amino]oxazolo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-10-1 USPATFULL

CN Carbamic acid, (2,3-dihydro-2-phenyl-1H-1,2,3-triazolo[4,5-c]pyridine-4,6-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 646073-11-2 USPATFULL

CN Carbamic acid, [5-amino-3-[[4-methoxyphenyl)methylamino]methyl]-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-12-3 USPATFULL


CN Carbamic acid, [6-amino-4-[(aminoiminomethyl)thio]-5-nitro-2-pyridinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 646073-13-4 USPATFULL


CN Carbamic acid, (11-amino-6,6a-dihydro-5H-naphtho[2,1-b]pyrido[3,4-e][1,4]oxazin-9-yl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 646073-14-5 USPATFULL

CN Carbamic acid, [5-amino-1,2-dihydro-2-methyl-3-[3-[[4-(2-triazenyl)benzoyl]amino]phenyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-15-6 USPATFULL

CN Carbamic acid, [7-[[bis(4-chlorophenyl)methyl]amino]-1H-imidazo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-16-7 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-3-[4-(trifluoromethyl)phenyl]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-17-8 USPATFULL

CN Carbamic acid, (7-amino-3-phenyl-3H-imidazo[4,5-b]pyridin-5-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-18-9 USPATFULL

CN Carbamic acid, [4-[(2-phenylethyl)(phenylmethyl)amino]-2-(3,4,5-trimethoxyphenyl)oxazolo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-19-0 USPATFULL

CN Carbamic acid, [4-amino-6-[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-20-3 USPATFULL

CN Carbamic acid, [6-[[2-(4-chlorophenyl)-2-(hydroxyimino)ethyl]amino]-4-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-21-4 USPATFULL

CN Carbamic acid, [5-amino-3-(2-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-22-5 USPATFULL


CN Carbamic acid, [6-amino-4-[[1-methyl-2-oxo-3-(phenylmethoxy)propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-23-6 USPATFULL


CN Carbamic acid, [2-(4-chlorophenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]o

xazolo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-24-7 USPATFULL

CN Carbamic acid, [2-(4-methylphenyl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-25-8 USPATFULL

CN Carbamic acid, [6-[(ethoxycarbonyl)amino]-4-[[2-(hydroxyimino)-1-methyl-2-phenylethyl]amino]-3,5-dinitro-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-26-9 USPATFULL

CN Carbamic acid, [2-(1,3-benzodioxol-5-yl)-4-[(2-phenylethyl)(phenylmethyl)amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-27-0 USPATFULL

CN Carbamic acid, [6-amino-4-[[[(1R)-2-(hydroxyimino)-1-methyl-2-phenylethyl]amino]-3,5-dinitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 646073-28-1 USPATFULL


CN Carbamic acid, [(2R)-5-amino-3-[4-[[[(butylamino)carbonyl]oxy]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 646073-29-2 USPATFULL


CN Carbamic acid, [5,6-diamino-4-[[[1-(1-hydroxyethyl)pentyl]amino]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-30-5 USPATFULL


CN Carbamic acid, [6-[(diphenylmethyl)amino]-5-nitro-2,4-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)

oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-35-0 USPATFULL

CN Carbamic acid, [5-amino-3-(4-methoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-36-1 USPATFULL

CN Carbamic acid, [5-amino-3-(3,4-dimethoxyphenyl)-2H-pyrido[4,3-b]-1,4-oxazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-37-2 USPATFULL

CN Carbamic acid, [6-amino-4-[[[(3,4-dimethylphenyl)methyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-38-3 USPATFULL

CN Carbamic acid, [7-[(diphenylmethyl)amino]-1H-1,2,3-triazolo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-39-4 USPATFULL

CN Carbamic acid, [6-amino-4-[[3-(dimethylamino)-2-hydroxypropyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-40-7 USPATFULL


CN Carbamic acid, (5,6-diamino-2-pyridinyl)-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 646073-41-8 USPATFULL

CN Carbamic acid, [3-(4-chlorophenyl)-8-(diphenylamino)pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-42-9 USPATFULL

CN Carbamic acid, [2-[[[(2,4-dichlorophenyl)methylene]amino]-8-[(diphenylmethyl)amino]pyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-43-0 USPATFULL

CN Carbamic acid, [3-amino-8-[(diphenylmethyl)amino]-2-nitropyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-44-1 USPATFULL

CN Carbamic acid, [4-[(3-amino-2-hydroxypropyl)amino]-3-nitro-2,6-pyridinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 646073-46-3 USPATFULL


CN Carbamic acid, 1H-imidazo[4,5-c]pyridine-4,6-diylbis-, diethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 646073-49-6 USPATFULL

CN Carbamic acid, [2-(3-methylphenyl)-4-[[3-phenyl-1-(phenylmethyl)propyl]amino]-1H-imidazo[4,5-c]pyridin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-50-9 USPATFULL


CN Carbamic acid, [6-amino-4-[(2-[1,1'-biphenyl]-4-yl)-2-oxoethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 646073-52-1 USPATFULL


CN Carbamic acid, [6-amino-4-[[2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646073-53-2 USPATFULL

CN Carbamic acid, [4-[[[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 646073-54-3 USPATFULL


CN Carbamic acid, [4-[[[(1R)-1-methyl-2-oxo-2-phenylethyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 646073-55-4 USPATFULL

CN Carbamic acid, [7-(2-triazenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-56-5 USPATFULL

CN Carbamic acid, (1,2-dihydropyrido[3,4-e]-1,2,4-triazine-5,7-diyl)bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 646073-57-6 USPATFULL

CN Carbamic acid, [6-amino-4-(methylamino)-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-58-7 USPATFULL

CN Carbamic acid, [6-amino-4-[[2-[(aminocarbonyl)hydrazono]propyl]amino]-5-nitro-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646073-59-8 USPATFULL

CN Carbamic acid, [5,6-diamino-4-[(2-hydroxy-1-methyl-3-phenoxypropyl)amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 646073-60-1 USPATFULL

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 646073-61-2 USPATFULL

CN Carbamic acid, (9-amino-4,5-dihydro-2-phenyl-3H-pyrido[2,3-b][1,4]diazepin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-62-3 USPATFULL


CN Carbamic acid, [8-[[[4-(aminosulfonyl)phenyl]methyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-63-4 USPATFULL


CN Carbamic acid, [(2S)-5-amino-3-butyl-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 646073-64-5 USPATFULL

CN Carbamic acid, (5-amino-2,3-diphenyl-2H-pyrido[4,3-b]-1,4-oxazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-65-6 USPATFULL


CN Carbamic acid, (5-ethoxy-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-66-7 USPATFULL


CN Carbamic acid, (5-amino-2,3-diphenylpyrido[3,4-b]pyrazin-7-yl)-, methyl

ester (9CI) (CA INDEX NAME)



RN 646073-67-8 USPATFULL


CN Carbamic acid, [5-amino-1,2-dihydro-3-[[4-methoxyphenyl)methylamino]methyl]pyrido[3,4-b]pyrazin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 646073-68-9 USPATFULL

CN Carbamic acid, [(2S)-5-amino-3-[4-[[4-methoxyphenyl)methylamino]methyl]phenyl]-1,2-dihydro-2-methylpyrido[3,4-b]pyrazin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



STRUCTURE/METHOD SEARCH

=> fil reg
 FILE 'REGISTRY' ENTERED AT 12:37:38 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 SEP 2008 HIGHEST RN 1045602-82-1
 DICTIONARY FILE UPDATES: 1 SEP 2008 HIGHEST RN 1045602-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.




TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d stat que l7
 L4 STR



Ak @24



X @30

VAR G1=11/17/23
 VAR G2=N/30/OH/24/25
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 24
 CONNECT IS E1 RC AT 26
 DEFAULT MLEVEL IS ATOM
 MLEVEL IS CLASS AT 24 26 30
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
 L7 1933 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 14517 ITERATIONS
 SEARCH TIME: 00.00.02

1933 ANSWERS

=> fil hcapl; d que nos 148; d que nos 149; d que nos 151
 FILE 'HCAPLUS' ENTERED AT 12:39:08 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Sep 2008 VOL 149 ISS 10
 FILE LAST UPDATED: 1 Sep 2008 (20080901/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

L3 1 SEA FILE=REGISTRY ABB=ON 1404-26-8
 L4 STR
 L7 1933 SEA FILE=REGISTRY SSS FUL L4
 L15 985 SEA FILE=HCAPLUS ABB=ON L7
 L16 2755 SEA FILE=HCAPLUS ABB=ON L3
 L48 1 SEA FILE=HCAPLUS ABB=ON L15 AND L16

L4 STR
 L7 1933 SEA FILE=REGISTRY SSS FUL L4
 L15 985 SEA FILE=HCAPLUS ABB=ON L7
 L17 3190 SEA FILE=HCAPLUS ABB=ON GRAM-POSITIVE BACTERIA/CT
 L18 433 SEA FILE=HCAPLUS ABB=ON ACTINOBACTERIA+NT/CT
 L19 4108 SEA FILE=HCAPLUS ABB=ON ACTINOMYCETES/CT
 L20 3910 SEA FILE=HCAPLUS ABB=ON ACTINOMYCETALES+NT/CT
 L21 678 SEA FILE=HCAPLUS ABB=ON ACTINOPLANETES+NT/CT
 L22 17 SEA FILE=HCAPLUS ABB=ON ACTINOSYNNEMATACEAE+NT/CT
 L23 5 SEA FILE=HCAPLUS ABB=ON ARSENICOCOCCUS+NT/CT
 L24 898 SEA FILE=HCAPLUS ABB=ON CORYNEFORM BACTERIA+NT/CT
 L25 5800 SEA FILE=HCAPLUS ABB=ON MICROCOCCACEAE+NT/CT
 L26 1189 SEA FILE=HCAPLUS ABB=ON MICROMONOSPORACEAE+NT/CT
 L27 175 SEA FILE=HCAPLUS ABB=ON MICROTHRUX/CW
 L28 7309 SEA FILE=HCAPLUS ABB=ON NOCARDIOFORM ACTINOMYCETES+NT/CT
 L29 1455 SEA FILE=HCAPLUS ABB=ON PSEUDONOCARDIACEAE+NT/CT

```

L30      324 SEA FILE=HCAPLUS ABB=ON STREPTOSPORANGIACEAE+NT/CT
L31     112336 SEA FILE=HCAPLUS ABB=ON BACILLALES+NT/CT
L32      14 SEA FILE=HCAPLUS ABB=ON ACIDAMINOCOCCACEAE/CT
L33      4 SEA FILE=HCAPLUS ABB=ON AEROCOCCACEAE/CT
L34     23025 SEA FILE=HCAPLUS ABB=ON CLOSTRIDIACEAE+NT/CT
L35      134 SEA FILE=HCAPLUS ABB=ON CLOSTRIDIALES+NT/CT
L36      16 SEA FILE=HCAPLUS ABB=ON EUBACTERIACEAE/CT
L37      48 SEA FILE=HCAPLUS ABB=ON HALANAEROBIAEAE+NT/CT
L38     1062 SEA FILE=HCAPLUS ABB=ON LACHNOSPIRACEAE+NT/CT
L39     22915 SEA FILE=HCAPLUS ABB=ON LACTOBACILLACEAE+NT/CT
L40     6759 SEA FILE=HCAPLUS ABB=ON MYCOPLASMATAEAE+NT/CT
L41      1 SEA FILE=HCAPLUS ABB=ON PARASPOROBACTERIUM/CW
L42      7 SEA FILE=HCAPLUS ABB=ON PEPTOSTREPTOCOCCACEAE/CT
L43     41508 SEA FILE=HCAPLUS ABB=ON STREPTOCOCCACEAE+NT/CT
L44     36336 SEA FILE=HCAPLUS ABB=ON MYCOBACTER*/OBI
L45      15 SEA FILE=HCAPLUS ABB=ON "LOW G+C GRAM-POSITIVE BACTERIA"/CT
L49      12 SEA FILE=HCAPLUS ABB=ON L15 AND (L17 OR L18 OR L19 OR L20 OR
L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR
L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR
L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45)

```

```

L4      STR
L7      1933 SEA FILE=REGISTRY SSS FUL L4
L15     985 SEA FILE=HCAPLUS ABB=ON L7
L50     875 SEA FILE=HCAPLUS ABB=ON FTSZ/OBI
L51      4 SEA FILE=HCAPLUS ABB=ON L15 AND L50

```

=> s 148,149,151 not 147

```
L192      7 (L48 OR L49 OR L51) NOT L47      L47=INVENTOR SEARCH ANSWER SET
```

=> fil uspatf; d que nos 1121; d que nos 1122

FILE 'USPATFULL' ENTERED AT 12:39:09 ON 02 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 26 Aug 2008 (20080826/PD)
FILE LAST UPDATED: 2 Sep 2008 (20080902/ED)
HIGHEST GRANTED PATENT NUMBER: US7421742
HIGHEST APPLICATION PUBLICATION NUMBER: US20080209606
CA INDEXING IS CURRENT THROUGH 2 Sep 2008 (20080902/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 26 Aug 2008 (20080826/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2008

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

```

L3      1 SEA FILE=REGISTRY ABB=ON 1404-26-8
L4      STR
L7      1933 SEA FILE=REGISTRY SSS FUL L4
L55     767 SEA FILE=REGISTRY ABB=ON L7 AND (IFIPAT/LC OR USPATFULL/LC OR
L56     SCISEARCH/LC)
L60     156 SEA FILE=USPATFULL ABB=ON ACTINOBACTER?
L61     6565 SEA FILE=USPATFULL ABB=ON ACTINOMYCET?
L62      31 SEA FILE=USPATFULL ABB=ON ACTINOPLANET?

```

L63 17 SEA FILE=USPATFULL ABB=ON ACTINOSYNNEMAT?
 L64 0 SEA FILE=USPATFULL ABB=ON ARSENICOCC?
 L65 858 SEA FILE=USPATFULL ABB=ON CORYNEFORM
 L66 15370 SEA FILE=USPATFULL ABB=ON CORYNEBACTER?
 L67 4998 SEA FILE=USPATFULL ABB=ON MICROCOCC?
 L68 863 SEA FILE=USPATFULL ABB=ON MICROMONOSPOR?
 L69 13 SEA FILE=USPATFULL ABB=ON MICROTIRIX
 L70 4286 SEA FILE=USPATFULL ABB=ON NOCARDI?
 L71 162 SEA FILE=USPATFULL ABB=ON PSEUDONOCARDI?
 L72 206 SEA FILE=USPATFULL ABB=ON STREPTOSPORANG?
 L74 91 SEA FILE=USPATFULL ABB=ON ACIDAMINOCOCC?
 L75 257 SEA FILE=USPATFULL ABB=ON AEROCOCC?
 L76 12882 SEA FILE=USPATFULL ABB=ON CLOSTRIDI?
 L77 6291 SEA FILE=USPATFULL ABB=ON EUBACTERI?
 L78 5 SEA FILE=USPATFULL ABB=ON HALANAEROBI?
 L79 36 SEA FILE=USPATFULL ABB=ON LACHNOSPIR?
 L81 1 SEA FILE=USPATFULL ABB=ON PARASPOROBACTER?
 L82 1333 SEA FILE=USPATFULL ABB=ON PEPTOSTREPTOCOCC?
 L84 20639 SEA FILE=USPATFULL ABB=ON MYCOBACTER?
 L85 3506 SEA FILE=USPATFULL ABB=ON M TUBERCULOSIS
 L86 588 SEA FILE=USPATFULL ABB=ON L55
 L87 329 SEA FILE=USPATFULL ABB=ON L3
 L88 333 SEA FILE=USPATFULL ABB=ON FTSZ
 L121 14 SEA FILE=USPATFULL ABB=ON L86 AND (L87 OR L88 OR L60 OR L61
 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70
 OR L71 OR L72 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR L81
 OR L82 OR L84 OR L85)

L4 STR
 L7 1933 SEA FILE=REGISTRY SSS FUL L4
 L55 767 SEA FILE=REGISTRY ABB=ON L7 AND (IFIPAT/LC OR USPATFULL/LC OR
 SCISEARCH/LC)
 L59 27611 SEA FILE=USPATFULL ABB=ON GRAM(W) (POS OR POSITIVE)
 L73 48107 SEA FILE=USPATFULL ABB=ON BACILLUS OR BACILLALES
 L80 10838 SEA FILE=USPATFULL ABB=ON MYCOPLASMA?
 L83 28041 SEA FILE=USPATFULL ABB=ON STREPTOCOCC?
 L86 588 SEA FILE=USPATFULL ABB=ON L55
 L122 20 SEA FILE=USPATFULL ABB=ON L86 AND ((L59 AND (L73 OR L80 OR
 L83)) OR (L73 AND (L80 OR L83)) OR (L80 AND L83))

=> s l121,l122 not l90

L193 27 (L121 OR L122) NOT L90 L90=INVENTOR SEARCH ANSWER SET

=> fil ifipat; d que nos l158

FILE 'IFIPAT' ENTERED AT 12:39:11 ON 02 SEP 2008
 COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE COVERS 1950 TO PATENT PUBLICATION DATE: 28 Aug 2008 (20080828/PD)
 FILE LAST UPDATED: 29 Aug 2008 (20080829/ED)
 HIGHEST GRANTED PATENT NUMBER: US7418737
 HIGHEST APPLICATION PUBLICATION NUMBER: US20080209606
 UNITERM INDEXING IS AVAILABLE IN THE IFIUIDB FILE
 UNITERM INDEXING LAST UPDATED: 15 Aug 2008 (20080815/UP)
 INDEXING CURRENT THROUGH PAT PUB DATE: 29 Jul 2008 (20080729/PD)

IFIPAT reloaded on 7/27/08. Enter HELP RLOAD for details.

```

L3      1 SEA FILE=REGISTRY ABB=ON 1404-26-8
L4      STR
L7      1933 SEA FILE=REGISTRY SSS FUL L4
L55     767 SEA FILE=REGISTRY ABB=ON L7 AND (IFIPAT/LC OR USPATFULL/LC OR
        SCISEARCH/LC)
L127    3203 SEA FILE=IFIPAT ABB=ON GRAM(W) (POS OR POSITIVE)
L128    19 SEA FILE=IFIPAT ABB=ON ACTINOBACTER?
L129    670 SEA FILE=IFIPAT ABB=ON ACTINOMYCET?
L130    3 SEA FILE=IFIPAT ABB=ON ACTINOPLANET?
L131    0 SEA FILE=IFIPAT ABB=ON ACTINOSYNNEMAT?
L132    0 SEA FILE=IFIPAT ABB=ON ARSENICOCC?
L133    512 SEA FILE=IFIPAT ABB=ON CORYNEFORM
L134    1993 SEA FILE=IFIPAT ABB=ON CORYNEBACTER?
L135    721 SEA FILE=IFIPAT ABB=ON MICROCOCC?
L136    263 SEA FILE=IFIPAT ABB=ON MICROMONOSPOR?
L137    1 SEA FILE=IFIPAT ABB=ON MICROTHRIX
L138    851 SEA FILE=IFIPAT ABB=ON NOCARDI?
L139    37 SEA FILE=IFIPAT ABB=ON PSEUDONOCARDI?
L140    39 SEA FILE=IFIPAT ABB=ON STREPTOSPORANG?
L141    9006 SEA FILE=IFIPAT ABB=ON BACILLUS OR BACILLALES
L142    25 SEA FILE=IFIPAT ABB=ON ACIDAMINOCOCC?
L143    44 SEA FILE=IFIPAT ABB=ON AEROCOCC?
L144    2262 SEA FILE=IFIPAT ABB=ON CLOSTRIDI?
L145    355 SEA FILE=IFIPAT ABB=ON EUBACTERI?
L146    1 SEA FILE=IFIPAT ABB=ON HALANAEROBI?
L147    8 SEA FILE=IFIPAT ABB=ON LACHNOSPIR?
L148    1243 SEA FILE=IFIPAT ABB=ON MYCOPLASMA?
L149    0 SEA FILE=IFIPAT ABB=ON PARASPOROBACTER?
L150    181 SEA FILE=IFIPAT ABB=ON PEPTOSTREPTOCOCC?
L151    4607 SEA FILE=IFIPAT ABB=ON STREPTOCOCC?
L152    3329 SEA FILE=IFIPAT ABB=ON MYCOBACTER?
L153    735 SEA FILE=IFIPAT ABB=ON M TUBERCULOSIS
L154    4 SEA FILE=IFIPAT ABB=ON L3
L155    39 SEA FILE=IFIPAT ABB=ON FTSZ
L156    8 SEA FILE=IFIPAT ABB=ON L55
L158    0 SEA FILE=IFIPAT ABB=ON L156 AND (L127 OR L128 OR L129 OR L130
        OR L131 OR L132 OR L133 OR L134 OR L135 OR L136 OR L137 OR
        L138 OR L139 OR L140 OR L141 OR L142 OR L143 OR L144 OR L145
        OR L146 OR L147 OR L148 OR L149 OR L150 OR L151 OR L152 OR
        L153 OR L154 OR L155)

```

=> dup rem 1192,1193

FILE 'HCAPLUS' ENTERED AT 12:39:12 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:39:12 ON 02 SEP 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
 PROCESSING COMPLETED FOR L192
 PROCESSING COMPLETED FOR L193
 L194 33 DUP REM L192 L193 (1 DUPLICATE REMOVED)
 ANSWERS '1-7' FROM FILE HCAPLUS
 ANSWERS '8-33' FROM FILE USPATFULL

=> d ibib abs hitind hitstr 1-7; d ibib abs kwic hitstr 8-33; fil hom

L194 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2001:129905 HCAPLUS Full-text
 DOCUMENT NUMBER: 134:158469
 TITLE: Methods of bacterial gene function determination using
 peptide nucleic acids
 INVENTOR(S): Nielsen, Peter E.; Good, Liam
 PATENT ASSIGNEE(S): Den.
 SOURCE: U.S., 34 pp., Cont.-in-part of U. S. Ser. 932,140.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6190866	B1	20010220	US 1998-49190	19980327
US 6300318	B1	20011009	US 1997-932140	19970916

PRIORITY APPLN. INFO.: US 1997-932140 A2 19970916

AB Methods of and compns. for killing or inhibiting the growth of a bacteria are disclosed. Methods of determining bacterial gene functions are also disclosed. The methods comprise the use of peptide nucleic acid that is targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more sep. antibiotics.

IC ICM C12Q001-68

INCL 435006000

CC 3-1 (Biochemical Genetics)
 Section cross-reference(s): 10


IT Antibiotic resistance
 Antimicrobial agents
 Bacteria (Eubacteria)
 Candida albicans
 Enterococcus hirae
 Fungicides
 Klebsiella pneumoniae
 Proteus vulgaris
 Staphylococcus aureus
 Streptococcus pyogenes
 (methods of bacterial gene function determination using peptide nucleic acids)

IT 58026-12-3 72648-80-7 85301-38-8 163081-06-9 221362-47-6
 221362-48-7 325853-57-4
 RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (methods of bacterial gene function determination using peptide nucleic acids)


IT 221362-47-6 221362-48-7
 RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (methods of bacterial gene function determination using peptide nucleic acids)

RN 221362-47-6 HCAPLUS

CN 5-Pyrimidineacetic acid, 2-[[[1,1-dimethylethoxy]carbonyl]amino]-1,4-dihydro-4-oxo-, methyl ester (CA INDEX NAME)



RN 221362-48-7 HCAPLUS
 CN 5-Pyrimidineacetic acid, 2-[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dihydro-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L194 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:501125 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:441630

TITLE: Synthesis and antimicrobial activity of disubstituted pyridine and 1-substituted propynyl carbamates

AUTHOR(S): Yao, Bin; Sun, Wensheng; Jin, Yongsheng; Xu, Bingxiang
 CORPORATE SOURCE: Department of Organic Chemistry, School of Pharmacy, Second Military Medical University, Shanghai, 200433, Peop. Rep. China

SOURCE: Dier Junyi Daxue Xuebao (2005), 26(2), 186-188

CODEN: DJXUE5; ISSN: 0258-879X

PUBLISHER: Dier Junyi Daxue Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

OTHER SOURCE(S): CASREACT 146:441630

AB Disubstituted pyridine and 1-substituted propynyl carbamates were synthesized and their antimicrobial activities were studied in search for more potent and less toxic antimicrobial agents. The compds. were synthesized through a process involving electrophilic and nucleophilic substitution. Antimicrobial test in vitro was determined with 13 kinds of common mildew and bacteria (*Aspergillus niger*, *A. flavus*, *A. versicolor*, *Trichoderma viride*, *Paecilomyces variotii* Bainier, *Chaetomium globosum*, *Penicillium citrinum*, *Cladochytrium clodosporium*, *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas fluorescens*, *Bacillus fluorescens*, and *B. megatherium*). The chemical structures of all compds. were determined by IR, ¹HNMR, and elementary anal. Seven disubstituted pyridine and 1-substituted propynyl carbamates obtained were firstly reported. All compds. showed antimicrobial activity, preferably carbonothioic acid S-(1-oxido-2-pyridinyl) O-(-2-propynyl) ester (I) which had more potent activity compared with the that of 3-iodo-2-propynyl N-butylcarbamate (IPBC). MIC of I was (2-30) x 10⁻⁶ g/mL. I should be further studied.

CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 10

IT Anti-infective agents

Antibacterial agents

Antimicrobial agents

Bacillus fluorescens
Bacillus megaterium

Fungicides

Infection

Mycosis


Pseudomonas fluorescens

(preparation of (pyridinyl)carbamic acid propynyl esters, carbonothioic


acid

S-[(oxido)pyridinyl] O-(propynyl) ester and (pyridinyl)carbamic acid (iodo)propynyl esters and study of their activity as antimicrobial agents)

- IT 136099-73-5P 934626-09-2P, (5-Bromo-6-methyl-2-pyridinyl)carbamic acid 3-iodo-2-propynyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (pyridinyl)carbamic acid (iodo)propynyl esters and study of their activity as antimicrobial agents)
- IT 136099-72-4P, (6-Ethyl-5-iodo-2-pyridinyl)carbamic acid 2-propynyl ester 934626-07-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridinyl)carbamic acid propynyl esters and study of their activity as antimicrobial agents)
- IT 136099-73-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (pyridinyl)carbamic acid (iodo)propynyl esters and study of their activity as antimicrobial agents)
- RN 136099-73-5 HCAPLUS
- CN Carbamic acid, N-(6-ethyl-5-iodo-2-pyridinyl)-, 3-iodo-2-propyn-1-yl ester (CA INDEX NAME)



- IT 136099-72-4P, (6-Ethyl-5-iodo-2-pyridinyl)carbamic acid 2-propynyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyridinyl)carbamic acid propynyl esters and study of their activity as antimicrobial agents)
- RN 136099-72-4 HCAPLUS
- CN Carbamic acid, N-(6-ethyl-5-iodo-2-pyridinyl)-, 2-propyn-1-yl ester (CA INDEX NAME)



L194 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:236029 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 139:81899

TITLE: Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-Positive antibacterial activity

AUTHOR(S): Jarvest, Richard L.; Berge, John M.; Brown, Pamela; Houge-Frydrych, Catherine S. V.; O'Hanlon, Peter J.; McNair, David J.; Pope, Andrew J.; Rittenhouse, Stephen

CORPORATE SOURCE: GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1265-1268

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:81899

AB Conformationally restricted analogs of the central linker unit of bacterial methionyl tRNA synthetase inhibitors were prepared. The (1S,2R)-cyclopentylmethyl moiety was identified as the preferred cyclic linker, with significant diastereo- and enantioselectivity of activity. Combination of this linker with an optimal substituted aryl right-hand side has resulted in a compound with exceptionally good antibacterial activity against staphylococci and enterococci, including antibiotic resistant strains.

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)

Section cross-reference(s): 7

IT Antibacterial agents

Enterococcus faecalis

Gram-positive bacteria

Staphylococcus aureus

(conformational restriction of methionyl tRNA synthetase inhibitors

leading to analogs with potent inhibition and excellent gram-Pos.

antibacterial activity)

IT 4403-69-4 6287-38-3, 3,4-Dichlorobenzaldehyde 23153-61-9 95049-01-7

151294-66-5 151379-87-2 158414-41-6 158414-43-8 248607-85-4

248607-95-6 371115-17-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(conformational restriction of methionyl tRNA synthetase inhibitors

leading to analogs with potent inhibition and excellent gram-Pos.

antibacterial activity)

IT 248607-85-4

RL: RCT (Reactant); RACT (Reactant or reagent)


(conformational restriction of methionyl tRNA synthetase inhibitors

leading to analogs with potent inhibition and excellent gram-Pos.

antibacterial activity)

RN 248607-85-4 HCAPLUS

CN Carbamic acid, (4-ethoxy-2-quinolinyl)-, 2,2,2-trichloroethyl ester (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L194 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:293651 HCAPLUS Full-text
 DOCUMENT NUMBER: 136:325706
 TITLE: Preparation of pleuromutilin derivatives as antibacterial agents
 INVENTOR(S): Elder, John Stephen; Forrest, Andrew Keith; Jarvest, Richard Lewis; Sheppard, Robert John
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030929	A1	20020418	WO 2001-EP11603	20011008
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002018215	A	20020422	AU 2002-18215	20011008
EP 1351959	A1	20031015	EP 2001-986687	20011008
EP 1351959	B1	20050601		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004511482	T	20040415	JP 2002-534315	20011008
EP 1538150	A1	20050608	EP 2005-75608	20011008
EP 1538150	B1	20070627		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			
AT 296824	T	20050615	AT 2001-986687	20011008
PT 1351959	T	20050930	PT 2001-986687	20011008
ES 2240544	T3	20051016	ES 2001-986687	20011008
AT 365738	T	20070715	AT 2005-75608	20011008
ES 2288284	T3	20080101	ES 2005-75608	20011008
EP 1889845	A1	20080220	EP 2007-110721	20011008
R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR			
US 20040024059	A1	20040205	US 2003-399023	20030725

US 6900345 B2 20050531
 US 20050096357 A1 20050505
 US 7160907 B2 20070109


US 2004-4751 20041203

PRIORITY APPLN. INFO.:


GB 2000-24811 A 20001010
 EP 2001-986687 A3 20011008
 EP 2005-75608 A3 20011008
 WO 2001-EP11603 W 20011008
 US 2003-399023 A1 20030725

OTHER SOURCE(S): CASREACT 136:325706; MARPAT 136:325706

GI



I



II

AB Pleuromutilin derivs., such as I or II [R1 = (substituted) heterocycle, alkyl, cycloalkyl, heteroaryl; R2 = vinyl, Et; R3 = H, OH, F; R4 = H, F; R5, R6 = H, OH; R5R6 = oxo], were prepared for the use in antibacterial therapy. Thus, reaction between 2-(methylsulfonyl)ethyl chloroformate and (3R)-3-deoxy-11-deoxy-3-methoxy-11-oxo-4-epimutilin provided (3R)-3-deoxy-11-deoxy-3-methoxy-11-oxo-4-epimutilin 14-[N-(2-methylsulfonylethoxycarbonyl)]carbamate, which on selective oxidation of 3-methoxyl group and simultaneous reduction of 11-oxo group, afforded pleuromutilin derivative I [R1 = CH₂CH₂SO₂Me; R2 = CH:CH₂; R3, R4 = H; R5R6 = O (III)]. The prepared pleuromutilin derivs. were tested for antibacterial activity against *Staphylococcus aureus* Oxford, *Streptococcus pneumoniae* 1629, *Moraxella catarrhalis* 502 and *Haemophilus influenzae* Q1, e.g. III MIC = ≤4 µg/mL (*S. aureus*).

IC ICM C07D453-02

ICS C07C271-06; C07D205-04; C07D295-00; C07D213-04; C07D211-00

CC 30-20 (Terpenes and Terpenoids)

Section cross-reference(s): 1, 34

IT *Haemophilus influenzae*

Moraxella catarrhalis

Staphylococcus aureus

Streptococcus pneumoniae

(antibacterial activity of pleuromutilin alkoxycarbonyl carbamate derivs. against)

IT	18620-79-6P	51424-90-9P	61273-19-6P	61273-20-9P	81654-96-8P
	109384-24-9P	125653-58-9P	137682-88-3P	262444-52-0P	352514-21-7P
	387845-11-6P	387845-36-5P	412277-86-2P	412277-88-4P	
	412277-90-8P	412277-92-0P	412277-94-2P	412277-96-4P	
	412277-98-6P	412278-00-3P	412278-02-5P	412278-05-8P	412278-08-1P
	412278-12-7P	412278-14-9P	412278-16-1P	412278-20-7P	412278-22-9P
	412278-24-1P	412278-26-3P	412278-28-5P	412278-30-9P	412278-32-1P
	412278-34-3P	412278-37-6P	412278-39-8P	412278-41-2P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pleuromutilin alkoxycarbonyl carbamate derivs. as antibacterial agents)

IT 412277-90-8P 412277-92-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pleuromutilin alkoxy carbonyl carbamate derivs. as antibacterial agents)


RN 412277-90-8 HCAPLUS

CN 4-Pyrimidinecarboxylic acid, 2,6-bis[[[1,1-dimethylethoxy)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 412277-92-0 HCAPLUS

CN Carbamic acid, [4-[(2,2-dimethyl-1-oxopropyl)amino]-6-(hydroxymethyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L194 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:122965 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:167530

TITLE: Preparation of mutilin 14-ester derivatives as antibacterial agents

INVENTOR(S): Aitken, Steven; Brooks, Gerald; Dabbs, Steven; Frydrych, Colin Henry; Howard, Steven; Hunt, Eric

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012199	A1	20020214	WO 2001-EP8949	20010802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


AU 2001091725	A	20020218	AU 2001-91725	20010802
EP 1309565	A1	20030514	EP 2001-971856	20010802
EP 1309565	B1	20080409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004505953	T	20040226	JP 2002-518177	20010802
AT 391715	T	20080415	AT 2001-971856	20010802
US 20040058937	A1	20040325	US 2003-343596	20031017
US 6878704	B2	20050412		

PRIORITY APPLN. INFO.:


GB 2000-18951	A	20000803
WO 2001-EP8949	W	20010802

OTHER SOURCE(S): MARPAT 136:167530


GI



I



II



III

AB The invention discloses preparation of compds. I and II (R1 = (un)substituted aryl or heteroaryl comprising 5- or 6-membered heteroarom. ring; R2 = vinyl, ethyl; R3 = H, OH, F; R4 = H, F; R5R6 = oxo; R5, R6 = H, OH), for the treatment of bacterial infection. Thus, nalidixic acid was treated with oxalyl chloride and (3R)-3-deoxy-11-deoxy-3-methoxy-11-oxo-4-epimutinin to give III. I were found to have MIC $\leq 4\mu\text{g/mL}$ against *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Moraxella catarrhalis* (no data).

IC ICM C07D239-54

ICS A61K031-505; A61P031-04; C07D239-36; C07D237-24; C07D213-80;
C07D237-28; C07D487-04; C07D471-04; C07D241-24; C07D215-56;
C07D309-38; C07D231-22; C07D239-46; C07D241-26; C07D311-24;
C07D215-48; C07D401-04; C07D401-06; C07D487-06

CC 30-20 (Terpenes and Terpenoids)

Section cross-reference(s): 1, 10

IT Antibacterial agents

Esterification

Moraxella catarrhalis

Staphylococcus aureus

Streptococcus pneumoniae

(preparation of mutilin 14-ester derivs. with antibacterial activity)

IT 1445-55-2P 13721-01-2P 56406-43-0P 65754-04-3P 105652-03-7P
 120276-59-7P 127142-90-9P 186130-63-2P 223481-92-3P 257939-38-1P
 257939-45-0P 257939-46-1P 257939-47-2P 268550-54-5P 268550-55-6P
 397308-56-4P 397308-63-3P 397308-78-0P 397309-34-1P 397309-39-6P
 397309-41-0P 397309-43-2P 397309-45-4P 397309-47-6P 397309-49-8P
 397309-51-2P 397309-53-4P 397309-55-6P 397309-57-8P 397309-59-0P
 397309-62-5P 397309-64-7P 397309-67-0P 397309-69-2P 397309-72-7P
 397309-75-0P 397309-78-3P 397309-81-8P 397309-84-1P
 397309-87-4P 397309-89-6P 397309-91-0P 397309-93-2P 397309-95-4P
 397309-97-6P 397309-99-8P 397310-02-0P 397310-05-3P 397310-08-6P
 397310-11-1P 397310-14-4P 397310-17-7P 397310-20-2P 397310-23-5P
 397310-26-8P 397310-37-1P 397310-78-0P 397310-80-4P 397310-83-7P
 397311-05-6P 397311-08-9P 397311-11-4P 397311-14-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of mutilin 14-ester derivs. with antibacterial activity)

IT 397309-75-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of mutilin 14-ester derivs. with antibacterial activity)

RN 397309-75-0 HCAPLUS
 CN 5-Pyrimidinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dihydro-4-oxo-, (1R,3aR,4R,6S,8R,9R,9aS,10R)-6-ethenyldecahydro-1-methoxy-4,6,9,10-tetramethyl-5-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L194 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:475560 HCAPLUS Full-text
 DOCUMENT NUMBER: 133:109949
 TITLE: Pharmaceutical compositions for treatment of diseased tissues
 INVENTOR(S): Lee, Clarence C.; Lee, Feng-Min
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2000040269	A2	20000713	WO 2000-US191	20000105
WO 2000040269	A3	20001130		
W: AU, CA, CN, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.:

US 1999-114906P P 19990105

AB A method to treat diseased tissue is provided where a cytotoxic compound is administered to a patient in need of treatment in combination with an immunostimulant. Diseased cells and/or infectious microbes/viruses are killed by the cytotoxic compound in the presence of the immunostimulant. The cell components including cellular contents and cell membrane fragments are presented by the immunostimulant to the host animal as antigens to stimulate the immune responses toward other diseased cells of the same type(s), that either remain in the vicinity or reside in distant tissues or organs. The cytotoxic mol. and immunostimulant are preferably applied locally at high concns., either sequentially or, preferably, simultaneously. For example, the composition can be administered directly to a target cancer. The composition can be prepared in various forms, such as a paste, a time release molded solid shape, a solution, a mixture with emulsifier, etc. Alternatively, the cytotoxic mol. and immunostimulant are applied in sequence.

IC ICM A61K045-06

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2, 15

IT Bacteria (Eubacteria)

Bordetella pertussis

Corynebacterium parvum

Mycobacterium avium

Mycobacterium bovis

Mycobacterium fortuitum

Mycobacterium kansasii

Mycobacterium phlei

Mycobacterium smegmatis

Mycobacterium tuberculosis

Mycobacterium vaccae

Nocardia asteroides

Nocardia rubra

Rhodococcus

(antigens of; pharmaceutical compns. for treatment of diseased tissues)

IT 50-35-1, Thalidomide 50-76-0, Dactinomycin 50-81-7, Ascorbic acid, biological studies 51-21-8, 5-Fluorouracil 51-79-6, Urethan 52-67-5, Penicillamine 53-19-0, Mitotane 54-42-2, Idoxuridine 54-62-6, Aminopterin 55-86-7, Nitrogen mustard 56-53-1, Diethylstilbestrol 56-75-7D, Amphenicol, derivs. 58-40-2, Prazine 59-14-3, Budr 59-30-3D, Folic acid, analogs 60-00-4, Edta, biological studies 60-54-8D, Tetracycline, derivs. 62-33-9, Calcium disodium edetate 64-02-8, Sodium edetate 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 67-43-6, Pentetic acid 67-63-0, Isopropanol, biological studies 67-68-5, Dmsol, biological studies 68-76-8, Triaziquone 69-33-0, Tubercidin 70-51-9, Deferoxamine 73-03-0, Cordycepin 75-75-2D, Methanesulfonic acid, derivs. 112-24-3 120-73-0D, Purine, analogs 121-76-6 122-79-2, Phenylacetate 127-07-1, Hydroxyurea 127-07-1D, Hydroxyurea, derivs. 139-33-3, Disodium edetate 150-38-9, Trisodium edetate 151-56-4, Aziridine, biological studies 289-95-2D, Pyrimidine, analogs 302-79-4, Tretinoin 304-55-2, Succimer 320-67-2, 5-Azacytidine 366-70-1, Matulane 459-86-9, Mitoguanone 477-30-5, Demecolcine 518-28-5, Podophyllotoxin 569-57-3, Chlorotrianisene 636-47-5, Stallimycin 642-83-1, Aceglatone 645-05-6, Altretamine 671-16-9, Procarbazine 768-94-5, Amantadine 801-52-5, Porfiromycin 1174-11-4, Xenazoic acid

1310-73-2, Sodium hydroxide, biological studies 1402-44-4, Actinomycin F1 1404-00-8D, Mitomycin, derivs. 1508-45-8, Podophyllinic acid 2-ethylhydrazide 1910-68-5, Methisazone 1954-28-5, Etoglucid 2353-33-5 3572-60-9, Amidinomycin 3731-59-7, Moroxydine 3733-81-1, Defosfamide 3819-34-9, Phenamet 3930-19-6, Streptonigrin 4533-39-5, Nitracrine 4803-27-4, Anthramycin 5300-03-8, 9-cis-Retinoic acid 7440-06-4D, Platinum, complexes, biological studies 7647-01-0, Hydrochloric acid, biological studies 7647-17-8, Cesium chloride, biological studies 7664-93-9, Sulfuric acid, biological studies 7761-88-8, Silver nitrate, biological studies 9001-63-2, Lysozyme 9014-02-2, Zinostatin 9015-68-3, Asparaginase 10318-26-0, Mitolactol 11006-77-2, Statolon 11056-06-7D, Bleomycin, derivs. 12111-24-9, Calcium trisodium pentetate 13010-20-3D, Nitrosourea, derivs. 13311-84-7, Flutamide 13392-28-4, Rimantadine 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 15663-27-1, Cisplatin 18378-89-7, Plicamycin 20537-88-6, Amifostine 20830-81-3, Daunorubicin 21416-67-1, Razoxane 22668-01-5, Radinyl 23214-92-8, Doxorubicin 24967-93-9, Chondroitin sulfate A 26657-95-4, Dipalmitoylglycerol 26833-87-4, Homoharringtonine 27314-97-2, Tirapazamine 27762-78-3, Kethoxal 27778-66-1, Tenuazonic acid 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 36703-88-5, Isoprinosine 36791-04-5, Ribavirin 38819-10-2, Guanine arabinoside 39389-47-4, Distamycin 41992-23-8, Spirogermanium 50264-69-2, Lonidamine 51264-14-3, Amacrine 52205-73-9, Estramustine phosphate sodium 53678-77-6, Muramyl dipeptide 53783-83-8, Tromantidine 53910-25-1, Pentostatin 56741-95-8, Bopirimine 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58337-35-2, Elliptinium acetate 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 63585-09-1, Foscarnet sodium 63612-50-0, Nilutamide 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 66676-88-8D, Aclacinomycin, derivs. 70052-12-9, Eflornithine 72732-56-0, Piritrexim 74853-75-1 74913-06-7D, Chromomycin, derivs. 75706-12-6, SU101 78186-34-2, Bisantrene 80738-43-8D, Lincosamide, derivs. 82413-20-5, Droloxifene 82952-64-5, Trimetrexate glucuronate 83314-01-6, Bryostatins 1 84088-42-6, Linomide 85622-93-1, Temozolomide 89778-26-7, Toremifene 95058-81-4, Gemcitabine 96389-68-3, Crisnatol 97682-44-5, Irinotecan 97919-22-7 98631-95-9, Sobuzoxane 98930-34-8 107868-30-4, Exemestane 110042-95-0, Acemannan 110314-48-2, Adozelesin 112809-51-5, Letrozole 114977-28-5, Docetaxel 115575-11-6, Liarozole 116057-75-1, Idoxifene 120511-73-1, Anastrozole 121181-53-1, Filgrastim 123948-87-8, Topotecan 125317-39-7, Navelbine 126268-81-3, CI-980 127779-20-8, Saquinavir 129618-40-2, Nevirapine 129655-21-6, Bizelesin 133432-71-0, Peldesine 135467-16-2, Octreotide pamoate 136817-59-9, Delavirdine 144849-63-8, Bisnafide 150378-17-9, Indinavir 154361-50-9, Capecitabine 155213-67-5, Ritonavir 159768-75-9, RMP-7 159997-94-1, VX-710 282102-49-2 282102-50-5 282527-39-3 282527-40-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (pharmaceutical compns. for treatment of diseased tissues)

IT 126268-81-3, CI-980

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (pharmaceutical compns. for treatment of diseased tissues)

RN 126268-81-3 HCAPLUS


CN Ethanesulfonic acid, 2-hydroxy-, compd. with ethyl N-[(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]carbamate (1:1) (CA INDEX NAME)

CM 1

CRN 122332-18-7

CMF C17 H19 N5 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 107-36-8

CMF C2 H6 O4 S

HO-CH2-CH2-SO3H

L194 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:338551 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 127:65735

ORIGINAL REFERENCE NO.: 127:12567a,12570a

TITLE: Fungal and bacterial regioselective hydroxylation of pyrimidine heterocycles

AUTHOR(S): Gotor, Vicente; Quiros, Margarita; Liz, Ramon; Frigola, Jordi; Fernandez, Rosa

CORPORATE SOURCE: Laboratorio de Quimica Bioorganica, Facultad de Quimica, Universidad de Oviedo, Oviedo, 33071, Spain

SOURCE: Tetrahedron (1997), 53(18), 6421-6432

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:65735

AB The bacterium *Rhodococcus erythropolis* is employed to hydroxylate the anxiolytic lesopitron, and this bacterium, together with *Agrobacterium* sp. and the fungus *Beauveria bassiana*, are used to extend the field of hydroxylation of heteroarom. compds. to a series of unexplored pyrimidines. Of all the substrates investigated, only Me 4-(2-pyrimidinyl)-1-piperazinecarboxylate was regioselectively hydroxylated by *B. bassiana* at the C-5 position of the pyrimidine ring; in contrast, the bacteria were able to regioselectively oxidize, when free, the C-2 and/or C-4 positions of the pyrimidine moiety of all the substrates tested, up to a maximum of two oxidns.

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))


IT *Beauveria bassiana*

Regiochemistry


Rhodococcus erythropolis

(fungal or bacterial regioselective hydroxylation of pyrimidine

derivs.)
 IT 66-22-8P, Uracil, preparation 108-53-2P, Isocytosine 108-79-2P,
 4,6-Dimethyl-2-pyrimidinol 626-48-2P, 6-Methyluracil
 175991-30-7P 191487-43-1P 191487-44-2P 191487-45-3P
 191487-46-4P 191487-47-5P 191487-48-6P 191487-49-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 175991-30-7P 191487-44-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 175991-30-7 HCAPLUS
 CN Carbamic acid, (1,4-dihydro-4-oxo-2-pyrimidinyl)-, phenylmethyl ester
 (9CI) (CA INDEX NAME)



RN 191487-44-2 HCAPLUS
 CN Carbamic acid, (1,4-dihydro-4-oxo-2-pyrimidinyl)-, methyl ester (9CI) (CA
 INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L194 ANSWER 8 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2008:200837 USPATFULL [Full-text](#)
 TITLE: Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-
 Ylamine Analogues
 INVENTOR(S): Caldwell, Timothy M., Guilford, CT, UNITED STATES
 Chenard, Bertrand L., Waterford, CT, UNITED STATES
 Hodgetts, Kevin J., Killingworth, CT, UNITED STATES
 PATENT ASSIGNEE(S): NEUROGEN CORPORATION, BRANFORD, CT, UNITED STATES (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080175794	A1	20080724
APPLICATION INFO.:	US 2006-883005	A1	20060125 (11)
	WO 2006-US2871		20060125
			20070725 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-647190P	20050125 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: EDWARD ANGELL PALMER & DODGE, LLP, Client: NEUROGEN CORPORATION, P.O. BOX 55874, BOSTON, MA, 02205, US
 NUMBER OF CLAIMS: 38
 EXEMPLARY CLAIM: 1
 LINE COUNT: 3596
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD Chronic inflammatory pain is induced using one of the following protocols:

1. Essentially as described by Bertorelli et al. (1999) Br. J. Pharmacol. 128(6):1252-1258, and Stein et al. (1998) Pharmacol. Biochem. Behav. 31(2):455-51, 200 µl Complete Freund's Adjuvant (0.1 mg heat killed and dried *M. Tuberculosis*) is injected to the rats' hind paw: 100 µl into the dorsal surface and 100 µl into the plantar surface.
 2. Essentially as described by Abbadie et al. (1994) J Neurosci. 14(10):5865-5871 rats are injected with 150 µl of CFA (1.5 mg) in the tibio-tarsal joint.
- IT 3932-97-6, 2,4-Dichloro-5-(trifluoromethyl)pyrimidine 14432-14-5
 52334-81-3, 2-Chloro-5-trifluoromethylpyridine 74784-70-6,
 2-Amino-5-trifluoromethylpyridine 405160-55-6 749258-96-6,
 3-Chloro-4-(trifluoromethyl)pyridazine 868736-42-9, tert-Butyl
 4-chloro-3-formylpyridin-2-ylcarbamate 903872-66-2
 (preparation of substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogs for use in capsaicin VR1 receptor binding assays)
- IT 868736-42-9, tert-Butyl 4-chloro-3-formylpyridin-2-ylcarbamate
 (preparation of substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogs for use in capsaicin VR1 receptor binding assays)
- RN 868736-42-9 USPATFULL
- CN Carbamic acid, (4-chloro-3-formyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 9 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2008:51712 USPATFULL Full-text
 TITLE: ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS
 INVENTOR(S): Hanessian, Stephen, Beaconsfield, CANADA

Szychowski, Janek, Val Belair, CANADA
 Adhikari, Susanta Sekhar, Kankurgachi, INDIA
 Pachamuthu, Kandasamy, Montreal, CANADA
 Migawa, Michael T., Carlsbad, CA, UNITED STATES
 Griffey, Richard H., Vista, CA, UNITED STATES
 Swayze, Eric, Carlsbad, CA, UNITED STATES
 PATENT ASSIGNEE(S): ISIS PHARMACEUTICALS, INC., Carlsbad, CA, UNITED STATES, 92008-7208 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080045468	A1	20080221
APPLICATION INFO.:	US 2007-740998	A1	20070427 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2005-US40364, filed on 7 Nov 2005, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-625440P	20041105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2219	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2"-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Antibiotics are chemical substances produced by various species of microorganisms (bacteria, fungi, actinomycetes) that suppress the growth of other microorganisms and may eventually destroy them. However, common usage often extends the term antibiotics to include synthetic antibacterial agents, such as the sulfonamides, and quinolones, that are not products of microbes. The number of antibiotics that have been identified now extends into the hundreds, . . .

DETD Susceptible organisms generally include those gram positive and gram negative, aerobic and anaerobic organisms whose growth can be inhibited by the compounds of the invention such as Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Proteus, Campylobacter, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shigella, Serratia, Haemophilus, Brucella and other organisms.

DETD It has been found that the compounds of the present invention possess antibacterial activity against a wide spectrum of gram positive and gram negative bacteria, as well as enterobacteria and anaerobes. The compounds, by reason of their in vitro activity, may be used in scrub solutions for surface inhibition of bacterial growth e.g. in sterilization of glassware or as an additive in fabric laundering compositions.

IT	845790-88-7P	845790-89-8P	845790-90-1P	845790-91-2P	845790-92-3P
	845790-96-7P	845790-97-8P	845790-98-9P	845790-99-0P	845791-00-6P
	845883-89-8P	885611-27-8P	885611-28-9P	885611-29-0P	885611-30-3P
	885611-31-4P	885611-32-5P	885611-33-6P	885611-34-7P	885611-35-8P

885611-36-9P 885611-37-0P 885611-38-1P 885611-39-2P 885611-40-5P
 885611-41-6P 885611-42-7P 885611-43-8P 885611-44-9P 885611-45-0P
 885611-46-1P 885611-47-2P 885611-48-3P 885611-49-4P 885611-50-7P
 885611-51-8P 885611-52-9P 885611-53-0P 885611-54-1P
 885611-55-2P 885611-56-3P 885611-57-4P 885611-58-5P 885611-59-6P
 885611-60-9P 885611-61-0P 885611-62-1P 885611-63-2P 885611-64-3P
 885611-65-4P 885611-66-5P 885611-67-6P 885611-68-7P 886193-00-6P

(preparation of antimicrobial deoxystreptamine compds.)


IT 885611-53-0P

(preparation of antimicrobial deoxystreptamine compds.)

RN 885611-53-0 USPATFULL

CN D-Streptamine, 0-2,6-dideoxy-2,6-bis[[(phenylmethoxy)carbonyl]amino]-
 β -L-idopyranosyl-(1 \rightarrow 3)-O-2-O-[2-[[[2-[[(1,1-
 dimethylethoxy)carbonyl]amino]-4-pyridinyl]methyl]amino]ethyl]-5-O-[[(1,1-
 dimethylethyl)dimethylsilyl]- β -D-ribofuranosyl-(1 \rightarrow 5)-O-[2-
 deoxy-2-[[(phenylmethoxy)carbonyl]amino]-4,6-O-[(R)-phenylmethylene]-
 α -D-glucopyranosyl-(1 \rightarrow 4)]-2-deoxy-N,N'-
 bis[[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L194 ANSWER 10 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2006:167882 USPATFULL [Full-text](#)

TITLE: Bis(thio-hydrazide amides) for treatment of hyperplasia
 INVENTOR(S): Sherman, Matthew L., Newton, MA, UNITED STATES
 Vaghefi, Farid, Burlington, MA, UNITED STATES
 Chen, Lan Bo, Lexington, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060142393	A1	20060629
APPLICATION INFO.:	US 2005-226929	A1	20050914 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-610270P	20040916 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA
 ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US
 NUMBER OF CLAIMS: 44
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Page(s)
 LINE COUNT: 2506
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and medical devices for treating a proliferative disorder in a subject, e.g., restenosis in a blood vessel that has been implanted with a stent, employ a bis(thio-hydrazide amide) represented by Structural Formula I or a pharmaceutically acceptable salt or solvate thereof. ##STR1## Y is a covalent bond or an optionally substituted straight chained hydrocarbonyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group.

R.sub.1-R.sub.4 are independently --H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R.sub.1 and R.sub.3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R.sub.2 and R.sub.4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.

R.sub.7-R.sub.8 are independently --H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguanzone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A-mycobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullin; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxanumycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; . . .

IT 128-62-1, Narcosone 2068-78-2, Vincristine sulfate 2226-96-2, Tmpn 17313-52-9, Centaureidin 33927-09-2, Oncocidin al 74588-78-6, D-64131 76129-16-3, IDN 5005 103614-76-2, Halichondrin b 108885-68-3, Taccalonolide a 110417-88-4, Dolastatin 10 115268-43-4, Fijianolide b 124784-31-2, Erbulozole 126268-81-3, Mivobulin isethionate 127943-53-7, Diazoformolide 131727-01-0, Diazonamide a 134742-19-1, NSC-639829 143527-09-7 143842-96-0 149606-27-9, Auristatin pe 149715-96-8, Spongistatin 1 150624-44-5, Spongistatin 2 151852-31-2, Spongistatin 3 152044-53-6, Epothilone a 152044-54-7, Epothilone b 153698-80-7, Spongistatin 5 153745-94-9, Spongistatin 4 156294-36-9 156940-43-1 157207-90-4, Hemiassterlin 158080-65-0, Spongistatin 6 158681-42-6, Spongistatin 7 158734-18-0, Spongistatin 8 158734-19-1, Spongistatin 9 158809-58-6 158976-49-9 160237-10-5 160237-25-2


162084-71-1 162705-22-8, AC-7739 165659-77-8, KAR-2 170489-10-8,
 AM-97 172481-83-3 172837-41-1, Cemadotin hydrochloride 178927-85-0,
 Dz-3358 186256-67-7, Cryptophycin 52 186348-23-2 186692-73-9,
 Epothilone c 186697-74-5, GS-164 189453-10-9, Epothilone d
 191681-63-7, Vitilevuamide 195533-53-0, t-138067 197448-59-2
 200815-37-8, (-)-Phenylahistin 201049-37-8, Epothilone e 201137-02-2
 201417-51-8 204205-90-3, Nascapine 205304-86-5, Tubulysin a
 206866-02-6, Canadensol 208518-52-9, Epothilone f 209345-04-0
 212321-22-7, Epothilone a N-oxide 212953-45-2 213824-30-7,
 Desacetylleutherobin 216753-27-4, RPR-112378 218935-77-4, 3IAABU
 219990-27-9, Epothilone b N-oxide 228266-40-8, HTI-286 233256-51-4,
 FR 182877 252981-50-3, 21-Hydroxyepothilone d 253426-24-3, AC-7700
 256934-83-5, a-289099 259670-83-2, Desmethyleleutherobin 259670-84-3
 259728-67-1, Isoeleutherobin a 259728-79-5, Caribaeoside 259728-87-5,
 Caribaeolin 265646-19-3, Indanocine 265659-39-0 267893-27-6,
 RPR-115781 268749-50-4, 3IAABE 280578-49-6, 21-Aminoepothilone b
 288389-98-0 288389-99-1 288390-00-1 333327-20-1 343346-07-6,
 a-105972 343770-65-0 361431-27-8, Myoseverin b 370581-10-5, D 68144
 372513-31-0, AM-132 372513-32-1, AM-138 373647-71-3, A-204197
 489475-33-4 848866-33-1, T 607 857447-92-8, ABT 751 881184-44-7
 881184-45-8 881186-93-2, SC 12983 881186-98-7, D 82318 881187-05-9,
 D 82317 881187-08-2, A 318315 881187-15-1, D 43411 881187-18-4, D
 68836 881187-21-9, D 68838 881187-24-2, A 259754 881187-27-5, Tub
 245 881187-30-0, NPI 2350 881187-33-3, A 293620 881187-38-8, T
 138026 881187-43-5, DDE 313 881187-49-1, SDZ 268970 881187-55-9,
 SAH 49960 881187-60-6, GS 198 881187-66-2, LS 4559 881187-69-5, LS
 4477 881187-72-0, LS 4578 881187-75-3, LS 4559P
 (bis(thiohydrazide amides) for treatment of hyperplasia)
 IT 126268-81-3, Mivobulin isethionate
 (bis(thiohydrazide amides) for treatment of hyperplasia)
 RN 126268-81-3 USPATFULL
 CN Ethanesulfonic acid, 2-hydroxy-, compd. with ethyl N-[(2S)-5-amino-1,2-
 dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]carbamate (1:1) (CA
 INDEX NAME)

CM 1

CRN 122332-18-7

CMF C17 H19 N5 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 107-36-8

CMF C2 H6 O4 S



L194 ANSWER 11 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2006:125299 USPATFULL Full-text
 TITLE: Drug efflux pump inhibitor
 INVENTOR(S): Nakayama, Kiyoshi, Funabashi-shi, JAPAN
 Ohtsuka, Masami, Tokyo, JAPAN
 Kawato, Haruko, Tokyo, JAPAN
 Watkins, William, Sunnyvale, CA, UNITED STATES
 Zhang, Jason, Foster City, CA, UNITED STATES
 Palme, Monica, San Jose, CA, UNITED STATES
 Cho, Aesop, Mountain View, CA, UNITED STATES
 PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Tokyo, JAPAN
 (non-U.S. corporation)
 Trine Pharmaceuticals, Inc., Waltham, MA, UNITED STATES
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060106034	A1	20060518
APPLICATION INFO.:	US 2005-320229	A1	20051229 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-842234, filed on 26 Apr 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE PLACE, RESTON, VA, 20191, US		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7042		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): ##STR1## wherein, R.sup.1 and R.sup.2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W.sup.1 represents --CH.dbd.CH--, --CH.sub.2O--, --CH.sub.2CH.sub.2-- or the like; R.sup.3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R.sup.4 represents hydrogen atom, a group of --OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R.sup.5 represents a cyclic alkyl group, an aryl group or the like); W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)-(R.sup.8 and R.sup.9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W.sup.2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . in 1980 by the group of Levy, and the discovery was noted as a major factor of the resistance to tetracycline (L. McMurtry, Proc. Natl. Acad. Sci. U.S.A., 77, 3974, 1980). Furthermore, based on recent researches, the presence of multidrug-excreting drug efflux pumps was reported in Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus bacteria, Diplococcus pneumoniae, and Neisseria gonorrhoeae. Four multidrug efflux pumps have so far been reported as homological drug efflux pumps deriving from Pseudomonas aeruginosa, and

they have been considered as a cause of low drug sensitivity inherent to *Pseudomonas aeruginosa* (K. Poole et al., J. Bacteriol., 175, 7363, . . .

DETD Kinds of microbial infections that are applicable by the medicament of the present invention are not particularly limited. Bacteria are suitable as target microorganisms. The medicament of the present invention can be used for various infections by microorganisms including Gram-positive or Gram-negative bacteria, aerobic or anaerobic bacteria and the like. The medicament of the present invention can most suitably be used for infections by *Pseudomonas aeruginosa* with acquired resistance to one or more antimicrobial agents, or infections by *Pseudomonas aeruginosa* with low sensitivity to antimicrobial agents. The medicament of the . . .

IT 62-56-6, Thiourea, reactions 64-17-5, Ethanol, reactions 74-88-4, Iodomethane, reactions 75-65-0, tert-Butanol, reactions 77-78-1, Dimethyl sulfate 79-04-9, Chloroacetyl chloride 79-44-7, N,N-Dimethylcarbonyl chloride 85-44-9, 1,3-Isobenzofurandione 96-32-2, Methyl bromoacetate 98-09-9, Benzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 98-80-6, Phenylboronic acid 100-39-0, Benzyl bromide 107-97-1, Sarcosine 108-00-9, N,N-Dimethylethylenediamine 108-24-7, Acetic anhydride 109-01-3, N-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 124-41-4, Sodium methoxide 124-63-0, Methanesulfonyl chloride 136-95-8, 2-Aminobenzothiazole 141-43-5, 2-Aminoethanol, reactions 142-25-6, N,N'-Trimethylethylenediamine 144-48-9, Iodoacetamide 151-18-8, 2-Cyanoethylamine 280-57-9, 1,4-Diazabicyclo[2.2.2]octane 302-01-2, Hydrazine, reactions 358-23-6, Trifluoromethanesulfonyl anhydride 359-07-9, 2-Bromo-1,1-difluoroethane 530-62-1, N,N'-Carbonyldiimidazole 541-41-3, Ethyl chloroformate 542-28-9, δ -Valerolactone 624-76-0, Iodoethanol 762-49-2, 1-Bromo-2-fluoroethane 816-40-0, 1-Bromo-2-butanone 824-94-2, 4-Methoxybenzyl chloride 867-13-0, Ethyl diethylphosphonoacetate 1118-68-9, Dimethylaminoacetic acid 1122-54-9, 4-Acetylpyridine 1122-96-9, 4-Methoxypyridine N-oxide 1189-71-5, Chlorosulfonyl isocyanate 1795-01-3, 3-Ethylthiophene 1943-83-5, 2-Chloroethyl isocyanate 2055-46-1, 3,4,5,6-Tetrahydro-2-pyrimidinethiol 2295-31-0, 2,4-Thiazolidinedione 2356-16-3 2508-29-4, 5-Amino-1-pentanol 2524-64-3, Diphenylphosphoryl chloride 3019-25-8 3019-71-4, Trichloroacetyl isocyanate 3144-09-0, Methanesulfonamide 3303-84-2, Boc- β -alanine 3699-66-9, Triethyl 2-phosphonopropionate 3731-51-9, 2-(Aminomethyl)pyridine 4138-26-5, Nipecotamide 4595-60-2, 2-Bromopyrimidine 4637-24-5, Dimethylformamide dimethyl acetal 5292-43-3, tert-Butyl bromoacetate 5327-32-2 5382-16-1, 4-Hydroxypiperidine 5469-26-1, 1-Bromopinacolone 5717-37-3, (Carbomethoxyethylidene)triphenylphosphorane 6859-99-0, 3-Hydroxypiperidine 7664-41-7, Ammonia, reactions 7677-24-9, Trimethylsilyl cyanide 7803-49-8, Hydroxylamine, reactions 13010-19-0, 3-Chloropropyl isocyanate 13616-37-0 15128-89-9 15781-70-1, Bis(2,4,6-trichlorophenyl)malonate 16872-11-0, Tetrafluoroboric acid 16982-21-1 18162-48-6, tert-Butyldimethylsilyl chloride 21655-48-1, cis-2,6-Dimethylpiperazine 21901-40-6 22398-14-7, Dimethyl methoxymethylenemalonate 22795-99-9, (S)-(-)-2-Aminomethyl-1-ethylpyrrolidine 24424-99-5, Di-tert-butyl dicarbonate 26386-88-9, Diphenylphosphoryl azide 26628-22-8, Sodium azide 27219-07-4, 5-(tert-Butoxycarbonylamino)valeric acid 27532-96-3, Glycine tert-butyl ester hydrochloride 29858-07-9, Magnesium dibromide diethyl etherate 31460-03-4 35000-38-5, (tert-Butoxycarbonylmethylene)triphenylphosphorane 50541-93-0,

	1-Benzyl-4-piperidinamine	58479-61-1,	tert-Butyldiphenylsilyl chloride	
	62414-68-0	63052-91-5	66196-93-8	74370-93-7
	4-Oxo-1-(tert-butoxycarbonyl)piperidine	79932-19-7	88512-14-5,	79099-07-3,
	3,4-Dihydroxypiperidine hydrochloride	88738-78-7,	Bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate	90181-20-5
	90203-05-7, N,N-Dimethyl-N-(3-piperidylmethyl)amine	90354-15-7		
	93107-30-3	97745-69-2	108787-91-3	111279-72-2
	Pyridine-3-boronic acid 1,3-propanediol cyclic ester	132549-38-3		131534-65-1,
	132958-72-6	136088-69-2	149168-07-0	155784-47-7
	183483-09-2, 3-Carboxymethylpiperidine-1-carboxylic acid tert-butyl ester			156589-83-2
	198976-43-1	211940-29-3	474678-70-1	474678-92-7
	475058-41-4	475058-42-5	475058-43-6	475058-44-7
	475060-40-3	475060-41-4	475060-42-5	475060-43-6
	475060-45-8	475060-46-9	475060-47-0	475060-48-1
	475060-50-5	475060-51-6	475061-52-0	475061-54-2
	475062-49-8	475063-58-2,	(E)-2-(2-tert-Butoxycarbonylaminothiazol-5-yl)-3-pyridin-4-yl-2-propenoic acid ethyl ester	475063-59-3,
			(E)-2-(2-tert-Butoxycarbonylaminothiazol-5-yl)-3-pyridin-4-yl-2-propenoic acid	475063-60-6
			475063-61-7	475084-41-4
			(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)	
IT	1147-76-8P	3544-43-2P,	(2-Dimethylaminoacetyl)amino)acetic acid	
	5445-73-8P	6221-13-2P	7778-42-9P,	Sulfamoyl chloride
	21426-18-6P	30235-28-0P	36057-44-0P	53764-72-0P
	60343-28-4P	63273-48-3P	63984-03-2P	78585-25-8P
	90765-02-9P	91660-69-4P	91660-72-9P	119036-36-1P
	134848-96-7P	135716-08-4P,	4-(Ethoxycarbonylmethylene)-1-(tert-butoxycarbonyl)piperidine	135716-09-5P
			143900-43-0P	153493-64-2P
	155789-92-7P	169458-04-2P,	Piperidin-4-yl-acetic acid ethyl ester hydrochloride	184154-42-5P
			211942-98-2P	301222-66-2P
	422280-28-2P	474678-13-2P	474678-15-4P	474678-16-5P
	475057-67-1P	475057-68-2P	475057-69-3P	475057-70-6P
	475057-72-8P	475057-73-9P	475057-74-0P	475057-75-1P
	475057-77-3P	475057-78-4P	475057-79-5P	475057-80-8P
	475057-82-0P	475057-83-1P	475057-84-2P	475057-85-3P
	475057-87-5P	475057-88-6P	475057-89-7P	475057-90-0P
	475057-92-2P	475057-93-3P	475057-94-4P	475057-95-5P
	475057-97-7P	475057-98-8P	475057-99-9P	475058-00-5P
	475058-02-7P	475058-03-8P	475058-04-9P	475058-05-0P
	475058-07-2P	475058-08-3P	475058-09-4P	475058-10-7P
	475058-12-9P	475058-13-0P	475058-14-1P	475058-15-2P
	475058-17-4P	475058-18-5P	475058-19-6P	475058-20-9P
	475058-22-1P	475058-23-2P	475058-24-3P	475058-25-4P
	475058-27-6P	475058-28-7P	475058-29-8P	475058-30-1P
	475058-32-3P	475058-33-4P	475058-34-5P	475058-35-6P
	475058-37-8P	475058-38-9P	475058-39-0P	475059-47-3P
	475059-49-5P	475059-50-8P	475059-51-9P	475059-52-0P
	475059-54-2P	475059-55-3P	475059-56-4P	475059-57-5P
	475059-59-7P	475059-60-0P	475059-61-1P	475059-62-2P
	475059-64-4P	475059-65-5P	475059-66-6P	475059-67-7P
	475059-69-9P	475059-70-2P	475059-71-3P	475059-72-4P
	475059-74-6P	475059-75-7P	475059-76-8P	475059-77-9P
	475059-79-1P	475059-80-4P	475059-81-5P	475059-82-6P
	475059-84-8P	475059-85-9P	475059-86-0P	475059-87-1P
	475059-89-3P	475059-90-6P	475059-91-7P	475059-92-8P
	475059-94-0P	475059-95-1P	475059-96-2P	475059-97-3P
	475059-99-5P	475060-00-5P	475060-01-6P	475060-02-7P
	475060-03-8P	475060-04-9P	475060-05-0P	475060-06-1P
	475060-08-3P	475060-09-4P	475060-10-7P	475060-11-8P
	475060-13-0P	475060-14-1P	475060-15-2P	475060-16-3P
				475060-17-4P

475060-18-5P 475060-20-9P 475060-21-0P 475060-22-1P 475060-26-5P 475060-27-6P
 475060-23-2P 475060-24-3P 475060-25-4P 475060-31-2P 475060-32-3P
 475060-28-7P 475060-29-8P 475060-30-1P 475060-33-4P 475060-37-8P
 475060-33-4P 475060-34-5P 475060-35-6P 475060-36-7P 475060-37-8P
 475060-38-9P 475060-39-0P 475061-03-1P 475061-04-2P 475061-05-3P
 475061-06-4P 475061-07-5P 475061-08-6P 475061-09-7P 475061-10-0P
 475061-11-1P 475061-12-2P 475061-13-3P 475061-14-4P 475061-15-5P
 475061-16-6P 475061-17-7P 475061-18-8P 475061-19-9P 475061-20-2P
 475061-21-3P 475061-22-4P 475061-23-5P 475061-25-7P 475061-26-8P
 475061-29-1P 475061-31-5P 475061-33-7P 475061-36-0P 475061-39-3P
 475061-41-7P 475061-43-9P 475061-46-2P 475061-48-4P 475062-02-3P


(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

IT 90101-20-5

(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

RN 90101-20-5 USPATFULL

CN Carbamic acid, N-(4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 475060-01-6P 475060-22-1P

(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

RN 475060-01-6 USPATFULL

CN Carbamic acid, (3-methoxy-4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 475060-22-1 USPATFULL

CN Carbamic acid, (5-fluoro-4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 12 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2006:74885 USPATFULL Full-text
 TITLE: Pyrazole compounds
 INVENTOR(S): Hagihara, Masahiko, Yamaguchi, JAPAN
 Shibakawa, Nobuhiko, Yamaguchi, JAPAN
 Nishihara, Masamichi, Yamaguchi, JAPAN
 Shirai, Toshiyuki, Yamaguchi, JAPAN
 Shimizu, Motohisa, Yamaguchi, JAPAN
 Hasegawa, Tohru, Yamaguchi, JAPAN
 Tokunaga, Yasunori, Yamaguchi, JAPAN
 Suzuki, Naoto, Yamaguchi, JAPAN
 Wada, Yukinori, Yamaguchi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060063934	A1	20060323
	US 7294625	B2	2007/1113
APPLICATION INFO.:	US 2003-528994	A1	20030925 (10)
	WO 2003-JP12254		20030925
			20050324 PCT 371 date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747, US		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	12316		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pyrazole compounds represented by the formula (I): ##STR1## wherein R.sup.1 represents phenyl which may be substituted, R.sup.2 represents H, halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl or substituted amino, Q represents CH or N, R.sup.3 represents H, alkyl or amino, R.sup.4 represents the formula (II) to (V): ##STR2## wherein R.sup.7 represents H or alkyl, R.sup.8 represents H, alkyl or substituted amino, R.sup.9 represents H or alkyl, R.sup.12 represents H, alkyl, halogeno alkyl or substituted amino, or pharmaceutically acceptable salts thereof, and a medical composition containing the same as effective ingredient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD Heat-killed bacteria of *Mycobacterium butyricum* (available from Difco) were pulverized by agate mortar, and this was suspended in dry-heat sterilized liquid paraffin (available from Wako Pure Chemical Industries, Ltd.) so as to have 10 mg/ml, and subjected to ultrasonic wave treatment to obtain an adjuvant. 500 µg/50 µl/paw of the adjuvant was administered into. . .

IT 74-88-4, Methyl iodide, reactions 75-03-6, Ethyl iodide 75-30-9, Isopropyl iodide 75-36-5, Acetyl chloride 79-22-1, Methyl chloroformate 98-88-4, Benzoyl chloride 108-24-7, Acetic anhydride 124-41-4, Sodium methoxide 124-63-0, Methanesulfonyl chloride 141-30-0, 3,6-Dichloropyridazine 302-01-2, Hydrazine, reactions 618-36-0, 1-Phenylethylamine 2393-23-9, 4-Methoxybenzylamine 4023-34-1, Cyclopropylcarbonyl chloride 4524-93-0, Cyclopentylcarbonyl chloride 4637-24-5 6226-25-1, 2,2,2-Trifluoroethyl triflate 6576-04-1 6576-05-2 7197-01-5 19064-64-3, 3,6-Dichloro-4-methylpyridazine 40971-95-7 53890-39-4 90101-29-5 178383-09-0 188345-25-7 198967-24-7 216076-14-1 217661-99-9

302839-09-4 365427-98-1 365427-99-2 365428-06-4 365428-07-5
677320-78-4


(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

IT 90101-20-5

(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

RN 90101-20-5 USPATFULL

CN Carbamic acid, N-(4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



L194 ANSWER 13 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2005:280470 USPATFULL Full-text

TITLE: Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents

INVENTOR(S): Adolf, Guenther, Vienna, AUSTRIA

Baum, Anke, Alland, AUSTRIA

Heider, Karl-Heinz, Stockerau, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050244413	A1	20051103
APPLICATION INFO.:	US 2005-172320	A1	20050630 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-645215, filed on 21 Aug 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-18686	20020821
	US 2002-405956P	20020826 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KAPLAN GILMAN GIBSON & DERNIER L.L.P., 900 ROUTE 9 NORTH, WOODBRIDGE, NJ, 07095, US	

NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1-50
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates contain maytansinoids as cytotoxic compounds, and preferred chemotherapeutic agents are taxanes, epothilones, and vinca alkaloids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

- SUMM . . . large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A 93: 8618-23, 1996; U.S. Pat. No. 5,208,020). They have developed antibody conjugates wherein the antibody is linked to a maytansinoid via a disulfide linkage. Maytansines belong to the class of Ansa macrolide antibiotics, which derive from *Nocardia* sp. The maytansine ansamitocin P-3, produced by bacterial fermentation, is used as a precursor molecule to manufacture maytansinoid DML. Maytansine and derivatives act as anti-mitotic agents (inhibitors of tubulin polymerization), similar as vincristine, but with markedly higher potency than vincristine or other established chemotherapeutic agents (DML is toxic to cells. . .
- DETD . . . preparing such maytansinoids are known in the art (see in particular U.S. Pat. No. 5,208,020, Example 1). Conveniently, in a first step the maytansinoid C-3 ester ansamitocin P3 may be produced by bacterial fermentation (U.S. Pat. No. 4,356,265; U.S. Pat. No. 4,450,234; WO 01/77360) of microorganisms belonging to the genus *Nocardia* or *Actinosynnema*, e.g. ATCC 31565, ATCC 31281. Ansamitocin P3 may be extracted from the culture using organic solvents like ethyl acetate or toluene, and further purified by adsorption chromatography using e.g. silica gel. It may then be reduced to maytansinol using LiAlH₄.sub.4 (U.S. Pat. No. 4,360,462) or, as suggested more recently. . .
- IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 57-22-7, Vincristine 59-05-2, Methotrexate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2, Azacytidine 645-05-6, Altretenamine 671-16-9, Procarbazine 865-21-4, Vinblastine 1404-00-8, Mitomycin 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4375-07-9, Epiodophyllotoxin 7440-06-4D, Platinum, compound 7689-03-4, Camptothecin 11056-06-7, Bleomycin 13010-47-4, Lomustine 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 53643-48-4, Vindesine 53910-25-1, Pentostatin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 62816-98-2, Ormaplatin 62928-11-4, Iroplatin 71486-22-1, Vinorelbine 75607-67-9, Fludarabine phosphate 91421-43-1, 9-Aminocamptothecin 97682-44-5, Irinotecan 114977-28-5, Docetaxel 123948-87-8, Topotecan 125317-39-7, Navelbine 126268-81-3, Mivobulin isethionate 136638-72-7D, derivative 141430-65-1, E-7010 149715-96-8, Spongistatin 1 150624-44-5, Spongistatin 2 151852-31-2, Spongistatin 3 152044-53-6, Epothilone A 152044-54-7, Epothilone B 153698-80-7, Spongistatin 5 153745-94-9, Spongistatin 4 158080-65-0, Spongistatin 6 158681-42-6, Spongistatin 7 158734-18-0, Spongistatin 8 158734-19-1, Spongistatin 9 162652-95-1, Vinflunine 172837-41-1 186692-73-9, Epothilone C 189453-10-9, Epothilone D 201049-37-8, Epothilone E 208518-52-9, Epothilone F 219989-84-1, BMS-247550 222030-63-9, Combretastatin A4-phosphate 253426-24-3, AVE 8062 280578-49-6, BMS-310705 339179-41-8, BIWA 4 663957-22-0, Hydroxphenastatin 663957-23-1, RPR 116258A
(comps. and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents)
- IT 126268-81-3, Mivobulin isethionate
(comps. and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents)
- RN 126268-81-3 USPATFULL
- CN Ethanesulfonic acid, 2-hydroxy-, compd. with ethyl N-[(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]carbamate (1:1) (CA


INDEX NAME)

CM 1

CRN 122332-18-7

CMF C17 H19 N5 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 107-36-8

CMF C2 H6 O4 S



L194 ANSWER 14 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2005:112272 USPATFULL Full-text
 TITLE: Novel pleuromutilin derivatives
 INVENTOR(S): Elder, John Stephen, Harlow, UNITED KINGDOM
 Forrest, Andrew Keith, Harlow, UNITED KINGDOM
 Jarvest, Richard Lewis, Harlow, UNITED KINGDOM
 Sheppard, Robert John, Harlow, UNITED KINGDOM
 PATENT ASSIGNEE(S): SmithKline Beecham p.l.c. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050096357	A1	20050505
	US 7160907	B2	20070109
	US 2004-4751	A1	20041203 (11)
APPLICATION INFO.:	Continuation of Ser. No. US 2003-399023, filed on 25 Jul 2003, PENDING A 371 of International Ser. No. WO 2001-EP11603, filed on 8 Oct 2001		
RELATED APPLN. INFO.:			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-24811	20001010
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1-15	
LINE COUNT:	1844	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pleuromutilin compounds of the formula: ##STR1## are of use in anti-bacterial therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . pharmaceutically acceptable salts or derivatives have antimicrobial properties and are therefore of use in therapy, in particular for treating microbial infections in animals, especially mammals, including humans, in particular humans and domesticated animals (including farm animals). The compounds may be used for the treatment of infections caused by, for example, Gram-positive and Gram-negative bacteria and mycoplasmas, including, for example, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus faecalis*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Haemophilus sp.*, *Neisseria sp.*, *Legionella sp.*, *Chlamydia sp.*, *Moraxella catarrhalis*, *Mycoplasma pneumoniae*, and *Mycoplasma gallisepticum*.

SUMM In addition, compounds of this invention are active against bacterial organisms which are resistant (including multiply-resistant) to other anti-bacterial agents, for instance, β -lactam antibiotics such as, for example, methicillin; macrolides; and quinolones. Such bacterial organisms include, for example, methicillin resistant *Staphylococcus aureus* (MESA) and drug-resistant *Streptococcus pneumoniae* (DRSP). Compounds of the present invention are therefore useful in the treatment of infections caused by these bacteria.

DETD Examples 1 to 130 were found to have MICs ≤ 4 ug/ml against *Staphylococcus aureus* Oxford, *Streptococcus pneumoniae* 1629, *Moraxella catarrhalis* 1502, and *Haemophilus influenzae* Q1.

CLM What is claimed is:
 . . and R.sup.5 and R.sup.6 together form an oxo group; or R.sup.3 and R.sup.4 is each H, R.sup.5 is OH or H and R.sup.6 is H, or R.sup.5 is H and R.sup.6 is OH or H; or a pharmaceutically acceptable salt thereof; and wherein said microbial infection is caused by a Gram-positive bacteria, a Gram-negative bacteria, or a mycoplasma.

CLM What is claimed is:
 18. The method of claim 16 wherein the infection is caused by *Staphylococcus epidermidis*, *Enterococcus faecalis*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Haemophilus sp.*, *Neisseria sp.*, *Legionella sp.*, *Chlamydia sp.*, *Moraxella catarrhalis*, *Mycoplasma pneumoniae*, or *Mycoplasma gallisepticum*.

CLM What is claimed is:
 20. The method of claim 16 wherein the infection is caused by drug-resistant *Streptococcus pneumoniae*.

CLM What is claimed is:
 . . and R.sup.5 and R.sup.6 together form an oxo group; or R.sup.3 and R.sup.4 is each H, R.sup.5 is OH or H and R.sup.6 is H, or R.sup.5 is H and R.sup.6 is OH or H; or a pharmaceutically acceptable salt thereof; and wherein said microbial infection is caused by a Gram-positive bacteria, a Gram-negative bacteria, or a mycoplasma.


CLM What is claimed is:
 23. The method of claim 21 wherein the infection is caused by, *Staphylococcus epidermidis*, *Enterococcus faecalis*, *Streptococcus*

pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Haemophilus sp., Neisseria sp., Legionella sp., Chlamydia sp., Moraxella catarrhalis, Mycoplasma pneumoniae, or Mycoplasma gallisepticum.

CLM What is claimed is:


25. The method of claim 21 wherein the infection is caused by drug-resistant Streptococcus pneumoniae.

IT 18620-79-6P 51424-90-9P 61273-19-6P 61273-20-9P 81654-96-8P
 109384-24-9P 125653-58-9P 137682-88-3P 262444-52-0P 352514-21-7P
 387845-11-6P 387845-36-5P 412277-86-2P 412277-88-4P
 412277-90-8P 412277-92-0P 412277-94-2P 412277-96-4P
 412277-98-6P 412278-00-3P 412278-02-5P 412278-05-8P 412278-08-1P
 412278-12-7P 412278-14-9P 412278-16-1P 412278-20-7P 412278-22-9P
 412278-24-1P 412278-26-3P 412278-28-5P 412278-30-9P 412278-32-1P
 412278-34-3P 412278-37-6P 412278-39-8P 412278-41-2P
 (preparation of pleuromutilin alkoxycarbonyl carbamate derivs. as antibacterial agents)
 IT 412277-90-8P 412277-92-0P
 (preparation of pleuromutilin alkoxycarbonyl carbamate derivs. as antibacterial agents)
 RN 412277-90-8 USPATFULL
 CN 4-Pyrimidinecarboxylic acid, 2,6-bis[[(1,1-dimethylethoxy) carbonyl] amino]-, methyl ester (CA INDEX NAME)



RN 412277-92-0 USPATFULL

CN Carbamic acid, [4-[(2,2-dimethyl-1-oxopropyl)amino]-6-(hydroxymethyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 15 OF 33 USPATFULL on STN

ACCESSION NUMBER:

2005:11708 USPATFULL [Full-text](#)

TITLE:

Medicine for inhibiting drug elimination pump

INVENTOR(S):

Nakayama, Kiyoshi, Tokyo, JAPAN

Ohtsuka, Masami, Tokyo, JAPAN

Kawato, Haruko, Tokyo, JAPAN

Okumura, Ryo, Tokyo, JAPAN

Hoshino, Kazuki, Tokyo, JAPAN
 Watkins, William, Waltham, MA, UNITED STATES
 Zhang, Jason, Waltham, MA, UNITED STATES
 Palme, Monica, Waltham, MA, UNITED STATES
 Cho, Aesop, Waltham, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050009843	A1	20050113
APPLICATION INFO.:	US 2004-475091	A1	20040628 (10)
	WO 2002-JP4087		20020424
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-842234, filed on 26 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-33133	20020208
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE PLACE, RESTON, VA, 20191	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	14109	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): ##STR1##

wherein, R.sup.1 and R.sup.2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W.sup.1 represents --CH.dbd.CH--, --CH.sub.2O--, --CH.sub.2CH.sub.2-- or the like; R.sup.3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R.sup.4 represents hydrogen atom, a group of --OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R.sup.5 represents a cyclic alkyl group, an aryl group or the like); W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)--(R.sup.8 and R.sup.9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W.sup.2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . in 1980 by the group of Levy, and the discovery was noted as a major factor of the resistance to tetracycline (L. McMurtry, Proc. Natl. Acad. Sci. U.S.A., 77, 3974, 1980). Furthermore, based on recent researches, the presence of multidrug-excreting drug efflux pumps was reported in *Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, *Staphylococcus bacteria*, *Diplococcus pneumoniae*, and *Neisseria gonorrhoeae*. Four multidrug efflux pumps have so far been reported as homological drug efflux pumps deriving from *Pseudomonas aeruginosa*, and they have been considered as a cause of low drug sensitivity inherent to *Pseudomonas aeruginosa* (K. Poole et al., J. Bacteriol., 175, 7363, . . .

DETD [0088] Kinds of microbial infections that are applicable by the medicament of the present invention are not particularly limited. Bacteria are suitable as target microorganisms. The medicament of the

present invention can be used for various infections by microorganisms including Gram-positive or Gram-negative bacteria, aerobic or anaerobic bacteria and the like. The medicament of the present invention can most suitably be used for infections by *Pseudomonas aeruginosa* with acquired resistance to one or more antimicrobial agents, or infections by *Pseudomonas aeruginosa* with low sensitivity to antimicrobial agents. The medicament of the the . . .

IT 62-56-6, Thiourea, reactions 64-17-5, Ethanol, reactions 74-88-4, Iodomethane, reactions 75-65-0, tert-Butanol, reactions 77-78-1, Dimethyl sulfate 79-04-9, Chloroacetyl chloride 79-44-7, N,N-Dimethylcarbamoyl chloride 85-44-9, 1,3-Isobenzofurandione 96-32-2, Methyl bromoacetate 98-09-9, Benzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 98-80-6, Phenylboronic acid 100-39-0, Benzyl bromide 107-97-1, Sarcosine 108-00-9, N,N-Dimethylethylenediamine 108-24-7, Acetic anhydride 109-01-3, N-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 124-41-4, Sodium methoxide 124-63-0, Methanesulfonyl chloride 136-95-8, 2-Aminobenzothiazole 141-43-5, 2-Aminoethanol, reactions 142-25-6, N,N'-Trimethylethylenediamine 144-48-9, Iodoacetamide 151-18-8, 2-Cyanoethylamine 280-57-9, 1,4-Diazabicyclo[2.2.2]octane 302-01-2, Hydrazine, reactions 358-23-6, Trifluoromethanesulfonic anhydride 359-07-9, 2-Bromo-1,1-difluoroethane 530-62-1, N,N'-Carbonyldiimidazole 541-41-3, Ethyl chloroformate 542-28-9, δ -Valerolactone 624-76-0, Iodoethanol 762-49-2, 1-Bromo-2-fluoroethane 816-40-0, 1-Bromo-2-butanone 824-94-2, 4-Methoxybenzyl chloride 867-13-0, Ethyl diethylphosphonoacetate 1118-68-9, Dimethylaminoacetic acid 1122-54-9, 4-Acetylpyridine 1122-96-9, 4-Methoxypyridine N-oxide 1189-71-5, Chlorosulfonyl isocyanate 1795-01-3, 3-Ethylthiophene 1943-83-5, 2-Chloroethyl isocyanate 2055-46-1, 3,4,5,6-Tetrahydro-2-pyrimidinethiol 2295-31-0, 2,4-Thiazolidinedione 2356-16-3 2508-29-4, 5-Amino-1-pentanol 2524-64-3, Diphenylphosphoryl chloride 3019-25-8 3019-71-4, Trichloroacetyl isocyanate 3144-09-0, Methanesulfonamide 3303-84-2, Boc- β -alanine 3699-66-9, Triethyl 2-phosphonopropionate 3731-51-9, 2-(Aminomethyl)pyridine 4138-26-5, Nipecotamide 4595-60-2, 2-Bromopyrimidine 4637-24-5, Dimethylformamide dimethyl acetal 5292-43-3, tert-Butyl bromoacetate 5327-32-2 5382-16-1, 4-Hydroxypiperidine 5469-26-1, 1-Bromopinacolone 5717-37-3, (Carbethoxyethylidene)triphenylphosphorane 6859-99-0, 3-Hydroxypiperidine 7664-41-7, Ammonia, reactions 7677-24-9, Trimethylsilyl cyanide 7803-49-8, Hydroxylamine, reactions 13010-19-0, 3-Chloropropyl isocyanate 13616-37-0 15128-89-9 15781-70-1, Bis(2,4,6-trichlorophenyl)malonate 16872-11-0, Tetrafluoroboric acid 16982-21-1 18162-48-6, tert-Butyldimethylsilyl chloride 21655-48-1, cis-2,6-Dimethylpiperazine 21901-40-6 22398-14-7, Dimethyl methoxymethylenemalonate 22795-99-9, (S)-(-)-2-Aminomethyl-1-ethylpyrrolidine 24424-99-5, Di-tert-butyl dicarbonate 26386-88-9, Diphenylphosphoryl azide 26628-22-8, Sodium azide 27219-07-4, 5-(tert-Butoxycarbonylamino)valeric acid 27532-96-3, Glycine tert-butyl ester hydrochloride 29858-07-9, Magnesium dibromide diethyl etherate 31460-03-4 35000-38-5, (tert-Butoxycarbonylmethylene)triphenylphosphorane 50541-93-0, 1-Benzyl-4-piperidinamine 58479-61-1, tert-Butyldiphenylsilyl chloride 62414-68-0 63052-91-5 66196-93-8 74370-93-7 79099-07-3, 4-Oxo-1-(tert-butoxycarbonyl)piperidine 79932-19-7 88512-14-5, 3,4-Dihydroxypiperidine hydrochloride 88738-78-7, Bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate 90161-29-5 90203-05-7, N,N-Dimethyl-N-(3-piperidylmethyl)amine 90354-15-7

	93107-30-3	97745-69-2	108787-91-3	111279-72-2	131534-65-1,
	Pyridine-3-boronic acid 1,3-propanediol cyclic ester				132549-38-3
	132958-72-6	136088-69-2	149168-07-0	155784-47-7	156589-83-2
	183483-09-2, 3-Carboxymethylpiperidine-1-carboxylic acid tert-butyl ester				
	198976-43-1	211940-29-3	474678-70-1	474678-92-7	475058-40-3
	475058-41-4	475058-42-5	475058-43-6	475058-44-7	475058-45-8
	475060-40-3	475060-41-4	475060-42-5	475060-43-6	475060-44-7
	475060-45-8	475060-46-9	475060-47-0	475060-48-1	475060-49-2
	475060-50-5	475060-51-6	475061-52-0	475061-54-2	475062-48-7
	475062-49-8	475063-58-2, (E)-2-(2-tert-Butoxycarbonylaminothiazol-5-yl)-3-pyridin-4-yl-2-propenoic acid ethyl ester		475063-59-3,	
	(E)-2-(2-tert-Butoxycarbonylaminothiazol-5-yl)-3-pyridin-4-yl-2-propenoic acid	475063-60-6	475063-61-7	475084-41-4	
	(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)				
IT	1147-76-8P	3544-43-2P, (2-Dimethylaminoacetylaminio)acetic acid			
	5445-73-8P	6221-13-2P	7778-42-9P, Sulfamoyl chloride	13362-30-6P	
	21426-18-6P	30235-28-0P	36057-44-0P	53764-72-0P	54221-95-3P
	60343-28-4P	63273-48-3P	63984-03-2P	78585-25-8P	89855-60-7P
	90765-02-9P	91660-69-4P	91660-72-9P	119036-36-1P	128312-69-6P
	134848-96-7P	135716-08-4P, 4-(Ethoxycarbonylmethylene)-1-(tert-butoxycarbonyl)piperidine	135716-09-5P	143900-43-0P	153493-64-2P
	155789-92-7P	169458-04-2P, Piperidin-4-yl-acetic acid ethyl ester			
	hydrochloride	184154-42-5P	211942-98-2P	301222-66-2P	422280-25-9P
	422280-28-2P	474678-13-2P	474678-15-4P	474678-16-5P	474679-13-5P
	475057-67-1P	475057-68-2P	475057-69-3P	475057-70-6P	475057-71-7P
	475057-72-8P	475057-73-9P	475057-74-0P	475057-75-1P	475057-76-2P
	475057-77-3P	475057-78-4P	475057-79-5P	475057-80-8P	475057-81-9P
	475057-82-0P	475057-83-1P	475057-84-2P	475057-85-3P	475057-86-4P
	475057-87-5P	475057-88-6P	475057-89-7P	475057-90-0P	475057-91-1P
	475057-92-2P	475057-93-3P	475057-94-4P	475057-95-5P	475057-96-6P
	475057-97-7P	475057-98-8P	475057-99-9P	475058-00-5P	475058-01-6P
	475058-02-7P	475058-03-8P	475058-04-9P	475058-05-0P	475058-06-1P
	475058-07-2P	475058-08-3P	475058-09-4P	475058-10-7P	475058-11-8P
	475058-12-9P	475058-13-0P	475058-14-1P	475058-15-2P	475058-16-3P
	475058-17-4P	475058-18-5P	475058-19-6P	475058-20-9P	475058-21-0P
	475058-22-1P	475058-23-2P	475058-24-3P	475058-25-4P	475058-26-5P
	475058-27-6P	475058-28-7P	475058-29-8P	475058-30-1P	475058-31-2P
	475058-32-3P	475058-33-4P	475058-34-5P	475058-35-6P	475058-36-7P
	475058-37-8P	475058-38-9P	475058-39-0P	475059-47-3P	475059-48-4P
	475059-49-5P	475059-50-8P	475059-51-9P	475059-52-0P	475059-53-1P
	475059-54-2P	475059-55-3P	475059-56-4P	475059-57-5P	475059-58-6P
	475059-59-7P	475059-60-0P	475059-61-1P	475059-62-2P	475059-63-3P
	475059-64-4P	475059-65-5P	475059-66-6P	475059-67-7P	475059-68-8P
	475059-69-9P	475059-70-2P	475059-71-3P	475059-72-4P	475059-73-5P
	475059-74-6P	475059-75-7P	475059-76-8P	475059-77-9P	475059-78-0P
	475059-79-1P	475059-80-4P	475059-81-5P	475059-82-6P	475059-83-7P
	475059-84-8P	475059-85-9P	475059-86-0P	475059-87-1P	475059-88-2P
	475059-89-3P	475059-90-6P	475059-91-7P	475059-92-8P	475059-93-9P
	475059-94-0P	475059-95-1P	475059-96-2P	475059-97-3P	475059-98-4P
	475059-99-5P	475060-00-5P	475060-01-6P	475060-02-7P	
	475060-03-8P	475060-04-9P	475060-05-0P	475060-06-1P	475060-07-2P
	475060-08-3P	475060-09-4P	475060-10-7P	475060-11-8P	475060-12-9P
	475060-13-0P	475060-14-1P	475060-15-2P	475060-16-3P	475060-17-4P
	475060-18-5P	475060-20-9P	475060-21-0P	475060-22-1P	
	475060-23-2P	475060-24-3P	475060-25-4P	475060-26-5P	475060-27-6P
	475060-28-7P	475060-29-8P	475060-30-1P	475060-31-2P	475060-32-3P
	475060-33-4P	475060-34-5P	475060-35-6P	475060-36-7P	475060-37-8P
	475060-38-9P	475060-39-0P	475061-03-1P	475061-04-2P	475061-05-3P
	475061-06-4P	475061-07-5P	475061-08-6P	475061-09-7P	475061-10-8P

475061-11-1P 475061-12-2P 475061-13-3P 475061-14-4P 475061-15-5P
 475061-16-6P 475061-17-7P 475061-18-8P 475061-19-9P 475061-20-2P
 475061-21-3P 475061-22-4P 475061-23-5P 475061-25-7P 475061-26-8P
 475061-29-1P 475061-31-5P 475061-33-7P 475061-36-0P 475061-39-3P
 475061-41-7P 475061-43-9P 475061-46-2P 475061-48-4P 475062-02-3P


(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

IT 90161-20-5

(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

RN 90101-20-5 USPATFULL

CN Carbamic acid, N-(4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 475060-01-6P 475060-22-1P

(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

RN 475060-01-6 USPATFULL

CN Carbamic acid, (3-methoxy-4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 475060-22-1 USPATFULL

CN Carbamic acid, (5-fluoro-4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 16 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:202970 USPATFULL [Full-text](#)

TITLE: Pulmonary delivery for bioconjugation

INVENTOR(S): Ezrin, Alan M., Moraga, CA, UNITED STATES

Fleser, Angelica, Montreal, CANADA
 Robitaille, Martin, Granby, CANADA
 Milner, Peter G., Los Altos Hills, CA, UNITED STATES
 Bridon, Dominique P., Ville Mont-Royal, CANADA
 PATENT ASSIGNEE(S): CONJUCHEM, INC., Montreal, CANADA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040156859	A1	20040812
APPLICATION INFO.:	US 2004-756774	A1	20040412 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-656121, filed on 6 Sep 2000, GRANTED, Pat. No. US 6706892		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152681P	19990907 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 425 MARKET STREET, SAN FRANCISCO, CA, 94105-2482	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5112	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosuppressants, anti-infective and anti-cancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD [0052] Antibiotics: Antibiotics are natural chemical substances of relatively low molecular weight produced by various species of microorganisms, such as bacteria (including *Bacillus* species), actinomycetes (including *Streptomyces*) and fungi, that inhibit growth of or destroy other microorganisms. Substances of similar structure and mode of action may be synthesized chemically, or natural compounds may be modified to produce semi-synthetic antibiotics. These biosynthetic and semi-synthetic derivatives are also effective as antibiotics. The major classes of antibiotics are. . .

DETD . . . 558-561). Compounds which inhibit the production or action of TNF are thought to be potentially useful for the treatment or prophylaxis of many inflammatory, infectious, immunological or malignant diseases. These include, but are not restricted to, septic shock, haemodynamic shock and sepsis syndrome, post ischaemic reperfusion injury, malaria, Crohn's disease, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, rheumatic arthritis, multiple sclerosis, radiation damage, toxicity following administration of immunosuppressive monoclonal antibodies such as OKT3 or CAMPATH-1 and hyperoxic alveolar injury. Since excessive TNF production has been noted in several diseases or conditions also characterized. . .

IT 65026-79-1P 80234-20-4P 133524-69-3P 329364-69-4P 329364-70-7P
 329364-73-0P 329364-74-1P 329364-75-2P
 329364-76-3P 329364-77-4P 329364-78-5P
 329364-80-9P 329364-81-0P 329364-82-1P
 (preparation and formulation of long lasting antineoplastic agents)


IT 329364-74-1P 329364-75-2P 329364-76-3P
329364-77-4P 329364-78-5P

(preparation and formulation of long lasting antineoplastic agents)

RN 329364-74-1 USPATFULL

CN L-Glutamic acid, N-[4-[[[2,4-bis[[[1,1-dimethylethoxy)carbonyl]amino]-6-pteridinyl]methyl]methylamino]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 329364-75-2 USPATFULL

CN Carbamic acid, [6-[[methyl[4-[[[(3S)-tetrahydro-2,6-dioxo-2H-pyran-3-yl]amino]carbonyl]phenyl]amino]methyl]-2,4-pteridinediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 329364-76-3 USPATFULL


CN 3,6-Dioxo-9,12-diazaheptadecan-17-oic acid, 16-[[[4-[[[2,4-bis[[[1,1-dimethylethoxy)carbonyl]amino]-6-pteridinyl]methyl]methylamino]benzoyl]amino]-1-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-8,13-dioxo-, (16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 329364-77-4 USPATFULL


CN 12,15-Dioxo-6,9-diazaheptadecanoic acid, 4-[[[4-[[[2,4-bis[[[(1,1-dimethylethoxy)carbonyl]amino]-6-pteridinyl]methyl]methylamino]benzoyl]amino]-17-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-5,10-dioxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 329364-78-5 USPATFULL


CN Hexanoic acid, 6-[[[(4S)-4-[[4-[[[2,4-bis[(1,1-dimethylethoxy)carbonyl]amino]-6-pteridiny]methyl]methylamino]benzoyl]amino]-4-carboxy-1-oxobutyl]amino]-, 1-(2,5-dioxo-1-pyrrolidinyl) ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L194 ANSWER 17 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2004:164893 USPATFULL Full-text
 TITLE: Compositions and methods for treating cancer using
 cytotoxic CD44 antibody immunoconjugates and
 chemotherapeutic agents
 INVENTOR(S): Adolf, Guenther, Vienna, AUSTRIA
 Baum, Anke, Alland, AUSTRIA
 Heider, Karl-Heinz, Stockerau, AUSTRIA
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim,
 GERMANY, FEDERAL REPUBLIC OF, 55216 (non-U.S.
 corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20040126379	A1	20040701
APPLICATION INFO.:	US 2003-645215	A1	20030821 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	EP 2002-18686	20020821
	US 2002-405956P	20020826 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
 P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 50
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Page(s)
 LINE COUNT: 2027
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates contain maytansinoids as cytotoxic compounds, and preferred chemotherapeutic agents are taxanes, epothilones, and vinca alkaloids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A. 93: 8618-23, 1996; U.S. Pat. No. 5,208,020). They have developed antibody conjugates wherein the antibody is linked to a maytansinoid via a disulfide linkage. Maytansines belong to the class of Ansa macrolide antibiotics, which derive from *Nocardia* sp. The maytansine ansamitocin P-3, produced by bacterial fermentation, is used as a precursor molecule to manufacture maytansinoid DM1. Maytansine and derivatives act as anti-mitotic agents (inhibitors of tubulin polymerization), similar as vincristine, but with markedly higher potency than vincristine or other established chemotherapeutic agents (DM1 is toxic to cells. . .

DETD . . . preparing such maytansinoids are known in the art (see in particular U.S. Pat. No. 5,208,020, Example 1). Conveniently, in a first step the maytansinoid C-3 ester ansamitocin P3 may be produced by bacterial fermentation (U.S. Pat. No. 4,356,265; U.S. Pat. No. 4,450,234; WO 01/77360) of microorganisms belonging to the genus *Nocardia* or *Actinosynnema*, e.g. ATCC 31565, ATCC 31281. Ansamitocin P3 may be extracted from the culture using organic solvents like ethyl acetate or toluene, and further purified by adsorption chromatography using e.g. silica gel. It may then be reduced to maytansinol using LiAlH₄.sub.4 (U.S. Pat. No. 4,360,462) or, as suggested more. . .

IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 57-22-7, Vincristine 59-05-2, Methotrexate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2, Azacitidine 645-05-6, Altrexamine 671-16-9, Procarbazine 865-21-4, Vinblastine 1404-00-8, Mitomycin 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4375-07-9, Epipodophyllotoxin 7440-06-4D, Platinum, compound 7689-03-4, Camptothecin 11056-06-7, Bleomycin 13010-47-4, Lomustine 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 53643-48-4, Vindesine 53910-25-1, Pentostatin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 62816-98-2, Ormaplatin 62928-11-4, Iproplatin 71486-22-1, Vinorelbine 75607-67-9, Fludarabine phosphate 91421-43-1, 9-Aminocamptothecin 97682-44-5, Irinotecan 114977-28-5, Docetaxel 123948-87-8, Topotecan 125317-39-7, Navelbine 126268-81-3, Mivobulin isethionate 136638-72-7D, derivative 141430-65-1, E-7010 149715-96-8, Spongistatin 1 150624-44-5, Spongistatin 2 151852-31-2, Spongistatin 3 152044-53-6, Epothilone A 152044-54-7, Epothilone B 153698-80-7, Spongistatin 5 153745-94-9, Spongistatin 4 158080-65-0, Spongistatin 6 158681-42-6, Spongistatin 7 158734-18-0, Spongistatin 8 158734-19-1, Spongistatin 9 162652-95-1, Vinflunine 172837-41-1 186692-73-9, Epothilone C 189453-10-9, Epothilone D 201049-37-8, Epothilone E 208518-52-9, Epothilone F 219989-84-1, BMS-247550 222030-63-9, Combretastatin A4-phosphate 253426-24-3, AVE 8062 280578-49-6, BMS-310705 339179-41-8, BINA 4 663957-22-0, Hydroxphenastatin 663957-23-1, RPR 116258A


(comps. and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents)
 IT 126268-81-3, Mivobulin isethionate
 (comps. and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents)
 RN 126268-81-3 USPATFULL
 CN Ethanesulfonic acid, 2-hydroxy-, compd. with ethyl N-[(2S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl]carbamate (1:1) (CA INDEX NAME)

CM 1

CRN 122332-18-7

CMF C17 H19 N5 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 107-36-8

CMF C2 H6 O4 S

HO-CH₂-CH₂-SO₃H

L194 ANSWER 18 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:77158 USPATFULL Full-text

TITLE: Heterocyclic mutilin esters and their use as antibacterials

INVENTOR(S): Aitken, Steven, Harlow, UNITED KINGDOM
 Brooks, Gerald, Harlow, UNITED KINGDOM
 Dabbs, Steven, Harlow, UNITED KINGDOM
 Frydrych, Colin Henry, Harlow, UNITED KINGDOM
 Howard, Steven, Cambridge, UNITED KINGDOM
 Hunt, Eric, Harlow, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040058937	A1	20040325
	US 6878704	B2	20050412
APPLICATION INFO.:	US 2003-343596	A1	20031017 (10)
	WO 2001-EP8949		20010802

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-18951	20000803

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL
 PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA,
 PA, 19406-0939
 NUMBER OF CLAIMS: 22
 EXEMPLARY CLAIM: 1
 LINE COUNT: 2720
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Pleuromutilin compounds of the formula: ##STR1##

are of use in anti-bacterial therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . pharmaceutically acceptable salts or derivatives have
 antimicrobial properties and are therefore of use in therapy, in
 particular for treating microbial infections in animals, especially
 mammals, including humans, in particular humans and domesticated animals
 (including farm animals). The compounds may be used for the treatment of
 infections caused by, for example, Gram-positive and
 Gram-negative bacteria and mycoplasmas, including, for
 example, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus*
faecalis, *Streptococcus pyogenes*, *Streptococcus*
agalactiae, *Streptococcus pneumoniae*, *Haemophilus* sp.,
Neisseria sp., *Legionella* sp., *Chlamydia* sp., *Moraxella catarrhalis*,
Mycoplasma pneumoniae, and *Mycoplasma gallisepticum*.

DETD [0460] The compounds of Examples 1 to 169 were found to have MICs
 ≤ 4 ug/ml against *Staphylococcus aureus* Oxford,
Streptococcus pneumoniae 1629 and *Moraxella catarrhalis* Ravasio.
 IT 1445-55-2P 13721-01-2P 56406-43-0P 65754-04-3P 105652-03-7P
 120276-59-7P 127142-90-9P 186130-63-2P 223481-92-3P 257939-38-1P
 257939-45-0P 257939-46-1P 257939-47-2P 268550-54-5P 268550-55-6P
 397308-56-4P 397308-63-3P 397308-78-0P 397309-34-1P 397309-39-6P
 397309-41-0P 397309-43-2P 397309-45-4P 397309-47-6P 397309-49-8P
 397309-51-2P 397309-53-4P 397309-55-6P 397309-57-8P 397309-59-0P
 397309-62-5P 397309-64-7P 397309-67-0P 397309-69-2P 397309-72-7P
 397309-75-0P 397309-78-3P 397309-81-8P 397309-84-1P
 397309-87-4P 397309-89-6P 397309-91-0P 397309-93-2P 397309-95-4P
 397309-97-6P 397309-99-8P 397310-02-0P 397310-05-3P 397310-08-6P
 397310-11-1P 397310-14-4P 397310-17-7P 397310-20-2P 397310-23-5P
 397310-26-8P 397310-37-1P 397310-78-0P 397310-80-4P 397310-83-7P
 397311-05-6P 397311-08-9P 397311-11-4P 397311-14-7P


(preparation of mutilin 14-ester derivs. with antibacterial activity)

IT 397309-75-0P
 (preparation of mutilin 14-ester derivs. with antibacterial activity)

RN 397309-75-0 USPATFULL

CN 5-Pyrimidinecarboxylic acid, 2-[[[1,1-dimethylethoxy)carbonyl]amino]-1,4-
 dihydro-4-oxo-, (1R,3aR,4R,6S,8R,9R,9aS,10R)-6-ethenyldecahydro-1-
 methoxy-4,6,9,10-tetramethyl-5-oxo-3a,9-propano-3aH-cyclopentacycloocten-
 8-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L194 ANSWER 19 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:31917 USPATFULL [Full-text](#)

TITLE: Novel pleuromutilin derivatives

INVENTOR(S): Elder, John Stephen, Essex, UNITED KINGDOM

Forrest, Andrew Keith, Essex, UNITED KINGDOM

Jarvest, Richard Lewis, Essex, UNITED KINGDOM

Sheppard, Robert John, Essex, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040024059	A1	20040205
	US 6900345	B2	20050531
APPLICATION INFO.:	US 2003-399023	A1	20030725 (10)
	WO 2001-EP11603		20011008

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-24811	20001010
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1976	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Pleuromutilin compounds of the formula (A) & (B) are of use in anti-bacterial therapy.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . pharmaceutically acceptable salts or derivatives have antimicrobial properties and are therefore of use in therapy, in particular for treating microbial infections in animals, especially mammals, including humans, in particular humans and domesticated animals (including farm animals). The compounds may be used for the treatment of infections caused by, for example, Gram-positive and Gram-negative bacteria and mycoplasmas, including, for example, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus faecalis*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Haemophilus* sp., *Neisseria* sp., *Legionella* sp., *Chlamydia* sp., *Moraxella catarrhalis*, *Mycoplasma pneumoniae*, and *Mycoplasma gallisepticum*.

SUMM [0120] In addition, compounds of this invention are active against bacterial organisms which are resistant (including multiply-resistant)

to other anti-bacterial agents, for instance, β -lactam antibiotics such as, for example, methicillin; macrolides; and quinolones. Such bacterial organisms include, for example, methicillin resistant *Staphylococcus aureus* (MRSA) and drug-resistant *Streptococcus pneumoniae* (DRSP). Compounds of the present invention are therefore useful in the treatment of infections caused by these bacteria.


DETD [0267] Examples 1 to 130 were found to have MICs ≤ 4 μ g/ml against *Staphylococcus aureus* Oxford, *Streptococcus pneumoniae* 1629, *Moraxella catarrhalis* 1502, and *Haemophilus influenzae* Q1.

IT 18620-79-6P 51424-90-9P 61273-19-6P 61273-20-9P 81654-96-8P
 109384-24-9P 125653-58-9P 137682-88-3P 262444-52-0P 352514-21-7P
 387845-11-6P 387845-36-5P 412277-86-2P 412277-88-4P
 412277-90-8P 412277-92-0P 412277-94-2P 412277-96-4P
 412277-98-6P 412278-00-3P 412278-02-5P 412278-05-8P 412278-08-1P
 412278-12-7P 412278-14-9P 412278-16-1P 412278-20-7P 412278-22-9P
 412278-24-1P 412278-26-3P 412278-28-5P 412278-30-9P 412278-32-1P
 412278-34-3P 412278-37-6P 412278-39-8P 412278-41-2P
 (preparation of pleuromutilin alkoxycarbonyl carbamate derivs. as antibacterial agents)

IT 412277-90-8P 412277-92-0P
 (preparation of pleuromutilin alkoxycarbonyl carbamate derivs. as antibacterial agents)


RN 412277-90-8 USPATFULL

CN 4-Pyrimidinecarboxylic acid, 2,6-bis[[1,1-dimethylethoxy)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 412277-92-0 USPATFULL

CN Carbamic acid, [4-[(2,2-dimethyl-1-oxopropyl)amino]-6-(hydroxymethyl)-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 20 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:116757 USPATFULL Full-text

TITLE: Peptide nucleic acids having antibacterial activity

INVENTOR(S): Nielsen, Peter E., Hjortev.oe butted.nget 509, DK-2980
 Kokkedal, DENMARK
 Good, Liam, Sveavagen, SWEDEN

PATENT ASSIGNEE(S): Nielsen, Peter E., DENMARK (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6734161	B1	20040511
	WO 9913893		19990325
APPLICATION INFO.:	US 2000-486623		20000706 (9)
	WO 1998-US19199		19980916
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-932140, filed on 16 Sep 1997, now patented, Pat. No. US 6300318		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Marschel, Ardin H.		
LEGAL REPRESENTATIVE:	Woodcock Washburn LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1463		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Methods of and compositions for killing or inhibiting the growth of a bacteria are disclosed. The methods comprise the use of peptide nucleic acids that are targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more separate antibiotics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD A. *Streptococcus pyogenes* (Gram Positive Specie)

DETD Compounds are assayed in duplicate at a single dose. Compounds which show inhibitory activity are re-tested in duplicate at multiple doses to determine minimum inhibitory concentration (MIC). Such compounds may be further tested with one or more gram positive bacteria such as but not limited to the Tier II et seq. organisms described in the following sections.

DETD A. Gram Positive

DETD The following gram positive strains are used to test compounds which showed activity in at least one of the Tier I organisms: *Staphylococcus aureus* (ATCC #13709), *Enterococcus hirae* (ATCC #10541), *Streptococcus pyogenes* (ATCC #49399). To initiate the exponential phase of bacterial growth prior to the assay, a sample of bacteria is grown for 6 hours in Todd Hewitt Broth (Difco 0492-17-6) at 37° C. then re-inoculated into fresh media and grown overnight at 37° C. The bacterial cells are collected by . . .

IT 34046-07-6P 72648-80-7P 85301-38-8P 163081-00-3P

163081-01-4P 163081-02-5P 163081-03-6P

163081-06-9P 202999-28-8P

(preparation and reactions of; peptide nucleic acids antisense to mRNA or rRNA as antibacterial or bacteriostatic antibiotics)


IT 163081-00-3P 163081-01-4P 163081-02-5P

163081-03-6P

(preparation and reactions of; peptide nucleic acids antisense to mRNA or rRNA as antibacterial or bacteriostatic antibiotics)


RN 163081-00-3 USPATFULL

CN 5-Pyrimidineacetic acid, 3,4-dihydro-4-oxo-2-[(phenylmethoxy)carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 163081-01-4 USPATFULL

CN 5-Pyrimidineacetic acid, 3,4-dihydro-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]- (CA INDEX NAME)




RN 163081-02-5 USPATFULL

CN Glycine, N-[[[1,4-dihydro-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-5-pyrimidinyl]acetyl]-N-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 163081-03-6 USPATFULL

CN Glycine, N-[[[1,4-dihydro-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-5-pyrimidinyl]acetyl]-N-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, (9CI) (CA INDEX NAME)



L194 ANSWER 21 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2004:66015 USPATFULL [Full-text](#)

TITLE: Pulmonary delivery for bioconjugation

INVENTOR(S): Ezrin, Alan M., Moraga, CA, United States

Fleser, Angelica, Montreal, CANADA
 Robitaille, Martin, Terrasse-Vaudreuil, CANADA
 Milner, Peter G., Los Altos Hills, CA, United States
 Bridon, Dominique P., Outremont, CANADA
 Conjuchem, Inc., Montreal, CANADA (non-U.S.
 corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6706892	B1	20040316
APPLICATION INFO.:	US 2000-656121		20000906 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-152681P	19990907 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Webman, Edward J.	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	5043	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosuppressants, anti-infective and anti-cancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Antibiotics are natural chemical substances of relatively low molecular weight produced by various species of microorganisms, such as bacteria (including Bacillus species), actinomycetes (including Streptomyces) and fungi, that inhibit growth of or destroy other microorganisms. Substances of similar structure and mode of action may be synthesized chemically, or natural compounds may be modified to produce semi-synthetic antibiotics. These biosynthetic and semi-synthetic derivatives are also effective as antibiotics. The major classes of antibiotics are. . .

SUMM . . . 558-561). Compounds which inhibit the production or action of TNF are thought to be potentially useful for the treatment or prophylaxis of many inflammatory, infectious, immunological or malignant diseases. These include, but are not restricted to, septic shock, haemodynamic shock and sepsis syndrome, post ischaemic reperfusion injury, malaria, Crohn's disease, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, rheumatic arthritis, multiple sclerosis, radiation damage, toxicity following administration of immunosuppressive monoclonal antibodies such as OKT3 or CAMPATH-1 and hyperoxic alveolar injury. Since excessive TNF production has been noted in several diseases or conditions also characterized. . .

IT 65026-79-1P 80234-20-4P 133524-69-3P 329364-69-4P 329364-70-7P
 329364-73-0P 329364-74-1P 329364-75-2P
 329364-76-3P 329364-77-4P 329364-78-5P
 329364-80-9P 329364-81-0P 329364-82-1P
 (preparation and formulation of long lasting antineoplastic agents)


IT 329364-74-1P 329364-75-2F 329364-76-3P
329364-77-4P 329364-78-5P

(preparation and formulation of long lasting antineoplastic agents)

RN 329364-74-1 USPATFULL

CN L-Glutamic acid, N-[4-[[[2,4-bis[[[1,1-dimethylethoxy)carbonyl]amino]-6-pteridinyl]methyl]methylamino]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 329364-75-2 USPATFULL

CN Carbamic acid, [6-[[methyl[4-[[[(3S)-tetrahydro-2,6-dioxo-2H-pyran-3-yl]amino]carbonyl]phenyl]amino]methyl]-2,4-pteridinediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 329364-76-3 USPATFULL


CN 3,6-Dioxo-9,12-diazaheptadecan-17-oic acid, 16-[[[4-[[[2,4-bis[[[1,1-dimethylethoxy)carbonyl]amino]-6-pteridinyl]methyl]methylamino]benzoyl]amino]-1-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-8,13-dioxo-, (16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 329364-77-4 USPATFULL


CN 12,15-Dioxo-6,9-diazaheptadecanoic acid, 4-[[[4-[[[2,4-bis[[[1,1-dimethylethoxy)carbonyl]amino]-6-pteridinyl]methyl]methylamino]benzoyl]amino]-17-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-5,10-dioxo-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 329364-78-5 USPATFULL


CN Hexanoic acid, 6-[[[(4S)-4-[[4-[[[2,4-bis[[[(1,1-dimethylethoxy)carbonyl]amino]-6-pteridiny]methyl]methylamino]benzoyl]amino]-4-carboxy-1-oxobutyl]amino]-, 1-(2,5-dioxo-1-pyrrolidinyl) ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L194 ANSWER 22 OF 33 USPTAFULL on STN
 ACCESSION NUMBER: 2003:200449 USPTAFULL Full-text
 TITLE: Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
 INVENTOR(S): Glazier, Arnold, Newton, MA, UNITED STATES
 PATENT ASSIGNEE(S): Drug Innovation & Design, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030138432	A1	20030724
APPLICATION INFO.:	US 2000-738625	A1	20001215 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-712465, filed on 15 Nov 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-165485P	19991115 (60)
	US 2000-239478P	20001011 (60)
	US 2000-241939P	20001010 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: N. Scott Pierce, Esq., HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two Militia Drive, Lexington, MA, 02421-4799

NUMBER OF CLAIMS: 29
 EXEMPLARY CLAIM: 1
 LINE COUNT: 18716
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this

invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM [1620] A high percentage of human γ/δ T cells are activated by phosphoantigens derived from mycobacterium such as prenyl pyrophosphate analogs. 3-Formyl-1-butyl-pyrophosphate and related derivatives are extremely potent activators of γ/δ T cells. The following references relate to this matter: Belmant C, et al., "3-Formyl-1-butyl Pyrophosphate a Novel Mycobacterial Metabolite-Activating Human Gammadelta T Cells," J Biol Chem, 274(45):32079-84 (1999); and Huber H., et al., "Activation of Murine Epidermal TCR-Gamma Delta+ T Cells by Keratinocytes Treated with Contact Sensitizers," J Immunol, 155(6):2888-94 (1995); and Groh V., et al., "Broad Tumor-Associated Expression and Recognition by Tumor-Derived $\gamma\delta$ T Cells of MICA. . . Bialasiewicz A. A., et al., "Alpha/Beta- and Gamma/Delta TCR(+) Lymphocyte Infiltration in Necrotising Choroidal Melanomas," Br J Ophthalmol, 83(9):1069-73 (1999); and Gan Y. H.; Malkovsky M., "Mechanisms of Simian Gamma Delta T Cell Cytotoxicity against Tumor and Immunodeficiency Virus-Infected Cells," Immunol Lett, 49(3): 191-6 (1996) Manfredi A. A., et al., "Mycobacterium Tuberculosis Exploits the CD95/CD95 Ligand System of Gammadelta T Cells to Cause Apoptosis," Eur J Immunol, 28(6):1798-806 (1998); and Tanaka Y., et al., "Natural and Synthetic Non-Peptide Antigens Recognized by Human Gamma Delta T Cells," Nature, 375(6527):155-8 (1995); and Tanaka Y., et al., "Nonpeptide Ligands for Human Gamma Delta T. . . De Libero G., et al., "Selection by Two Powerful Antigens may Account for the Presence of the Major Population of Human Peripheral Gamma/Delta T Cells," J Exp Med, 173(6):1311-22 (1991); and Boullier S., et al., "Regulation by Cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T Cell Response to Mycobacterial Phosphoantigens in Responder and Anergic HIV-Infected Persons," Eur J Immunol, 29(1):90-9 (1999); and Ferrini S., et al., "Retargeting of T-Cell-Receptor Gamma/Delta+ Lymphocytes against Tumor Cells by Bispecific Monoclonal Antibodies. Induction of Cytolytic Activity and Lymphokine Production," Int J Cancer Suppl, 4:53-5 (1989); and Salerno A., et al., "Role of Gamma. . . by Recurrent Gamma Delta Tumor-Infiltrating Lymphocytes from Renal Carcinoma," J Immunol, 154(8):3932-40 (1995); and Catalfamo M., et al., "Self-Reactive Cytotoxic Gamma Delta T Lymphocytes in Graves' Disease Specifically Recognize Thyroid Epithelial Cells," J Immunol, 156(2):804-11 (1996); and Constant P., et al., "Stimulation of Human Gamma Delta T Cells by Nonpeptidic Mycobacterial Ligands," Science, 264(5156):267-70 (1994); and Li H., et al., "Structure of the Vdelta Domain of a Human Gammadelta T-Cell Antigen Receptor," Nature, 391(6666):502-6 (1998); and Zhao X., et al., "Accumulation of Gamma/Delta T Cells in Human Dysgerminoma and Seminoma: Roles in Autologous Tumor Killing and Granuloma Formation," Immunol Invest, 24(4):607-18. . . Immunother, 47(2):97-103 (1998); and Poccia F., et al., "Phosphoantigen-Reactive Vgamma9Vdelta2 T Lymphocytes Suppress In Vitro Human Immunodeficiency Virus Type 1 Replication by Cell-Released Antiviral Factors Including CC Chemokines," J Infect Dis, 180(3):858-61 (1999); and Wesch D., et al.,

"Comparative Analysis of Alpha Beta and Gamma Delta T Cell Activation by Mycobacterium Tuberculosis and Isopentenyl Pyrophosphate," Eur J Immunol, 27(4):952-6 (1997); and the contents are hereby incorporated by reference in their entirety.

DETD

. . . unmasked by an esterase activated clock like trigger that will have a half life of about 90 minutes. Synergy between the innate and adaptive immune response is expected to augment the antitumor immune response. The following references relate to this subject matter: Belmont C, et al., "3-Formyl-1-butyl Pyrophosphate a Novel Mycobacterial Metabolite-Activating Human Gammadelta T Cells," J Biol Chem, 274(45):32079-84 (1999), the contents of which are incorporated herein by reference in their entirety. ##STR458##

IT 1194-98-5P 1499-29-2P 6974-29-4P 51819-63-7P 90359-20-9P
 138915-62-5P 147281-71-8P 165172-57-6P 165454-06-8P 177575-34-7P
 214532-01-1P 216220-13-2P 240428-96-0P 341549-88-0P 341549-89-1P
 341549-90-4P 341549-91-5P 341549-92-6P 341549-93-7P 341549-94-8P
 341549-95-9P 341549-96-0P 341549-97-1P 341549-98-2P 341549-99-3P
 341550-00-3P 341550-01-4P 341550-02-5P 341550-03-6P 341550-04-7P
 341550-05-8P 341550-06-9P 341550-07-0P 341550-08-1P 341550-09-2P
 341550-10-5P 341550-11-6P 341550-12-7P 341550-13-8P 341550-14-9P
 341550-15-0P 341550-16-1P 341550-17-2P 341550-18-3P 341550-19-4P
 341550-20-7P 341550-21-8P 341550-22-9P 341550-23-0P 341550-24-1P
 341550-25-2P 341550-26-3P 341550-27-4P 341550-28-5P 341550-29-6P
 341550-30-9P 341550-31-0P 341550-32-1P 341550-33-2P 341550-34-3P
 341550-35-4P 341550-36-5P 341550-37-6P 341550-38-7P 341550-39-8P
 341550-40-1P 341550-41-2P 341550-42-3P 341550-43-4P 341550-44-5P
 341550-45-6P 341550-46-7P 341550-47-8P 341550-48-9P 341550-49-0P
 341550-50-3P 341550-51-4P 341550-52-5P 341550-53-6P 341550-54-7P
 341550-55-8P 341550-56-9P 341550-57-0P 341550-58-1P 341550-59-2P
 341550-60-5P 341550-61-6P 341550-62-7P 341550-63-8P 341550-64-9P
 341550-65-0P 341550-66-1P 341550-67-2P 341550-68-3P 341550-69-4P
 341550-70-7P 341550-71-8P 341550-72-9P 341550-73-0P 341550-74-1P
 341550-75-2P 341550-76-3P 341550-77-4P 341550-78-5P 341550-79-6P
 341550-80-9P 341550-81-0P 341550-82-1P 341550-83-2P
 341550-84-3P 341550-85-4P 341550-86-5P
 341550-87-6P 341550-88-7P 341550-89-8P 341550-90-1P
 341550-91-2P 341550-92-3P 341550-93-4P 341550-94-5P
 341550-95-6P 341550-96-7P 341550-97-8P 341550-98-9P 341550-99-0P
 341551-00-6P 341551-01-7P 341551-02-8P 341551-03-9P 341551-04-0P
 341551-05-1P 341551-06-2P 341551-07-3P 341551-08-4P 341551-09-5P
 341551-10-8P 341551-11-9P 341551-12-0P 341551-14-2P 341551-16-4P
 341551-17-5P 341551-18-6P 341551-19-7P 341551-20-0P 341551-21-1P
 341551-22-2P 341551-23-3P 341551-24-4P 341551-25-5P 341551-26-6P
 341551-27-7P 341551-28-8P 341551-29-9P 341551-30-2P 341551-31-3P
 341551-32-4P 341551-33-5P 341551-34-6P 341551-35-7P 341551-36-8P
 341551-37-9P 341551-38-0P 341551-39-1P 341551-40-4P 341551-41-5P
 341551-42-6P 341551-43-7P 341551-44-8P 341551-45-9P 341551-46-0P
 341551-47-1P 341551-48-2P 341551-49-3P 341551-50-6P 341551-51-7P
 341551-51-7P 341551-52-8P 341551-53-9P 341551-54-0P 341551-55-1P
 341551-56-2P 341551-57-3P 341551-58-4P 341551-59-5P 341551-60-8P
 341551-61-9P 341551-62-0P 341551-63-1P 341551-64-2P 341551-65-3P
 341551-67-5P 341551-68-6P 341551-69-7P 341551-70-0P 341551-71-1P
 341551-72-2P 341551-73-3P 341551-74-4P 341551-75-5P 341551-76-6P
 341551-77-7P 341551-78-8P 341551-79-9P 341551-80-2P 341551-81-3P
 341551-82-4P 341551-83-5P 341551-84-6P 341551-85-7P 341551-86-8P
 341551-87-9P 341551-88-0P 341551-89-1P 341551-90-4P 341551-91-5P
 341551-92-6P 341551-93-7P 341551-94-8P 341551-95-9P 341551-96-0P
 341551-97-1P 341551-98-2P 341551-99-3P 341552-00-9P 341552-01-0P
 341552-02-1P 341552-03-2P 341552-04-3P 341552-05-4P 341552-06-5P
 341552-07-6P 341552-08-7P

(multifunctional delivery vehicles for selective cellular targeting of drugs)

IT 341550-84-3P 341550-85-4P 341550-86-5P


341550-90-1P 341550-91-2P

(multifunctional delivery vehicles for selective cellular targeting of drugs)

RN 341550-84-3 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 2-[4,5-dihydro-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-3H-pyrrolo[3,2-d]pyrimidin-7-yl]-3,4-bis[[(phenylmethoxy)carbonyl]oxy]-5-[(triphenylmethoxy)methyl]-, phenylmethyl ester, (2S,3S,4R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 341550-85-4 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 2-[4,5-dihydro-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-3H-pyrrolo[3,2-d]pyrimidin-7-yl]-5-(hydroxymethyl)-3,4-bis[[(phenylmethoxy)carbonyl]oxy]-, phenylmethyl ester, (2S,3S,4R,5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 341550-86-5 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 2-[4,5-dihydro-4-oxo-2-[[(phenylmethoxy)carbonyl]amino]-3H-pyrrolo[3,2-d]pyrimidin-7-yl]-5-formyl-3,4-bis[[(phenylmethoxy)carbonyl]oxy]-, phenylmethyl ester, (2S,3S,4R,5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 341550-90-1 USPATFULL


CN 1-Pyrrolidinecarboxylic acid, 2-[2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4,5-dihydro-4-oxo-3H-pyrrolo[3,2-d]pyrimidin-7-yl]-3,4-bis[(9H-fluoren-9-ylmethoxy)carbonyloxy]-5-[(phosphonoxy)methyl]-, 1-[(4-methoxyphenyl)methyl] ester, (2S,3S,4R,5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 341550-91-2 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 2-[[bis(9H-fluoren-9-


ylmethoxy)phosphinyl]oxy)methyl]-5-[2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4,5-dihydro-4-oxo-3H-pyrrolo[3,2-d]pyrimidin-7-yl]-3,4-bis[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-, (4-methoxyphenyl)methyl ester, (2R,3R,4S,5S)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



TITLE: Drug efflux pump inhibitor
 INVENTOR(S): Nakayama, Kiyoshi, Funabashi-shi, JAPAN
 Ohtsuka, Masami, Tokyo, JAPAN
 Kawato, Haruko, Tokyo, JAPAN
 Watkins, William, Sunnyvale, CA, UNITED STATES
 Zhang, Jason, Foster City, CA, UNITED STATES
 Palme, Monica, San Jose, CA, UNITED STATES
 Cho, Aesop, Mountain View, CA, UNITED STATES
 PATENT ASSIGNEE(S): DAIICHI PHARMACEUTICAL CO., LTD, Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030092720	A1	20030515
	US 7056917	B2	20060606
APPLICATION INFO.:	US 2001-842234	A1	20010426 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GREENBLUM & BERNSTEIN, P.L.C., 1941 ROLAND CLARKE PLACE, RESTON, VA, 20191		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6685		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): ##STR1##

wherein, R.sup.1 and R.sup.2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W.sup.1 represents --CH.dbd.CH--, --CH.sub.2O--, --CH.sub.2CH.sub.2-- or the like; R.sup.3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R.sup.4 represents hydrogen atom, a group of --OZ.sub.0-4R.sup.5 (Z.sub.0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R.sup.5 represents a cyclic alkyl group, an aryl group or the like); W.sup.2 represents a single bond or --C(R.sup.8).dbd.C(R.sup.9)-- (R.sup.8 and R.sup.9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W.sup.2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . in 1980 by the group of Levy, and the discovery was noted as a major factor of the resistance to tetracycline (L. McMurtry, Proc. Natl. Acad. Sci. U.S.A., 77, 3974, 1980). Furthermore, based on recent researches, the presence of multidrug-excreting drug efflux pumps was reported in *Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, *Staphylococcus bacteria*, *Diplococcus pneumoniae*, and *Neisseria gonorrhoeae*. Four multidrug efflux pumps have so far been reported as homological drug efflux pumps deriving from *Pseudomonas aeruginosa*, and they have been considered as a cause of low drug sensitivity inherent to *Pseudomonas aeruginosa* (K. Poole et al., J. Bacteriol., 175, 7363, . . .

SUMM [0058] Kinds of microbial infections that are applicable by the medicament of the present invention are not particularly limited. Bacteria are suitable as target microorganisms. The medicament of the present invention can be used for various infections by microorganisms including Gram-positive or Gram-negative bacteria,

- aerobic or anaerobic bacteria and the like. The medicament of the present invention can most suitably be used for infections by *Pseudomonas aeruginosa* with acquired resistance to one or more antimicrobial agents, or infections by *Pseudomonas aeruginosa* with low sensitivity to antimicrobial agents. The medicament of the . . .
- II 62-56-6, Thiourea, reactions 64-17-5, Ethanol, reactions 74-88-4, Iodomethane, reactions 75-65-0, tert-Butanol, reactions 77-78-1, Dimethyl sulfate 79-04-9, Chloroacetyl chloride 79-44-7, N,N-Dimethylcarbamoyl chloride 85-44-9, 1,3-Isobenzofurandione 96-32-2, Methyl bromoacetate 98-09-9, Benzenesulfonyl chloride 98-59-9, p-Toluenesulfonyl chloride 98-80-6, Phenylboronic acid 100-39-0, Benzyl bromide 107-97-1, Sarcosine 108-00-9, N,N-Dimethylethylenediamine 108-24-7, Acetic anhydride 109-01-3, N-Methylpiperazine 109-55-7, N,N-Dimethyl-1,3-propanediamine 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 124-41-4, Sodium methoxide 124-63-0, Methanesulfonyl chloride 136-95-8, 2-Aminobenzothiazole 141-43-5, 2-Aminoethanol, reactions 142-25-6, N,N'-Trimethylethylenediamine 144-48-9, Iodoacetamide 151-18-8, 2-Cyanoethylamine 280-57-9, 1,4-Diazabicyclo[2.2.2]octane 302-01-2, Hydrazine, reactions 358-23-6, Trifluoromethanesulfonic anhydride 359-07-9, 2-Bromo-1,1-difluoroethane 530-62-1, N,N'-Carbonyldiimidazole 541-41-3, Ethyl chloroformate 542-28-9, δ -Valerolactone 624-76-0, Iodoethanol 762-49-2, 1-Bromo-2-fluoroethane 816-40-0, 1-Bromo-2-butanone 824-94-2, 4-Methoxybenzyl chloride 867-13-0, Ethyl diethylphosphonoacetate 1118-68-9, Dimethylaminoacetic acid 1122-54-9, 4-Acetylpyridine 1122-96-9, 4-Methoxypyridine N-oxide 1189-71-5, Chlorosulfonyl isocyanate 1795-01-3, 3-Ethylthiophene 1943-83-5, 2-Chloroethyl isocyanate 2055-46-1, 3,4,5,6-Tetrahydro-2-pyrimidinethiol 2295-31-0, 2,4-Thiazolidinedione 2356-16-3 2508-29-4, 5-Amino-1-pentanol 2524-64-3, Diphenylphosphoryl chloride 3019-25-8 3019-71-4, Trichloroacetyl isocyanate 3144-09-0, Methanesulfonamide 3303-84-2, Boc- β -alanine 3699-66-9, Triethyl 2-phosphonopropionate 3731-51-9, 2-(Aminomethyl)pyridine 4138-26-5, Nipecotamide 4595-60-2, 2-Bromopyrimidine 4637-24-5, Dimethylformamide dimethyl acetal 5292-43-3, tert-Butyl bromoacetate 5327-32-2 5382-16-1, 4-Hydroxypiperidine 5469-26-1, 1-Bromopinacolone 5717-37-3, (Carbethoxyethylidene)triphenylphosphorane 6859-99-0, 3-Hydroxypiperidine 7664-41-7, Ammonia, reactions 7677-24-9, Trimethylsilyl cyanide 7803-49-8, Hydroxylamine, reactions 13010-19-0, 3-Chloropropyl isocyanate 13616-37-0 15128-89-9 15781-70-1, Bis(2,4,6-trichlorophenyl)malonate 16872-11-0, Tetrafluoroboric acid 16982-21-1 18162-48-6, tert-Butyldimethylsilyl chloride 21655-48-1, cis-2,6-Dimethylpiperazine 21901-40-6 22398-14-7, Dimethyl methoxymethylenemalonate 22795-99-9, (S)-(-)-2-Aminomethyl-1-ethylpyrrolidine 24424-99-5, Di-tert-butyl dicarbonate 26386-88-9, Diphenylphosphoryl azide 26628-22-8, Sodium azide 27219-07-4, 5-(tert-Butoxycarbonylamino)valeric acid 27532-96-3, Glycine tert-butyl ester hydrochloride 29858-07-9, Magnesium dibromide diethyl etherate 31460-03-4 35000-38-5, (tert-Butoxycarbonylmethylene)triphenylphosphorane 50541-93-0, 1-Benzyl-4-piperidinamine 58479-61-1, tert-Butyldiphenylsilyl chloride 62414-68-0 63052-91-5 66196-93-8 74370-93-7 79099-07-3, 4-Oxo-1-(tert-butoxycarbonyl)piperidine 79932-19-7 88512-14-5, 3,4-Dihydroxypiperidine hydrochloride 88738-78-7, Bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate 90181-28-5 90203-05-7, N,N-Dimethyl-N-(3-piperidylmethyl)amine 90354-15-7 93107-30-3 97745-69-2 108787-91-3 111279-72-2 131534-65-1, Pyridine-3-boronic acid 1,3-propanediol cyclic ester 132549-38-3

	132958-72-6	136088-69-2	149168-07-0	155784-47-7	156589-83-2
	183483-09-2,	3-Carboxymethylpiperidine-1-carboxylic acid tert-butyl ester			
	198976-43-1	211940-29-3	474678-70-1	474678-92-7	475058-40-3
	475058-41-4	475058-42-5	475058-43-6	475058-44-7	475058-45-8
	475060-40-3	475060-41-4	475060-42-5	475060-43-6	475060-44-7
	475060-45-8	475060-46-9	475060-47-0	475060-48-1	475060-49-2
	475060-50-5	475060-51-6	475061-52-0	475061-54-2	475062-48-7
	475062-49-8	475063-58-2, (E)-2-(2-tert-Butoxycarbonylaminothiazol-5-yl)-3-pyridin-4-yl-2-propenoic acid	475063-59-3,		
		(E)-2-(2-tert-Butoxycarbonylaminothiazol-5-yl)-3-pyridin-4-yl-2-propenoic acid	475063-60-6	475063-61-7	475084-41-4
		(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)			
IT	1147-76-8P	3544-43-2P, (2-Dimethylaminoacetyl)amino)acetic acid			
	5445-73-8P	6221-13-2P	7778-42-9P, Sulfamoyl chloride	13362-30-6P	
	21426-18-6P	30235-28-0P	36057-44-0P	53764-72-0P	54221-95-3P
	60343-28-4P	63273-48-3P	63984-03-2P	78585-25-8P	89855-60-7P
	90765-02-9P	91660-69-4P	91660-72-9P	119036-36-1P	128312-69-6P
	134848-96-7P	135716-08-4P, 4-(Ethoxycarbonylmethylene)-1-(tert-butoxycarbonyl)piperidine	135716-09-5P	143900-43-0P	153493-64-2P
	155789-92-7P	169458-04-2P, Piperidin-4-yl-acetic acid ethyl ester hydrochloride			
	422280-28-2P	474678-13-2P	474678-15-4P	474678-16-5P	474679-13-5P
	475057-67-1P	475057-68-2P	475057-69-3P	475057-70-6P	475057-71-7P
	475057-72-8P	475057-73-9P	475057-74-0P	475057-75-1P	475057-76-2P
	475057-77-3P	475057-78-4P	475057-79-5P	475057-80-8P	475057-81-9P
	475057-82-0P	475057-83-1P	475057-84-2P	475057-85-3P	475057-86-4P
	475057-87-5P	475057-88-6P	475057-89-7P	475057-90-0P	475057-91-1P
	475057-92-2P	475057-93-3P	475057-94-4P	475057-95-5P	475057-96-6P
	475057-97-7P	475057-98-8P	475057-99-9P	475058-00-5P	475058-01-6P
	475058-02-7P	475058-03-8P	475058-04-9P	475058-05-0P	475058-06-1P
	475058-07-2P	475058-08-3P	475058-09-4P	475058-10-7P	475058-11-8P
	475058-12-9P	475058-13-0P	475058-14-1P	475058-15-2P	475058-16-3P
	475058-17-4P	475058-18-5P	475058-19-6P	475058-20-9P	475058-21-0P
	475058-22-1P	475058-23-2P	475058-24-3P	475058-25-4P	475058-26-5P
	475058-27-6P	475058-28-7P	475058-29-8P	475058-30-1P	475058-31-2P
	475058-32-3P	475058-33-4P	475058-34-5P	475058-35-6P	475058-36-7P
	475058-37-8P	475058-38-9P	475058-39-0P	475059-47-3P	475059-48-4P
	475059-49-5P	475059-50-8P	475059-51-9P	475059-52-0P	475059-53-1P
	475059-54-2P	475059-55-3P	475059-56-4P	475059-57-5P	475059-58-6P
	475059-59-7P	475059-60-0P	475059-61-1P	475059-62-2P	475059-63-3P
	475059-64-4P	475059-65-5P	475059-66-6P	475059-67-7P	475059-68-8P
	475059-69-9P	475059-70-2P	475059-71-3P	475059-72-4P	475059-73-5P
	475059-74-6P	475059-75-7P	475059-76-8P	475059-77-9P	475059-78-0P
	475059-79-1P	475059-80-4P	475059-81-5P	475059-82-6P	475059-83-7P
	475059-84-8P	475059-85-9P	475059-86-0P	475059-87-1P	475059-88-2P
	475059-89-3P	475059-90-6P	475059-91-7P	475059-92-8P	475059-93-9P
	475059-94-0P	475059-95-1P	475059-96-2P	475059-97-3P	475059-98-4P
	475059-99-5P	475060-00-5P	475060-01-6P	475060-02-7P	
	475060-03-8P	475060-04-9P	475060-05-0P	475060-06-1P	475060-07-2P
	475060-08-3P	475060-09-4P	475060-10-7P	475060-11-8P	475060-12-9P
	475060-13-0P	475060-14-1P	475060-15-2P	475060-16-3P	475060-17-4P
	475060-18-5P	475060-20-9P	475060-21-0P	475060-22-1P	
	475060-23-2P	475060-24-3P	475060-25-4P	475060-26-5P	475060-27-6P
	475060-28-7P	475060-29-8P	475060-30-1P	475060-31-2P	475060-32-3P
	475060-33-4P	475060-34-5P	475060-35-6P	475060-36-7P	475060-37-8P
	475060-38-9P	475060-39-0P	475061-03-1P	475061-04-2P	475061-05-3P
	475061-06-4P	475061-07-5P	475061-08-6P	475061-09-7P	475061-10-0P
	475061-11-1P	475061-12-2P	475061-13-3P	475061-14-4P	475061-15-5P
	475061-16-6P	475061-17-7P	475061-18-8P	475061-19-9P	475061-20-2P

475061-21-3P 475061-22-4P 475061-23-5P 475061-25-7P 475061-26-8P
 475061-29-1P 475061-31-5P 475061-33-7P 475061-36-0P 475061-39-3P
 475061-41-7P 475061-43-9P 475061-46-2P 475061-48-4P 475062-02-3P


(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

IT 90101-20-5

(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

RN 90101-20-5 USPATFULL

CN Carbamic acid, N-(4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 475060-01-6P 475060-22-1P

(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump of microorganisms)

RN 475060-01-6 USPATFULL

CN Carbamic acid, (3-methoxy-4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 475060-22-1 USPATFULL

CN Carbamic acid, (5-fluoro-4-methyl-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 24 OF 33 USPATFULL on STN

ACCESSION NUMBER: 2001:209008 USPATFULL Full-text

TITLE: Quinolones used as MRS inhibitors and bactericides

INVENTOR(S): Berge, John Michael, Merstham, United Kingdom

Brown, Pamela, Harpenden, United Kingdom

Elder, John Stephen, Hoddesdon, United Kingdom

Forrest, Andrew Keith, Epping, United Kingdom
 Hamprecht, Dieter Wolfgang, Roydon, United Kingdom
 Jarvest, Richard Lewis, Ware, United Kingdom
 McNair, David Jonathan, Hatfield, United Kingdom
 Sheppard, Robert John, Harlow, United Kingdom
 SmithKline Beecham plc, Brentford, United Kingdom
 (non-U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6320051	B1	20011120
	WO 9955677		19991104
APPLICATION INFO.:	US 2000-674102		20001026 (9)
	WO 1999-EP2648		19990415
			20001026 PCT 371 date
			20001026 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-9050	19980429
	GB 1998-24571	19981109
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Hall, Linda E., Venetianer, Stephen A., Kinzig, Charles M.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2643	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB ##STR1##		

Compounds of formula (I) are inhibitors of the bacterial enzyme S aureus methionyl tRNA synthetase and are of use in treating bacterial infections.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The compounds of this invention are active against both Gram negative and Gram positive organisms, including Haemophilus, for instance H. influenzae Q1; Moraxella, for instance M. catarrhalis 1502; Streptococci, for instance S. pyogenes CN10 and S. pneumoniae R6; Staphylococci, for instance S. aureus Oxford; Escherichia, for instance E. Coli DC0, and Enterococci, for instance Ent. faecalis I. In addition, compounds of this invention are active against Staphylococci organisms such as S. aureus and coagulase negative strains of Staphylococci such. . .

IT 7328-91-8P, 2,2-Dimethyl-1,3-propanediamine 21544-02-5P 36316-76-4P

52397-81-6P	102878-18-2P	103323-79-1P	123637-53-6P	143185-43-7P
153749-72-5P	248607-42-3P	248607-43-4P	248607-44-5P	248607-45-6P
248607-46-7P	248607-47-8P	248607-48-9P	248607-49-0P	248607-50-3P
248607-51-4P	248607-52-5P	248607-53-6P	248607-54-7P	248607-55-8P
248607-56-9P	248607-57-0P	248607-58-1P	248607-59-2P	248607-60-5P
248607-61-6P	248607-62-7P	248607-63-8P	248607-64-9P	248607-65-0P
248607-66-1P	248607-67-2P	248607-68-3P	248607-69-4P	248607-70-7P
248607-71-8P	248607-72-9P	248607-73-0P	248607-74-1P	248607-75-2P
248607-76-3P	248607-77-4P	248607-78-5P	248607-79-6P	248607-80-9P
248607-81-0P	248607-82-1P	248607-83-2P	248607-84-3P	
248607-85-4P	248607-86-5P	248607-88-7P	248607-89-8P	
248607-90-1P	248607-92-3P	248607-93-4P	248607-94-5P	

(preparation of 2-aminoquinolin-4-ones as inhibitors of methionyl tRNA synthase)
 IT 248607-35-4P
 (preparation of 2-aminoquinolin-4-ones as inhibitors of methionyl tRNA synthase)
 RN 248607-85-4 USPATFULL
 CN Carbamic acid, (4-ethoxy-2-quinolinyl)-, 2,2,2-trichloroethyl ester (9CI)
 (CA INDEX NAME)



L194 ANSWER 25 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 2001:173572 USPATFULL [Full-text](#)
 TITLE: Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
 INVENTOR(S): Nielsen, Peter E., Hjortevanget 509, DK 2980, Kokkedal, Denmark
 Good, Liam, Copenhagen, Denmark
 PATENT ASSIGNEE(S): Nielsen, Peter E., Denmark (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6300318	B1	20011009
APPLICATION INFO.:	US 1997-932140		19970916 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Marschel, Ardin H.		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1332		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of and compositions for killing or inhibiting the growth of a bacteria are disclosed. The methods comprise the use of peptide nucleic acid that is targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more separate antibiotics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD A. *Streptococcus pyogenes* (Gram Positive Specie)

DETD Compounds are assayed in duplicate at a single dose. Compounds which show inhibitory activity are re-tested in duplicate at multiple doses to determine minimum inhibitory concentration (MIC). Such compounds may be further tested with one or more gram positive bacteria such as but not limited to the Tier II et seq. organisms described in the following sections.

DETD A. Gram Positive

DETD The following gram positive strains are used to test compounds which showed activity in at least one of the Tier I organisms:

Staphylococcus aureus (ATCC #13709), *Enterococcus hirae* (ATCC #10541), *Streptococcus pyogenes* (ATCC #49399). To initiate the exponential phase of bacterial growth prior to the assay, a sample of bacteria is grown for 6 hours in Todd Hewitt Broth (Difco 0492-17-6) at 37° C. then re-inoculated into fresh media and grown overnight at 37° C. The bacterial cells are collected by. . .

IT 34046-07-6P 72648-80-7P 85301-38-8P 163081-06-9P 202999-28-8P
221362-47-6P 221362-48-7P 221362-49-8P
221362-50-1P


(antibacterial peptide nucleic acids targeting rRNA or mRNA)

IT 221362-47-6P 221362-48-7P 221362-49-8P
221362-50-1P

(antibacterial peptide nucleic acids targeting rRNA or mRNA)


RN 221362-47-6 USPATFULL

CN 5-Pyrimidineacetic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dihydro-4-oxo-, methyl ester (CA INDEX NAME)




RN 221362-48-7 USPATFULL

CN 5-Pyrimidineacetic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dihydro-4-oxo- (CA INDEX NAME)




RN 221362-49-8 USPATFULL

CN Glycine, N-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dihydro-4-oxo-5-pyrimidinyl]acetyl]-N-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 221362-50-1 USPATFULL

CN Glycine, N-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,4-dihydro-4-oxo-5-pyrimidinyl]acetyl]-N-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 26 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1998:150969 USPATFULL Full-text
 TITLE: 6-membered nitrogen-containing heteroaryl-oxazolidinones

INVENTOR(S): Riedl, Bernd, Wuppertal, Germany, Federal Republic of
 Habich, Dieter, Wuppertal, Germany, Federal Republic of
 Stolle, Andreas, Wuppertal, Germany, Federal Republic of
 Wild, Hanno, Orange, CT, United States
 Endermann, Rainer, Wuppertal, Germany, Federal Republic of
 Bremm, Klaus Dieter, Recklinghausen, Germany, Federal Republic of
 Kroll, Hein-Peter, Wuppertal, Germany, Federal Republic of
 Labischinski, Harald, Wuppertal, Germany, Federal Republic of
 Schaller, Klaus, Wuppertal, Germany, Federal Republic of
 Werling, Hans-Otto, Wuppertal, Germany, Federal Republic of
 PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843967		19981201
APPLICATION INFO.:	US 1996-749581		19961115 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-503369, filed on 17 Jul 1995, now patented, Pat. No. US 5627181		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4425612	19940720
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Sprung Kramer Schaefer & Briscoe	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1909	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 6-membered nitrogen-containing heteroaryloxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The compounds of the general formulae (I), (Ia), (Ib), (Ic), (Id), (Ie) and (If) according to the invention have a broad antibacterial spectrum, specifically against Gram-positive bacteria and

Mycobacteria, Corynebacteria, Haemophilus influenzae and anaerobic germs, coupled with a low toxicity. These properties enable them to be used as chemotherapeutic active compounds in human and veterinary medicine.


SUMM The compounds according to the invention are active against a broad spectrum of microorganisms. Gram-positive bacteria and bacteria-like microorganisms, such as Mycoplasma, can be combated and the diseases caused by these pathogens can be prevented, alleviated and/or cured with the aid of the compounds.

IT 36802-74-1P, 2-Quinolonecarbonyl azide 175393-01-8P
 175393-02-9P 175393-03-0P 175393-04-1P 175393-05-2P
 175393-06-3P 175393-07-4P 175393-08-5P 175393-09-6P 175393-10-9P
 175393-11-0P 175393-12-1P 175393-13-2P 175393-14-3P 175393-15-4P
 175393-16-5P, 2-Quinoxalinecarbonyl azide 175393-17-6P
 (intermediate; preparation of heteroaryloxazolidinones as antibacterials)

IT 175393-01-8P 175393-02-9P
 (intermediate; preparation of heteroaryloxazolidinones as antibacterials)


RN 175393-01-8 USPATFULL

CN Carbamic acid, (6-methyl-2-pyridinyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 175393-02-9 USPATFULL

CN Carbamic acid, (5-bromo-6-methyl-2-pyridinyl)-, phenylmethyl ester (9CI)
 (CA INDEX NAME)



L194 ANSWER 27 OF 33 USPATFULL on STN

ACCESSION NUMBER: 1998:25236 USPATFULL [Full-text](#)

TITLE: Quinolizone type compounds

INVENTOR(S): Chu, Daniel T., Santa Clara, CA, United States
 Li, Qun, Gurnee, IL, United States
 Cooper, Curt S., Gurnee, IL, United States
 Fung, Anthony K. L., Gurnee, IL, United States
 Lee, Cheuk M., Libertyville, IL, United States
 Plattner, Jacob J., Libertyville, IL, United States
 Ma, Zhenkun, Gurnee, IL, United States
 Wang, Wei-Bo, Park City, IL, United States

PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5726182		19980310
APPLICATION INFO.:	US 1995-484632		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-469159, filed on 6 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-316319, filed on 30 Sep 1994, now patented, Pat. No. US 5580872 which is a continuation-in-part of Ser. No. US 1993-137236, filed on 14 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-940870, filed on 27 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-517780, filed on 2 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Kifle, Bruce		
LEGAL REPRESENTATIVE:	Anand, Mona, Brainard, Thomas D.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	12351		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds wherein

A is .dbd.CR.sup.6 --;

R.sup.1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl;

R.sup.2 is selected from the group consisting of ##STR2## R.sup.3 is halogen; R.sup.4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group;

R.sup.5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR.sup.13 R.sup.14 ; and

R.sup.6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl),

as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM There is a continuing need for new antibacterial agents. Although many compounds are known which are useful in the treatment of Gram-positive and Gram-negative bacterial infections as well as other microbial infections, the widespread use of such compounds continues to give rise to resistant strains of microorganisms, i.e., strains of

microorganisms against which a particular antibiotic or group of antibiotics, which was previously effective, is no longer useful. Also, known antibiotics may be effective against only certain strains of microorganisms or have limited activity against either Gram-positive or Gram-negative, aerobic or anaerobic organisms.

SUMM The above compounds of the invention are found to have a surprising degree of antimicrobial activity against a wide spectrum of Gram-positive and Gram-negative bacteria as well as enterobacteria. Susceptible organisms whose growth can be inhibited generally include both aerobic and anaerobic pathogens of the genera *Staphylococcus*, *Lactobacillus*, *Micrococcus*, *Enterococcus*, *Streptococcus*, *Sarcina*, *Escherichia*, *Enterobacter*, *Klebsiella*, *Pseudomonas*, *Acinobacter*, *Proteus*, *Providencia*, *Citrobacter*, *Nisseria*, *Baccillus*, *Bacteroides*, *Camphylobacter*, *Peptococcus*, *Clostridium*, *Salmonella*, *Shigella*, *Legionella*, *Serratia*, *Haemophilus*, *Brucella* and the like. It is therefore expected that the compounds of the present invention will be useful in the treatment and prevention of susceptible bacterial infections in both humans and lower animals. In addition, the compounds, by reason of their in vitro activity, may. . .

DETD . . . inhibitory concentrations (MICs) were determined by the agar dilution method, in which twelve petri dishes were prepared, each containing successive aqueous 2-fold dilutions of the test compounds mixed with 10 mL of sterilized Brain Heart Infusion (BHI) agar. Each plate was inoculated with 1:100 (or 1:10 for slow-growing strains, primarily *Micrococcus* and *Streptococcus*) dilutions of up to 32 different microorganisms, using a Steers replicator block calibrated to deliver approximately 10. sup.4 colony forming units (CFUs). The inoculated plates were incubated at from about 35° C. to about 37° C. for approximately 20-24 hours. In addition, a control plate using BHI agar containing no test. . .

SYSTEM LIMIT EXCEEDED DURING KWIC/STRING SEARCH

SYSTEM LIMIT EXCEEDED DURING KWIC/STRING SEARCH

DETD . . . 0.39

A5177

Staphylococcus aureus						
0.39	--	0.78	--	--	--	0.39

A-5278

Staphylococcus aureus						
0.39	0.78	0.78	6.2	--	--	0.39

642A

Staphylococcus aureus						
0.39	0.39	0.39	6.2	--	--	0.2

NCTC 10649

Staphylococcus aureus						
0.78	0.78	0.78	12.5	50	50	0.39

CMX 553

Staphylococcus aureus						
>100	--	25	--	--	--	25

1775

Staphylococcus						
0.39	0.78	0.78	12.5	50	25	0.39

epidermidis 3519

Micrococcus luteus						
1.56	50	50	25	25	25	3.1


ATCC 9341

Micrococcus luteus						
0.78	25	25	12.5	25	25	1.56

ATCC 4698

Enterococcus faecium						
0.39	25	25	50	100	50	1.56

ATCC 8043							
Streptococcus bovis							
1.56	25	25	25	25	100	3.1	
A5169							
Streptococcus							
0.39	12.5	12.5	25	50	100	1.56	
agalactaciae							
CMX 508							
Streptococcus							
0.39	6.2	6.2	25	50	100	1.56	
pyrogenes EES61							
Streptococcus							
0.78	6.2	6.2	25	50	50	1.56	
pyrogenes CONST							
Streptococcus							
0.39	3.1	3.1	25	50	50	0.39	
pyrogenes							
2548 INDUC							
Escherichia coli JUHL							
0.01	0.39	0.39	3.1	6.2	12.5	0.02	
Escherichia coli SS							
.005	<.05	0.05	0.39	1.56	1.56	0.01	
Escherichia coli DC-2							
0.2	12.5	12.5	25	100	>100	0.39	
Escherichia coli H560							
0.01	--	0.39	3.1	12.5	12.5	0.02	
Escherichia coli							
0.2	6.2	6.2	25	100.	.	.	
IT 866-48-8P	3430-14-6P	3678-63-5P	5239-82-7P,	Cyclopropaneacetic acid			
20967-28-6P	21203-68-9P	31181-53-0P	45673-79-8P	93856-98-5P			
113209-88-4P	113209-89-5P	114677-00-8P	131189-22-5P	139161-04-9P			
139161-05-0P	139161-06-1P	139161-07-2P	139161-08-3P	139161-09-4P			
139161-10-7P	139161-11-8P	139161-12-9P	139161-13-0P	139161-14-1P			
139161-15-2P	139161-16-3P	139161-17-4P	139161-18-5P				
139161-19-6P	139161-20-9P	139161-21-0P	139161-22-1P	139161-23-2P			
139161-24-3P	139161-25-4P	139161-26-5P	139161-27-6P	139161-28-7P			
139161-29-8P	139161-30-1P	139161-31-2P	139161-32-3P	139161-33-4P			
139161-34-5P	139161-35-6P	139161-36-7P	139161-37-8P	139161-38-9P			
139161-39-0P	139161-40-3P	139161-41-4P	139161-42-5P	139161-43-6P			
139161-44-7P	139161-45-8P	139161-46-9P	139161-47-0P	139161-48-1P			
139161-49-2P	139161-50-5P	139161-51-6P	139161-52-7P	139161-53-8P			
139161-54-9P	139161-55-0P	139161-56-1P	139161-57-2P	139161-58-3P			
139161-59-4P	139161-60-7P	139161-61-8P	139161-62-9P	139161-63-0P			
139161-64-1P	139161-65-2P	139161-66-3P	139161-67-4P	139161-68-5P			
139161-69-6P	139161-70-9P	139161-71-0P	139161-72-1P	139161-73-2P			
139161-74-3P	139161-75-4P	139161-76-5P	139161-77-6P	139161-78-7P			
139161-79-8P	139161-80-1P	139161-81-2P	139161-82-3P	139161-83-4P			
139161-84-5P	139161-85-6P	139161-86-7P	139161-87-8P	139161-88-9P			
139161-89-0P	139161-91-4P	139161-92-5P	139161-93-6P	139179-02-5P			
139179-03-6P	139179-04-7P	139240-37-2P					
(preparation and reaction of, in preparation of antibacterials)							
IT 139161-15-2P							
(preparation and reaction of, in preparation of antibacterials)							
RN 139161-15-2	USPATFULL						
CN	3-Pyridinecarboxylic acid, 2-chloro-5-cyclopropyl-6-[[[(4,5-dimethoxy-2-nitrophenyl)methoxy]carbonyl]amino]- (CA INDEX NAME)						



L194 ANSWER 28 OF 33 USPATFULL on STN

ACCESSION NUMBER: 97:38524 USPATFULL Full-text

TITLE: 6-membered nitrogen-containing heteroaryl-oxazolidinones

INVENTOR(S): Riedl, Bernd, Wuppertal, Germany, Federal Republic of
 H abich, Dieter, Wuppertal, Germany, Federal Republic of
 Stolle, Andreas, Wuppertal, Germany, Federal Republic of
 Wild, Hanno, Orange, CT, United States
 Endermann, Rainer, Wuppertal, Germany, Federal Republic of
 Bremm, Klaus D., Recklinghausen, Germany, Federal Republic of
 Kroll, Hein-Peter, Wuppertal, Germany, Federal Republic of
 Labischinski, Harald, Wuppertal, Germany, Federal Republic of
 Schaller, Klaus, Wuppertal, Germany, Federal Republic of
 Werling, Hans-Otto, Wuppertal, Germany, Federal Republic of

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627181		19970506
APPLICATION INFO.:	US 1995-503369		19950717 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4425612	19940720
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2121	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 6-membered nitrogen-containing heteroaryloxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM The compounds of the general formulae (I), (Ia), (Ib), (Ic), (Id), (Ie) and (If) according to the invention have a broad antibacterial spectrum, specifically against Gram-positive bacteria and Mycobacteria, Corynebacteria, Haemophilus influenzae and anaerobic germs, coupled with a low toxicity. These properties

enable them to be used as chemotherapeutic active compounds in human and veterinary medicine.


SUMM The compounds according to the invention are active against a broad spectrum of microorganisms. Gram-positive bacteria and bacteria-like microorganisms, such as *Mycoplasma*, can be combated and the diseases caused by these pathogens can be prevented, alleviated and/or cured with the aid of the compounds.

IT 36802-74-1P, 2-Quinolinecarbonyl azide 175393-01-8P
 175393-02-9P 175393-03-0P 175393-04-1P 175393-05-2P
 175393-06-3P 175393-07-4P 175393-08-5P 175393-09-6P 175393-10-9P
 175393-11-0P 175393-12-1P 175393-13-2P 175393-14-3P 175393-15-4P
 175393-16-5P, 2-Quinoxalinecarbonyl azide 175393-17-6P
 (intermediate; preparation of heteroaryloxazolidinones as antibacterials)

IT 175393-01-8P 175393-02-9P
 (intermediate; preparation of heteroaryloxazolidinones as antibacterials)


RN 175393-01-8 USPATFULL

CN Carbamic acid, (6-methyl-2-pyridinyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 175393-02-9 USPATFULL

CN Carbamic acid, (5-bromo-6-methyl-2-pyridinyl)-, phenylmethyl ester (9CI)
 (CA INDEX NAME)



L194 ANSWER 29 OF 33 USPATFULL on STN

ACCESSION NUMBER: 97:10039 USPATFULL Full-text

TITLE: Quinolizone type compounds

INVENTOR(S): Chu, Daniel T., Santa Clara, CA, United States
 Li, Qun, Gurnee, IL, United States
 Cooper, Curt S., Gurnee, IL, United States
 Fung, Anthony K. L., Gurnee, IL, United States
 Lee, Cheuk M., Libertyville, IL, United States
 Plattner, Jacob J., Libertyville, IL, United States
 Ma, Zhenkun, Gurnee, IL, United States
 Wang, Wei-Bo, Park City, IL, United States

PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5599816		19970204
APPLICATION INFO.:	US 1995-482249		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-469159, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-316319, filed on 30 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-137236, filed on 14 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-940870, filed on 27 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-517780, filed on 2 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia		
LEGAL REPRESENTATIVE:	Anand, Mona, Brainard, Thomas D.		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	12751		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds wherein

A is.dbd.CR.sup.6 --;

R.sup.1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl;

R.sup.2 is selected from the group consisting of ##STR2## R.sup.3 is halogen; R.sup.4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group;

R.sup.5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR.sup.13 R.sup.14 ; and

R.sup.6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl),

as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM There is a continuing need for new antibacterial agents. Although many compounds are known which are useful in the treatment of Gram-positive and Gram-negative bacterial infections as well as other microbial infections, the widespread use of such compounds continues to give rise to resistant strains of microorganisms, i.e., strains of microorganisms against which a particular antibiotic or group of antibiotics, which was previously effective, is no longer useful. Also, known antibiotics may be effective against only certain strains of microorganisms or have limited activity against either Gram-

positive or Gram-negative, aerobic or anaerobic organisms.

SUMM The above compounds of the invention are found to have a surprising degree of antimicrobial activity against a wide spectrum of Gram -positive and Gram-negative bacteria as well as enterobacteria. Susceptible organisms whose growth can be inhibited generally include both aerobic and anaerobic pathogens of the genera *Staphylococcus*, *Lactobacillus*, *Micrococcus*, *Enterococcus*, *Streptococcus*, *Sarcina*, *Escherichia*, *Enterobacter*, *Klebsiella*, *Pseudomonas*, *Acinobacter*, *Proteus*, *Providencia*, *Citrobacter*, *Nisseria*, *Bacillus*, *Bacteroides*, *Camphylobacter*, *Peptococcus*, *Clostridium*, *Salmonella*, *Shigella*, *Legionella*, *Serratia*, *Haemophilus*, *Brucella* and the like. It is therefore expected that the compounds of the present invention will be useful in the treatment and prevention of susceptible bacterial infections in both humans and lower animals. In addition, the compounds, by reason of their in vitro activity, may. . .

DETD . . . inhibitory concentrations (MICs) were determined by the agar dilution method, in which twelve petri dishes were prepared, each containing successive aqueous 2-fold dilutions of the test compounds mixed with 10 mL of sterilized Brain Heart Infusion (BHI) agar. Each plate was inoculated with 1:100 (or 1:10 for slow-growing strains, primarily *Micrococcus* and *Streptococcus*) dilutions of up to 32 different microorganisms, using a Steers replicator block calibrated to deliver approximately 10^{sup}.4 colony forming units (CFUs). The inoculated plates were incubated at from about 35° C. to about 37° C. for approximately 20-24 hours. In addition, a control plate using BHI agar containing no test. . .

DETD . . . -- -- -- 0.39

Staphylococcus aureus 642A
0.39 0.78
0.78
6.2 -- -- 0.39

Staphylococcus aureus NCTC 10649
0.39 0.39
0.39
6.2 -- -- 0.2

Staphylococcus aureus CMX 553
0.78 0.78
0.78
12.5
50 50 0.39

Staphylococcus aureus 1775
>100 -- 25 -- -- 25

Staphylococcus epidermidis 3519
0.39 0.78
0.78
12.5
50 25 0.39

Micrococcus luteus ATCC 9341
1.56 50 50 25 25 3.1

Micrococcus luteus ATCC 4698
0.78 25 25 12.5
25 25 1.56

Enterococcus faecium ATCC 8043
0.39 25 25 50 100 50 1.56

Streptococcus bovis A5169
1.56 25 25 25 25 100 3.1

Streptococcus agalactiae CMX 508
0.39 12.5
12.5
25 50 100 1.56

```

Streptococcus pyrogenes EES61
    0.39 6.2 6.2
                25 50 100 1.56
Streptococcus pyrogenes CONST
    0.78 6.2 6.2
                25 50 50 1.56
Streptococcus pyrogenes 2548 INDUC
    0.39 3.1 3.1
                25 50 50 0.39
Escherichia coli JUHL
    0.01 0.39
                0.39
                3.1 6.2 12.5 0.02
Escherichia coli SS
    .005 <.05
                0.05
                0.39
                1.56 1.56 0.01
Escherichia coli DC-2
    0.2 12.5
                12.5
                25 100 >100 0.39
Escherichia coli H560
    0.01 -- 0.39
                3.1 12.5 12.5 0.02
Escherichia coli KNK 437
    0.2. . . .
SYSTEM LIMIT EXCEEDED DURING KWIC/STRING SEARCH
DETD . . . 0.1
P. aeruginosa K799/WT
    0.05 0.1 0.2 0.2 0.05 0.1
P. aeruginosa K799/61
    0.01 0.01 0.05 0.05 0.01 0.02
P. aeruginosa 5263
    0.78 1.56 3.1 12.5 0.39 12.5
P. aeruginosa 2863
    0.78 1.56 1.56 12.5 0.39 12.5
Acinetobacter calcoaceticus CMX 669
    0.01 0.05 0.01 0.1 0.02 0.39
Myco. smegmatis ATCC 114
    0.02 0.1 0.2 0.78 0.2 0.78
Nocardia asteroides ATCC 9970
    0.2 0.1 0.2 0.39 0.2 12.5
Candida albicans CCH 442
    >100 >100 >100 >100 >100 >100

```

```

Organisms      Ex. 258
                Ex. 259
                Ex. 260
                Ex. 261
                Ex. 262
                cipro-
                floxacin

```

```

Staph. aureus ATCC 6538P
    0.1 0.05 0.05 0.05 0.05 0.2
Staph. aureus A5177
    0.1 0.1 0.1 0.05 0.05 0.39
Staph. aureus 5278
    0.1. . . cepacia 2961

```

	3.1	1.56	12.5	50	3.1	3.1
Acinetobacter calcoaceticus CMX 669	0.05	0.1	0.78	0.39	0.2	0.39
P. aeruginosa 5263	6.2	3.1	50	>100	3.1	12.5
P. aeruginosa 2863	6.2	3.1	25	>100	3.1	12.5
Candida albicans CCH 442	>100	>100	>100	>100	>100	>100
Myco. smegmatis ATCC 114	0.78	0.2	1.56	50	1.56	0.78
Nocardia asteroides ATCC 9970	12.5	1.56	1.56	50	0.78	12.5

Organisms	Cipro-					
	Ex. 263					
	Ex. 264					
	Ex. 265					
	Ex. 266					
	Ex. 267	floxacin				

Staph. aureus ATCC 6538P	0.01	0.02	0.02	0.02	0.1	0.2
Staph. aureus A5177	0.02	0.05	0.1	0.05	0.1	0.39
Staph. aureus 5278	0.02	0.05	0.05	0.05	0.1	0.39
Staph. aureus 642A	0.02	0.1	.	.	cepacia 296I	
	0.78	3.1	6.2	3.1	3.1	3.1
Acinetobacter calcoaceticus CMX 669	0.1	0.2	1.56	0.78	0.05	0.39
P. aeruginosa 5263	3.1	6.2	>100	50	25	12.5
P. aeruginosa 2863	3.1	6.2	>100	25	12.5	12.5
Candida albicans CCH 442	>100	>100	>100	>100	>100	>100
Myco. smegmatis ATCC 114	0.2	0.2	25	3.1	0.2	0.78
Nocardia asteroides ATCC 9970	0.2	3.1	12.5	1.56	6.2	12.5

Organisms	Cipro-					
	Ex. 268					
	Ex. 269					
	Ex. 270					
	Ex. 271					
	Ex. 272	floxacin				

Staph. aureus ATCC 6538P	0.05	0.01	0.02	0.01	0.1	0.2
Staph. aureus A5177	0.1	0.02	0.02	0.02	0.1	0.39
Staph. aureus 5278	0.1	0.02	0.02	0.01	0.1	0.39
Staph. aureus 642A	0.1	0.05	.	.	cepacia 296I	

	3.1	1.56	3.1	0.1	1.56	3.1
Acinetobacter calcoaceticus CMX 669	0.1	0.02	0.2	0.01	0.05	0.39
P. aeruginosa 5263	3.1	3.1	50	6.2	12.5	12.5
P. aeruginosa 2863	3.1	3.1	25	6.2	6.2	12.5
Candida albicans CCH 442	>100	>100	>100	>100	>100	>100
Myco. smegmatis ATCC 114	0.78	0.1	0.78	0.78	1.56	0.78
Nocardia asteroides ATCC 9970	3.1	0.39	1.56	0.78	1.56	12.5

Organisms	Ex. 273	Cipro-				
	Ex. 274					
	Ex. 275					
	Ex. 276					
	Ex. 277	floxacin				

Staph. aureus ATCC 6538P	0.2	0.1	0.05	0.02	0.01	0.2
Staph. aureus A5177	0.2	0.2	0.05	0.05	0.02	0.39
Staph. aureus 5278	0.2	0.2	0.05	0.02	0.02	0.39
Staph. aureus 642A	0.39	0.2	.	.	cepacia 296I	
	6.2	3.1	3.1	1.56	0.78	3.1
Acinetobacter calcoaceticus CMX 669	0.2	0.2	0.1	0.02	0.02	0.39
P. aeruginosa 5263	12.5	12.5	6.2	1.56	1.56	12.5
P. aeruginosa 2863	6.2	6.2	3.1	1.56	1.56	12.5
Candida albicans CCH 442	>100	>100	>100	>100	>100	>100
Myco. smegmatis ATCC 114	6.2	0.2	0.78	0.78	0.05	0.78
Nocardia asteroides ATCC 9970	6.2	3.1	0.78	0.39	0.39	12.5

Organisms	Ex. 278	Cipro-				
	Ex. 279					
	Ex. 280					
	Ex. 281					
	Ex. 282	floxacin				

Staph. aureus ATCC 6538P	0.39	3.1	0.39	0.39	0.78	0.2
Staph. aureus A5177	0.39	25	0.78	0.39	3.1	0.39
Staph. aureus 5278	0.39	12.5	0.78	0.39	3.1	0.39
Staph. aureus 642A	0.39	25.	.	.	1.56	6.2
					0.1	

P. aeruginosa K799/61	0.2	6.2	=	<0.39		
				0.39	3.1	0.02
Pseudomonas cepacia 296I	6.2	100	6.2	3.1	25	3.1
Acinetobacter calcoaceticus CMX 669	0.2	6.2	3.1	1.56	12.5	0.39
P. aeruginosa 5263	50	>100		12.5	25	12.5
P. aeruginosa 2863	25	>100		12.5	25	12.5
Candida albicans CCH 442						>100
Myco. smegmatis ATCC 114						0.78
Nocardia asteroides ATCC 9970						12.5

Organisms	Ex. 284	Ex. 285	Ex. 296	Ciprofloxacin		
Staph. aureus ATCC 6538P	0.78	0.78	0.02	0.2		
Staph. aureus A5177	1.56	0.78	0.05	0.39		
Staph. aureus 5278	0.78	0.78	0.05	0.39		
Staph. aureus 642A	1.56	0.78	0.05	0.39		
Staph. aureus NCTC10649	0.78	1.56	0.05	0.39		
Staph. aureus CMX 553	3.1	0.78	0.05	0.78		
Staph. aureus . . .	0.39	0.1				
P. aeruginosa K799/WT	12.5	1.56	0.39	0.1		
P. aeruginosa K799/61	1.56	0.39	0.1	0.02		
Pseudomonas cepacia 296I	12.5	25	0.78	3.1		
Acinetobacter calcoaceticus CMX 669	3.1	0.39	0.02	0.39		
P. aeruginosa 5263	50	>100	3.1	12.5		
P. aeruginosa 2863	50	>100	3.1	12.5		
Candida albicans CCH 442	>100		>100	>100		
Myco. smegmatis ATCC 114	25		0.05	0.78		
Nocardia asteroides ATCC 9970	25		3.1	12.5		
IT	866-48-8P	3430-14-6P	3678-63-5P	5239-82-7P	Cyclopropaneacetic acid	
	20967-28-6P	21203-68-9P	31181-53-0P	45673-79-8P	93856-98-5P	
	113209-88-4P	113209-89-5P	114677-00-8P	131189-22-5P	139161-04-9P	
	139161-05-0P	139161-06-1P	139161-07-2P	139161-08-3P	139161-09-4P	
	139161-10-7P	139161-11-8P	139161-12-9P	139161-13-0P	139161-14-1P	
	139161-15-2P	139161-16-3P	139161-17-4P	139161-18-5P		
	139161-19-6P	139161-20-9P	139161-21-0P	139161-22-1P	139161-23-2P	
	139161-24-3P	139161-25-4P	139161-26-5P	139161-27-6P	139161-28-7P	
	139161-29-8P	139161-30-1P	139161-31-2P	139161-32-3P	139161-33-4P	
	139161-34-5P	139161-35-6P	139161-36-7P	139161-37-8P	139161-38-9P	
	139161-39-0P	139161-40-3P	139161-41-4P	139161-42-5P	139161-43-6P	
	139161-44-7P	139161-45-8P	139161-46-9P	139161-47-0P	139161-48-1P	
	139161-49-2P	139161-50-5P	139161-51-6P	139161-52-7P	139161-53-8P	

139161-54-9P	139161-55-0P	139161-56-1P	139161-57-2P	139161-58-3P
139161-59-4P	139161-60-7P	139161-61-8P	139161-62-9P	139161-63-0P
139161-64-1P	139161-65-2P	139161-66-3P	139161-67-4P	139161-68-5P
139161-69-6P	139161-70-9P	139161-71-0P	139161-72-1P	139161-73-2P
139161-74-3P	139161-75-4P	139161-76-5P	139161-77-6P	139161-78-7P
139161-79-8P	139161-80-1P	139161-81-2P	139161-82-3P	139161-83-4P
139161-84-5P	139161-85-6P	139161-86-7P	139161-87-8P	139161-88-9P
139161-89-0P	139161-91-4P	139161-92-5P	139161-93-6P	139179-02-5P
139179-03-6P	139179-04-7P	139240-37-2P		


(preparation and reaction of, in preparation of antibacterials)

IT 139161-15-2P

(preparation and reaction of, in preparation of antibacterials)

RN 139161-15-2 USPATFULL

CN 3-Pyridinecarboxylic acid, 2-chloro-5-cyclopropyl-6-[[[(4,5-dimethoxy-2-nitrophenyl)methoxy]carbonyl]amino]- (CA INDEX NAME)



L194 ANSWER 30 OF 33 USPATFULL on STN

ACCESSION NUMBER: 81:50477 USPATFULL Full-text

TITLE: Penicillins

INVENTOR(S): Wetzel, Bernd, Biberach an der Riss, Germany, Federal Republic of

Woitun, Eberhard, Biberach an der Riss, Germany, Federal Republic of

Reuter, Wolfgang, Laupertshausen, Germany, Federal Republic of

Maier, Roland, Biberach an der Riss, Germany, Federal Republic of

Lechner, Uwe, Ummendorf, Germany, Federal Republic of
Goeth, Hanns, Biberach an der Riss, Germany, Federal Republic of

PATENT ASSIGNEE(S): Karl Thomae GmbH, Biberach an der Riss, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4289775		19810915
APPLICATION INFO.:	US 1980-149839		19800514 (6)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1980-117103, filed on 31 Jan 1980, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1979-2910190	19790315
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Trousof, Natalie	
ASSISTANT EXAMINER:	Clarke, Vera C.	
LEGAL REPRESENTATIVE:	Hammond & Littell, Weissenberger & Muserlian	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1,5	
LINE COUNT:	1220	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1## wherein A is phenyl, p-hydroxy-phenyl, 2-thienyl, 3-thienyl or 3,4-disubstituted phenyl, where the substituents, which may be identical to or different from each other, are each chlorine, hydroxyl or methoxy;

R is --NH--Z--X;

Z is straight or branched alkylene of 1 to 6 carbon atoms or cycloalkylene of 3 to 6 carbon atoms;

X is cyano, hydroxyl, mercapto, aminocarbonyl, aminosulfonyl, ##STR2##
 R.sub.1 is straight or branched alkyl of 1 to 4 carbon atoms or phenyl;
 R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms; and

R.sub.1 and R.sub.2, together with an adjacent nitrogen atom to which they are attached, form a 3- to 6-membered heterocyclic ring;

and non-toxic, pharmacologically acceptable salts thereof formed with inorganic or organic bases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD The compounds embraced by formulas I and I' and their non-toxic, pharmacologically acceptable salts formed with inorganic and organic bases have useful pharmacodynamic properties. More particularly, they exhibit broad-spectrum antibiotic activity, both in vivo and in vitro, against pathogenic microorganisms, especially against gram-positive and gram-negative bacteria. After parenteral or peroral administration to warm-blooded animals, such as mice, high levels of the compounds of this invention are found in tissue, serum, organs and urine. The antibacterial activity of the compounds of this invention was determined and compared to a known penicillin by the test. . . .

DETD The nutrient medium consisted of: 10 gm of peptone, 8 gm of meat extract oxid, 3 gm of sodium chloride, and 2 gm of sec. sodium phosphate diluted with distilled water to 1000 ml (pH 7.2-7.4). Only in the test against streptococci was 1% of glucose added. The age of the primary cultures was about 20 hours. The standardization of the microorganism suspension was effected by means of a photometer according to the method of Eppendorf (test tube diameter 14 mm, filter 546 nm), using for comparison a barium sulfate suspension formed by the addition of 3.0 ml of 1% barium chloride solution to 97 ml of 1% sulfuric acid. After the standardization, the Streptococcus aranson was further diluted to a concentration of 1:15 and the other microorganisms to a concentration of 1:1500 using a sodium chloride solution. 16 mgm of the test compound were placed into a 10 ml measuring flask, and the flask was filled up to the mark with the solvent. The. . . .

DETD The compounds of this invention may also be incorporated into foodstuffs and into drinking water according to conventional methods, so as to prevent and/or cure infections by gram-negative and gram-positive bacteria and also to promote and improve utilization of the foodstuff.

IT	76592-11-5P	76592-12-6P	76592-13-7P	76592-14-8P	76592-15-9P
	76592-16-0P	76592-18-2P	76592-19-3P	76592-20-6P	76592-21-7P
	76592-23-9P	76592-24-0P	76592-25-1P	76592-26-2P	

76592-27-3P 76592-28-4P 76592-29-5P 76592-30-8P 76592-31-9P
 76592-32-0P 76592-33-1P


(preparation and reaction of, with aminoacetylaminopenams and phosgene)

IT 76592-25-1P

(preparation and reaction of, with aminoacetylaminopenams and phosgene)

RN 76592-25-1 USPATFULL

CN Carbamic acid, (5-amino-1,4-dihydro-4-oxo-2-pyrimidinyl)-, ethyl ester
 (9CI) (CA INDEX NAME)



L194 ANSWER 31 OF 33 USPATFULL on STN

ACCESSION NUMBER: 80:33258 USPATFULL Full-text

TITLE: Heavy metal derivatives of mercaptopyridine-1-oxide

INVENTOR(S): Douglass, Miriam L., Piscataway, NJ, United States

PATENT ASSIGNEE(S): Colgate-Palmolive Company, New York, NY, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4211871		19800708
APPLICATION INFO.:	US 1978-932065		19780808 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1977-791613, filed on 27 Apr 1977, now patented, Pat. No. US 4122084, issued on 24 Oct 1978 which is a division of Ser. No. US 1975-629436, filed on 6 Nov 1975, now patented, Pat. No. US 4048181, issued on 13 Sep 1977		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Berch, Mark L.		
LEGAL REPRESENTATIVE:	Miller, Richard N., Grill, Murray M., Sylvester, Herbert S.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	850		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heavy metal salts of 2-amino derivatives of 6-mercaptopyridine-1-oxide, including 2-acylamino- and 2-alkoxycarbonylamino-6-mercaptopyridine-1-oxide, having particular utility as antimicrobial agents per se and in skin cleansing detergent composition, shampoos, hair dressings, disinfectants, preservatives and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . as the zinc salts of the substituted amino-mercaptopyridine-1-oxides are insoluble and thus amenable to formulation only in opaque products. After use of such preparations, it appears that the effects of the present anti-microbial compounds are long lasting. The substituted amino mercaptopyridine-1-oxides, disulfides, and salts thereof, are effective against such potent gram-positive

organisms as *Staphylococcus aureus*, *Streptococcus mitis*, gram negative bacteria such as *Escherichia coli*, *Pseudomonas aeruginosa*, as well as against the yeasts such as *Candida albicans* and *Pityrosporum ovale* and the molds *Trichophyton mentagrophytes* and *Aspergillus niger*.

IT 25218-99-9P 64920-44-1P

(preparation and oxidation of)

IT 64920-42-9P 64920-45-2P


(preparation and reaction with sodium hydrosulfide)

IT 64920-44-1P

(preparation and oxidation of)

RN 64920-44-1 USPATFULL

CN Carbamic acid, (6-bromo-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 64920-45-2P

(preparation and reaction with sodium hydrosulfide)

RN 64920-45-2 USPATFULL

CN Carbamic acid, (6-bromo-1-oxido-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 32 OF 33 USPATFULL on STN

ACCESSION NUMBER: 78:59994 USPATFULL Full-text

TITLE: Derivatives of mercaptopyridine-1-oxide

INVENTOR(S): Douglass, Miriam Lois, Piscataway, NJ, United States

PATENT ASSIGNEE(S): Colgate-Palmolive Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4122085		19781024
APPLICATION INFO.:	US 1977-791613		19770427 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1975-629436, filed on 6 Nov 1975, now patented, Pat. No. US 4048181		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Miller, Richard N., Grill, Murray M., Sylvester, Herbert S.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
LINE COUNT:	985		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Quaternary ammonium salts and benzyl mercaptans of amino derivatives of mercaptopyrindine-1-oxide, including 1-acylamino- and 2-alkoxycarbonylamino-6-pyrindine-1-oxide, having particular utility as antimicrobial agents per se and in skin cleansing detergent compositions, shampoos, hair dressings, disinfectants, preservatives and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . the substituted amino-mercaptopyridine-1-oxides are insoluble and thus amenable to formulation only in opaque products. After use of such preparations, it appears that the effects of the present anti-microbial compounds are long lasting. The substituted amino mercaptopyridine-1-oxides, disulfides, and salts thereof, are effective against such potent grampositive organisms as *Staphylococcus aureus*, *Streptococcus mitis*, gram negative bacteria such as *Escherichia coli*, *Pseudomonas aeruginosa*, as well as against the yeasts such as *Candida albicans* and *Pityrosporum ovale* and the molds *Trichophyton mentagrophytes* and *Aspergillus niger*.

SUMM . . . as the zinc salts of the substituted amino-mercaptopyridine-1-oxides are insoluble and thus amenable to formulation only in opaque products. After use of such preparations, it appears that the effects of the present anti-microbial compounds are long lasting. The substituted amino mercaptopyridine-1-oxides, disulfides, and salts thereof, are effective against such potent gram-positive organisms as *Staphylococcus aureus*, *Streptococcus mitis*, gram negative bacteria such as *Escherichia coli*, *Pseudomonas aeruginosa*, as well as against the yeasts such as *Candida albicans* and *Pityrosporum ovale* and the molds *Trichophyton mentagrophytes* and *Aspergillus niger*.


IT 25218-99-9P 64920-44-1P
(preparation and oxidation of)

IT 64920-42-9P 64920-45-2P
(preparation and reaction with sodium hydrosulfide)

IT 64920-44-1P
(preparation and oxidation of)

RN 64920-44-1 USPATFULL


CN Carbamic acid, (6-bromo-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT 64920-45-2P
(preparation and reaction with sodium hydrosulfide)

RN 64920-45-2 USPATFULL

CN Carbamic acid, (6-bromo-1-oxido-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L194 ANSWER 33 OF 33 USPATFULL on STN
 ACCESSION NUMBER: 78:59993 USPATFULL Full-text
 TITLE: Disulfides of amino-substituted mercaptopyridine-1-oxide
 INVENTOR(S): Douglass, Miriam L., Piscataway, NJ, United States
 PATENT ASSIGNEE(S): Colgate-Palmolive Company, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4122084		19781024
APPLICATION INFO.:	US 1977-791612		19770427 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1975-629436, filed on 6 Nov 1975, now patented, Pat. No. US 4048181		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rotman, Alan L.		
LEGAL REPRESENTATIVE:	Miller, Richard N., Grill, Murray M., Sylvester, Herbert S.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	848		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disulfide of amino-containing mercaptopyridine-1-oxide having particular utility as antimicrobial agents per se and in skin cleansing detergent compositions, shampoos, hair dressings, disinfectants, preservatives and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PARN . . . as the zinc salts of the substituted amino-mercaptopyridine-1-oxides are insoluble and thus amenable to formulation only in opaque products. After use of such preparations, it appears that the effects of the present anti-microbial compounds are long lasting. The substituted amino mercaptopyridine-1-oxides, disulfides, and salts thereof, are effective against such potent gram-positive organisms as *Staphylococcus aureus*, *Streptococcus mitis*, gram negative bacteria such as *Escherichia coli*, *Pseudomonas aeruginosa*, as well as against the yeasts such as *Candida albicans* and *Pityrosporum ovale* and the molds *Trichophyton mentagrophytes* and *Aspergillus niger*.


IT 25218-99-9P 64920-44-1P
 (preparation and oxidation of)

IT 64920-42-9P 64920-45-2P
 (preparation and reaction with sodium hydrosulfide)

IT 64920-44-1P
 (preparation and oxidation of)


RN 64920-44-1 USPATFULL

CN Carbamic acid, (6-bromo-2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT 64920-45-2P
 (preparation and reaction with sodium hydrosulfide)

RN 64920-45-2 USPATFULL

CN Carbamic acid, (6-bromo-1-oxido-2-pyridinyl)-, ethyl ester (9CI) (CA
INDEX NAME)

SPECIES SEARCH

=> fil reg; d ide l54 l-
 FILE 'REGISTRY' ENTERED AT 12:41:26 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 SEP 2008 HIGHEST RN 1045602-82-1
 DICTIONARY FILE UPDATES: 1 SEP 2008 HIGHEST RN 1045602-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y


L54 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 19270-29-2 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Carbamic acid, {8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-
 diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX
 NAME)
 OTHER CA INDEX NAMES:
 CN Fyrido[2,3-b]pyrazine-6-carbamic acid, 8-[[4-(diethylamino)-1-
 methylbutyl]amino]-2,3-diphenyl-, ethyl ester (6CI)
 MF C31 H36 N6 O2
 CI COM
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L54 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 19254-73-0 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Carbamic acid, 1-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazine-6-yl]-, ethyl ester, monohydrochloride {9CI} (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrido[2,3-b]pyrazine, carbamic acid deriv.
 CN Pyrido[2,3-b]pyrazine-6-carbamic acid, 6-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenyl-, ethyl ester, monohydrochloride {8CI}
 OTHER NAMES:
 CN NSC 107487
 MF C21 H38 N6 O2 . Cl H
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 CRN (19270-29-2)



● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> => fil hcapl; d que nos l196
 FILE 'HCAPLUS' ENTERED AT 12:42:15 ON 02 SEP 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Sep 2008 VOL 149 ISS 10
 FILE LAST UPDATED: 1 Sep 2008 (20080901/ED)

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

```

L3      1 SEA FILE=REGISTRY ABB=ON 1404-26-8
L4      STR
L7      1933 SEA FILE=REGISTRY SSS FUL L4
L11     1845 SEA FILE=HCAPLUS ABB=ON WHITE E7/AU
L12     1355 SEA FILE=HCAPLUS ABB=ON REYNOLDS R7/AU
L13     50 SEA FILE=HCAPLUS ABB=ON SULING W7/AU
L14     1 SEA FILE=HCAPLUS ABB=ON US2005-519731/APPS
L15     985 SEA FILE=HCAPLUS ABB=ON L7
L16     2755 SEA FILE=HCAPLUS ABB=ON L3
L17     3190 SEA FILE=HCAPLUS ABB=ON GRAM-POSITIVE BACTERIA/CT
L18     433 SEA FILE=HCAPLUS ABB=ON ACTINOBACTERIA+NT/CT
L19     4108 SEA FILE=HCAPLUS ABB=ON ACTINOMYCETES/CT
L20     3910 SEA FILE=HCAPLUS ABB=ON ACTINOMYCETALES+NT/CT
L21     678 SEA FILE=HCAPLUS ABB=ON ACTINOPLANETES+NT/CT
L22     17 SEA FILE=HCAPLUS ABB=ON ACTINOSYNMEMATACEAE+NT/CT
L23     5 SEA FILE=HCAPLUS ABB=ON ARSENICOCOCCUS+NT/CT
L24     898 SEA FILE=HCAPLUS ABB=ON CORYNEFORM BACTERIA+NT/CT
L25     5800 SEA FILE=HCAPLUS ABB=ON MICROCOCOCCACEAE+NT/CT
L26     1189 SEA FILE=HCAPLUS ABB=ON MICROMONOSPORACEAE+NT/CT
L27     175 SEA FILE=HCAPLUS ABB=ON MICROTHRUX/CW
L28     7309 SEA FILE=HCAPLUS ABB=ON NOCARDIOFORM ACTINOMYCETES+NT/CT
L29     1455 SEA FILE=HCAPLUS ABB=ON PSEUDONOCARDIACEAE+NT/CT
L30     324 SEA FILE=HCAPLUS ABB=ON STREPTOSPORANGIACEAE+NT/CT
L31     112336 SEA FILE=HCAPLUS ABB=ON BACILLALES+NT/CT
L32     14 SEA FILE=HCAPLUS ABB=ON ACIDAMINOCOCCACEAE/CT
L33     4 SEA FILE=HCAPLUS ABB=ON AEROCOCCACEAE/CT
L34     23025 SEA FILE=HCAPLUS ABB=ON CLOSTRIDIACEAE+NT/CT
L35     134 SEA FILE=HCAPLUS ABB=ON CLOSTRIDIALES+NT/CT
L36     16 SEA FILE=HCAPLUS ABB=ON EUBACTERIACEAE/CT
L37     48 SEA FILE=HCAPLUS ABB=ON HALANAEROBIAEAE+NT/CT
L38     1062 SEA FILE=HCAPLUS ABB=ON LACHNOSPIRACEAE+NT/CT
L39     22915 SEA FILE=HCAPLUS ABB=ON LACTOBACILLACEAE+NT/CT
L40     6759 SEA FILE=HCAPLUS ABB=ON MYCOPLASMATAEAE+NT/CT
L41     1 SEA FILE=HCAPLUS ABB=ON PARASPOROBACTERIUM/CW
L42     7 SEA FILE=HCAPLUS ABB=ON PEPTOSTREPTOCOCCACEAE/CT
L43     41508 SEA FILE=HCAPLUS ABB=ON STREPTOCOCCACEAE+NT/CT
L44     36336 SEA FILE=HCAPLUS ABB=ON MYCOBACTER?/OBI
L45     15 SEA FILE=HCAPLUS ABB=ON "LOW G+C GRAM-POSITIVE BACTERIA"/CT
L47     5 SEA FILE=HCAPLUS ABB=ON (L11 OR L12 OR L13 OR L14) AND L15
      AND (L16 OR L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR
      L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR
      L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR
      L42 OR L43 OR L44 OR L45)
L48     1 SEA FILE=HCAPLUS ABB=ON L15 AND L16
L49     12 SEA FILE=HCAPLUS ABB=ON L15 AND (L17 OR L18 OR L19 OR L20 OR
      L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR
      L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR
      L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45)
L50     875 SEA FILE=HCAPLUS ABB=ON FTSZ/OBI
L51     4 SEA FILE=HCAPLUS ABB=ON L15 AND L50
L52     184 SEA FILE=REGISTRY ABB=ON C31H38N6O2?
L53     3 SEA FILE=REGISTRY ABB=ON L52 AND L7
L54     2 SEA FILE=REGISTRY ABB=ON L53 AND CARBAMIC/CNS
L192    7 SEA FILE=HCAPLUS ABB=ON (L48 OR L49 OR L51) NOT L47

```

L196 1 SEA FILE=HCAPLUS ABB=ON L54 AND (L192 OR L47)

=> d scan ti l196 THIS REFERENCE WAS PRINTED IN FULL ON p.4

L196 1 ANSWERS HCAPLUS COPYRIGHT 2008 ACS on STN
TI Antibacterial inhibitors of Ftsz protein

ALL ANSWERS HAVE BEEN SCANNED

=> s l54 not l196

3 L54
L197 2 L54 NOT L196 UNIQUE REFERENCES

=> d ibib abs hitstr 1-2

L197 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1969:4042 HCAPLUS Full-text

DOCUMENT NUMBER: 70:4042

ORIGINAL REFERENCE NO.: 70:757a,760a

TITLE: Synthesis of potential antimalarial agents. II.

6,8-Disubstituted pyrido[2,3-b]pyrazines

AUTHOR(S): Temple, Carroll, Jr.; Rose, Jerry D.; Elliott, Robert D.; Montgomery, John A.

CORPORATE SOURCE: Kettering-Meyer Lab., Southern Res. Inst., Birmingham, AL, USA

SOURCE: Journal of Medicinal Chemistry (1968), 11(6), 1216-18
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB The preparation of five Et 6-amino-5-nitro-4-substituted amino-2-pyridinecarbamates, 4 similar compds. having the nitro group reduced to an amine group, and 38 pyrido[2,3-b]pyrazines (I) containing benzenesulfonamido, p-chloroanilino, or similar antimalarial groups is described.

IT 19254-73-0F

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 19254-73-0 HCAPLUS

CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester, monohydrochloride (9CI)
(CA INDEX NAME)




L197 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1968:26426 HCAPLUS Full-text
 DOCUMENT NUMBER: 68:26426
 ORIGINAL REFERENCE NO.: 68:5083a,5086a
 TITLE: Square-planar sulfur complexes. VI. Reactions of bases with xanthates, dithiocarbamates, and dithiolates of nickel(II)
 AUTHOR(S): Coucouvanis, Dimitri; Fackler, John P., Jr.
 CORPORATE SOURCE: Case Western Reserve Univ., Cleveland, OH, USA
 SOURCE: Inorganic Chemistry (1967), 6(11), 2047-53
 CODEN: INOCAJ; ISSN: 0020-1669
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Nitrogenous bases interact strongly with Ni(II) complexes of 1,1-dithio ligands of the type S2CCR3-, S2COR-, and S2CNH2- to form high-spin adducts. Little or no interaction is observed with Ni(II) complexes of the ligands S2CNR2-, S2CS2-, S2CNR2-, or S2CCR22-. The extent of metal-base interaction appears to be directly related to the ability of the ligand to mesomerically shift electron d. onto the metal through its π system. Several new sulfur chelates of the 1,1-dithio type are reported in this study. 38 references.
 IT 19270-29-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 19270-29-2 HCAPLUS
 CN Carbamic acid, [8-[[4-(diethylamino)-1-methylbutyl]amino]-2,3-diphenylpyrido[2,3-b]pyrazin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



SEARCH HISTORY

=> d stat que 17; d his nofile
L4 STR



VAR G1=11/17/23
VAR G2=N/30/OH/24/25
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 24
CONNECT IS E1 RC AT 26
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 24 26 30
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
L7 1933 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 14517 ITERATIONS 1933 ANSWERS
SEARCH TIME: 00.00.02

(FILE 'HOME' ENTERED AT 11:47:47 ON 02 SEP 2008)

FILE 'CAPLUS' ENTERED AT 11:48:28 ON 02 SEP 2008

E US2004-519731/APPS
E US2005-519731/APPS
L1 1 SEA ABB=ON US2005-519731/AP
D SCAN
E GRAM POSITIVE/CT
E GRAM-POSITIVE/CT
E E4+NT1/CT
SEL RN

FILE 'REGISTRY' ENTERED AT 11:50:20 ON 02 SEP 2008

L2 310 SEA ABB=ON (103220-14-0/BI OR 109182-31-2/BI OR 109182-32-3/BI
OR 109182-33-4/BI OR 109182-34-5/BI OR 109182-36-7/BI OR
109182-37-8/BI OR 109182-38-9/BI OR 109182-43-6/BI OR 109182-47
-0/BI OR 109182-48-1/BI OR 109182-53-8/BI OR 109182-54-9/BI OR
109182-55-0/BI OR 109182-68-5/BI OR 109182-69-6/BI OR 109182-70
-9/BI OR 109182-71-0/BI OR 109182-73-2/BI OR 109217-57-4/BI OR

116403-17-9/BI OR 116659-54-2/BI OR 121572-30-3/BI OR 121572-32-5/BI OR 121572-34-7/BI OR 121572-37-0/BI OR 121572-46-1/BI OR 121572-53-0/BI OR 121596-28-9/BI OR 122293-96-3/BI OR 122293-97-4/BI OR 122293-99-6/BI OR 122332-17-6/BI OR 122332-18-7/BI OR 123753-52-6/BI OR 123753-54-8/BI OR 123753-55-9/BI OR 123753-56-0/BI OR 123753-57-1/BI OR 123753-59-3/BI OR 123753-60-6/BI OR 123753-62-8/BI OR 123753-63-9/BI OR 123753-64-0/BI OR 123753-66-2/BI OR 123753-68-4/BI OR 123753-70-8/BI OR 123753-72-0/BI OR 123775-16-6/BI OR 130145-52-7/BI OR 130145-54-9/BI OR 130145-56-1/BI OR 130145-61-8/BI OR 130145-65-2/BI OR 135696-25-2/BI OR 135696-27-4/BI OR 135696-30-9/BI OR 135696-31-0/BI OR 135696-32-1/BI OR 135696-33-2/BI OR 135696-35-4/BI OR 135696-36-5/BI OR 135696-37-6/BI OR 135696-39-8/BI OR 135696-40-1/BI OR 135696-42-3/BI OR 135696-46-7/BI OR 135696-47-8/BI OR 135696-48-9/BI OR 135696-50-3/BI OR 135696-51-4/BI OR 135696-52-5/BI OR 135696-54-7/BI OR 139016-58-3/BI OR 139016-59-4/BI OR 139016-61-8/BI OR 139068-49-8/BI OR 139068-54-5/BI OR 139068-55-6/BI OR 139068-56-7/BI OR 1404-26-8/BI OR 143858-90-6/BI OR 144694-16-6/BI OR 144694-17-7/BI OR 144694-18-8/BI OR 144694-20-2/BI OR 144694-26-8/BI OR 144694-29-1/BI OR 15223-96-8/BI OR 15223-97-9/BI OR 15223-98-0/BI OR 15223-99-1/BI OR 16335-92-5/BI OR 16335-94-7/B I OR 16335-96-9/BI OR 16335-98-1/BI OR 16336-03-1/BI OR 16336-05-3/BI OR 16336-06-4/BI OR 19254-73-0/BI OR 19270-28-1/B I OR 19270-29-2/BI OR 19270-36-1/BI OR 19270-37-2/BI OR 19270-38-3/BI OR 19270-40-7/BI OR 19270-41-8/BI OR 19270-42-9/B I OR 19270-44-1/BI OR 19270-46-3/BI OR 21271-60-3/BI OR 21271-61-4/BI OR 21271-65-8/BI OR 21271-66-9/BI OR

L3 1 SEA ABB=ON 1404-26-8
D SCAN

L4 STR

L5 50 SEA SSS SAM L4

L6 14517 SEA SSS FUL L4 EXTEND

L7 1933 SEA SSS FUL L4
SAVE TEMP L7 SRI731FULL/A

L8 297 SEA ABB=ON L7 AND L2

L9 97 SEA ABB=ON 1404-26-8/CRN

L10 0 SEA ABB=ON L9 AND L7

FILE 'ZCAPLUS' ENTERED AT 11:56:35 ON 02 SEP 2008

E GRAM-POS/CT
E E8+ALL
E E2+NT1/CT
E ACTINOBACTERIA+ALL/CT
E ACTINOMYCETES+NT1/CT
E ACTINOMYCETALES+ALL/CT
E ACTINOPLANETES+NT/CT
E ACTINOSYNNEMATAACEAE+NT/CT
E ARSENICOCOCCUS+NT/CT
E CORYNEFORM BACTERIA+ALL/CT
E MICROCOCCACEAE+NT/CT
E MICROMONOSPORACEAE+NT/CT
E MICROTHRIX (BACTERIUM)/CT
E E3+ALL
E NOCARDIOFORM ACTINOMYCETES+ALL/CT
E PSEUDONOCARDIACEAE+ALL/CT
E STREPTOMYCETES+NT/CT
E STREPTOSPORANGIACEAE+ALL/CT
E BACILLALES+NTCT
E BACILLALES+NT/CT
E "LOW G+C GRAM-POSITIVE BACTERIA"+NT1/CT

E ACIDAMINOCOCCACEAE+NT/CT
 E AEROCOCCACEAE+NT/CT
 E CLOSTRIDIACEAE/CT
 E CLOSTRIDIACEAE+NT/CT
 E CLOSTRIDIALES+NT/CT
 E EUBACTERIACEAE+NT/CT
 E HALANAEROBIAACEAE+NT/CT
 E LACHNOSPIRACEAE+NT/CT
 E LACTOBACILLACEAE+NT/CT
 E MYCOPLASMATAACEAE+NT/CT
 E PARASPOROBACTERIUM+NT/CT
 E PEPTOSTREPTOCOCCACEAE+NT/CT
 E STREPTOCOCCACEAE+NT/CT

FILE 'HCAPLUS' ENTERED AT 12:11:44 ON 02 SEP 2008

L11 1845 SEA ABB=ON WHITE E7/AU
 L12 1355 SEA ABB=ON REYNOLDS R7/AU
 L13 50 SEA ABB=ON SULING W7/AU
 L14 1 SEA ABB=ON US2005-519731/APPS
 L15 985 SEA ABB=ON L7
 L16 2755 SEA ABB=ON L3
 L17 3190 SEA ABB=ON GRAM-POSITIVE BACTERIA/CT
 L18 433 SEA ABB=ON ACTINOBACTERIA+NT/CT
 L19 4108 SEA ABB=ON ACTINOMYCETES/CT
 L20 3910 SEA ABB=ON ACTINOMYCETALES+NT/CT
 L21 678 SEA ABB=ON ACTINOPLANETES+NT/CT
 L22 17 SEA ABB=ON ACTINOSYNMEMATAACEAE+NT/CT
 L23 5 SEA ABB=ON ARSENICICOCCUS+NT/CT
 L24 898 SEA ABB=ON CORYNEFORM BACTERIA+NT/CT
 L25 5800 SEA ABB=ON MICROCOCCACEAE+NT/CT
 L26 1189 SEA ABB=ON MICROMONOSPORACEAE+NT/CT
 L27 175 SEA ABB=ON MICROTHRIX/CW
 L28 7309 SEA ABB=ON NOCARDIOFORM ACTINOMYCETES+NT/CT
 L29 1455 SEA ABB=ON PSEUDONOCARDIACEAE+NT/CT
 L30 324 SEA ABB=ON STREPTOSPORANGIACEAE+NT/CT
 L31 112336 SEA ABB=ON BACILLALES+NT/CT
 L32 14 SEA ABB=ON ACIDAMINOCOCCACEAE/CT
 L33 4 SEA ABB=ON AEROCOCCACEAE/CT
 L34 23025 SEA ABB=ON CLOSTRIDIACEAE+NT/CT
 L35 134 SEA ABB=ON CLOSTRIDIALES+NT/CT
 L36 16 SEA ABB=ON EUBACTERIACEAE/CT
 L37 48 SEA ABB=ON HALANAEROBIAACEAE+NT/CT
 L38 1062 SEA ABB=ON LACHNOSPIRACEAE+NT/CT
 L39 22915 SEA ABB=ON LACTOBACILLACEAE+NT/CT
 L40 6759 SEA ABB=ON MYCOPLASMATAACEAE+NT/CT
 L41 1 SEA ABB=ON PARASPOROBACTERIUM/CW
 L42 7 SEA ABB=ON PEPTOSTREPTOCOCCACEAE/CT
 L43 41508 SEA ABB=ON STREPTOCOCCACEAE+NT/CT
 L44 36336 SEA ABB=ON MYCOBACTER?/OBI
 L45 15 SEA ABB=ON "LOW G+C GRAM-POSITIVE BACTERIA"/CT
 L46 5 SEA ABB=ON (L11 OR L12 OR L13 OR L14) AND L15
 L47 5 SEA ABB=ON (L11 OR L12 OR L13 OR L14) AND L15 AND (L16 OR L17
 OR L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26
 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35
 OR L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44
 OR L45)
 L48 1 SEA ABB=ON L15 AND L16
 L49 12 SEA ABB=ON L15 AND (L17 OR L18 OR L19 OR L20 OR L21 OR L22 OR
 L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
 L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40 OR

L50 L41 OR L42 OR L43 OR L44 OR L45)
 L50 875 SEA ABB=ON FTSZ/OBI
 L51 4 SEA ABB=ON L15 AND L50
 D SCAN

FILE 'STNGUIDE' ENTERED AT 12:14:46 ON 02 SEP 2008

FILE 'REGISTRY' ENTERED AT 12:17:07 ON 02 SEP 2008
 L52 184 SEA ABB=ON C31H38N6O2?
 L53 3 SEA ABB=ON L52 AND L7
 D SCAN
 L54 2 SEA ABB=ON L53 AND CARBAMIC/CNS
 D LC 1-2
 L55 767 SEA ABB=ON L7 AND (IFIPAT/LC OR USPATFULL/LC OR SCISEARCH/LC)

FILE 'STNGUIDE' ENTERED AT 12:19:25 ON 02 SEP 2008

FILE 'USPATFULL' ENTERED AT 12:26:51 ON 02 SEP 2008
 L56 206 SEA ABB=ON WHITE E7/AU
 L57 400 SEA ABB=ON REYNOLDS R7/AU
 L58 3 SEA ABB=ON SULING W7/AU
 L59 27611 SEA ABB=ON GRAM(W) (POS OR POSITIVE)
 L60 156 SEA ABB=ON ACTINOBACTER?
 L61 6565 SEA ABB=ON ACTINOMYCET?
 L62 31 SEA ABB=ON ACTINOPLANET?
 L63 17 SEA ABB=ON ACTINOSYNNEMAT?
 L64 0 SEA ABB=ON ARSENICOCC?
 L65 858 SEA ABB=ON CORYNEFORM
 L66 15370 SEA ABB=ON CORYNEBACTER?
 L67 4998 SEA ABB=ON MICROCOCC?
 L68 863 SEA ABB=ON MICROMONOSPOR?
 L69 13 SEA ABB=ON MICROTHRIX
 L70 4286 SEA ABB=ON NOCARDI?
 L71 162 SEA ABB=ON PSEUDONOCARDI?
 L72 206 SEA ABB=ON STREPTOSPORANG?
 L73 48107 SEA ABB=ON BACILLUS OR BACILLALES
 L74 91 SEA ABB=ON ACIDAMINOCOCC?
 L75 257 SEA ABB=ON AEROCOCC?
 L76 12882 SEA ABB=ON CLOSTRIDI?
 L77 6291 SEA ABB=ON EUBACTERI?
 L78 5 SEA ABB=ON HALANAEROBI?
 L79 36 SEA ABB=ON LACHNOSPIR?
 L80 10838 SEA ABB=ON MYCOPLASMA?
 L81 1 SEA ABB=ON PARASPOROBACTER?
 L82 1333 SEA ABB=ON PEPTOSTREPTOCOCC?
 L83 28041 SEA ABB=ON STREPTOCOCC?
 L84 20639 SEA ABB=ON MYCOBACTER?
 L85 3506 SEA ABB=ON M TUBERCULOSIS
 L86 588 SEA ABB=ON L55
 L87 329 SEA ABB=ON L3
 L88 333 SEA ABB=ON FTSZ
 L*** DEL 223 S GRAM-POSITIVE BACTERIA/CT
 L*** DEL 5 S ACTINOBACTERIA+NT/CT
 L*** DEL 344 S ACTINOMYCETES/CT
 L*** DEL 21 S ACTINOMYCETALES+NT/CT
 L*** DEL 0 S ACTINOPLANETES+NT/CT
 L*** DEL 0 S ACTINOSYNNEMATACEAE+NT/CT
 L*** DEL 0 S ARSENICOCCUS+NT/CT
 L*** DEL 348 S CORYNEFORM BACTERIA+NT/CT

```

L*** DEL      21 S MICROCOCCACEAE+NT/CT
L*** DEL      5 S MICROMONOSPORACEAE+NT/CT
L*** DEL      0 S MICROTHRUX/CW
L89           1 SEA ABB=ON (L56 OR L57 OR L58) AND L86 AND (L87 OR L88 OR L59
                OR L60 OR L61 OR L62 OR L63 OR L64 OR L65 OR L66 OR L67 OR L68
                OR L69 OR L70 OR L71 OR L72 OR L73 OR L74 OR L75 OR L76 OR L77
                OR L78 OR L79 OR L80 OR L81 OR L82 OR L83 OR L84 OR L85)
L90           1 SEA ABB=ON (L56 OR L57 OR L58) AND L86
L91          43 SEA ABB=ON L86 AND (L87 OR L88 OR L59 OR L60 OR L61 OR L62 OR
                L63 OR L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70 OR L71 OR
                L72 OR L73 OR L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR L80 OR
                L81 OR L82 OR L83 OR L84 OR L85)
L92           1 SEA ABB=ON L86 AND L87
L93           1 SEA ABB=ON L86 AND L88
L94          21 SEA ABB=ON L86 AND L59
L95           0 SEA ABB=ON L86 AND L60
L96           3 SEA ABB=ON L86 AND L61
L97           0 SEA ABB=ON L86 AND L62
L98           0 SEA ABB=ON L86 AND L63
L99           0 SEA ABB=ON L86 AND L64
L100          0 SEA ABB=ON L86 AND L65
L101          3 SEA ABB=ON L86 AND L66
L102          3 SEA ABB=ON L86 AND L67
L103          0 SEA ABB=ON L86 AND L68
L104          0 SEA ABB=ON L86 AND L69
L105          5 SEA ABB=ON L86 AND L70
L106          1 SEA ABB=ON L86 AND L71
L107          0 SEA ABB=ON L86 AND L72
L108          12 SEA ABB=ON L86 AND L73
L109          1 SEA ABB=ON L86 AND L74
L110          1 SEA ABB=ON L86 AND L75
L111          4 SEA ABB=ON L86 AND L76
L112          1 SEA ABB=ON L86 AND L77
L113          0 SEA ABB=ON L86 AND L78
L114          0 SEA ABB=ON L86 AND L79
L115          10 SEA ABB=ON L86 AND L80
L116          0 SEA ABB=ON L86 AND L81
L117          1 SEA ABB=ON L86 AND L82
L118          20 SEA ABB=ON L86 AND L83
L119          8 SEA ABB=ON L86 AND L84
L120          2 SEA ABB=ON L86 AND L85
L121          14 SEA ABB=ON L86 AND (L87 OR L88 OR L60 OR L61 OR L62 OR L63 OR
                L64 OR L65 OR L66 OR L67 OR L68 OR L69 OR L70 OR L71 OR L72 OR
                L74 OR L75 OR L76 OR L77 OR L78 OR L79 OR L81 OR L82 OR L84 OR
                L85)
L122          20 SEA ABB=ON L86 AND ((L59 AND (L73 OR L80 OR L83)) OR (L73 AND
                (L80 OR L83)) OR (L80 AND L83))
L123          28 SEA ABB=ON (L121 OR L122)

```

FILE 'STNGUIDE' ENTERED AT 12:32:38 ON 02 SEP 2008

FILE 'IFIPAT' ENTERED AT 12:33:24 ON 02 SEP 2008

```

L124          311 SEA ABB=ON WHITE E?/AU
L125          551 SEA ABB=ON REYNOLDS R?/AU
L126           3 SEA ABB=ON SULING W?/AU
L127          3203 SEA ABB=ON GRAM(W) (POS OR POSITIVE)
L128           19 SEA ABB=ON ACTINOBACTER?
L129          670 SEA ABB=ON ACTINOMYCET?
L130           3 SEA ABB=ON ACTINOPLANET?
L131           0 SEA ABB=ON ACTINOSYNNEMAT?

```

L132 0 SEA ABB=ON ARSENICOCC?
 L133 512 SEA ABB=ON CORYNEFORM
 L134 1993 SEA ABB=ON CORYNEBACTER?
 L135 721 SEA ABB=ON MICROCOCC?
 L136 263 SEA ABB=ON MICROMONOSPOR?
 L137 1 SEA ABB=ON MICROTHRIX
 L138 851 SEA ABB=ON NOCARDI?
 L139 37 SEA ABB=ON PSEUDONOCARDI?
 L140 39 SEA ABB=ON STREPTOSPORANG?
 L141 9006 SEA ABB=ON BACILLUS OR BACILLALES
 L142 25 SEA ABB=ON ACIDAMINOCOCC?
 L143 44 SEA ABB=ON AEROCOCC?
 L144 2262 SEA ABB=ON CLOSTRIDI?
 L145 355 SEA ABB=ON EUBACTERI?
 L146 1 SEA ABB=ON HALANAEROBI?
 L147 8 SEA ABB=ON LACHNOSPIR?
 L148 1243 SEA ABB=ON MYCOPLASMA?
 L149 0 SEA ABB=ON PARASPOROBACTER?
 L150 181 SEA ABB=ON PEPTOSTREPTOCOCC?
 L151 4607 SEA ABB=ON STREPTOCOCC?
 L152 3329 SEA ABB=ON MYCOBACTER?
 L153 735 SEA ABB=ON M TUBERCULOSIS
 L154 4 SEA ABB=ON L3
 L155 39 SEA ABB=ON FTSZ
 L156 8 SEA ABB=ON L55
 L157 0 SEA ABB=ON (L124 OR L125 OR L126) AND L156
 L158 0 SEA ABB=ON L156 AND (L127 OR L128 OR L129 OR L130 OR L131 OR
 L132 OR L133 OR L134 OR L135 OR L136 OR L137 OR L138 OR L139
 OR L140 OR L141 OR L142 OR L143 OR L144 OR L145 OR L146 OR
 L147 OR L148 OR L149 OR L150 OR L151 OR L152 OR L153 OR L154
 OR L155)

FILE 'STNGUIDE' ENTERED AT 12:34:40 ON 02 SEP 2008

FILE 'SCISEARCH' ENTERED AT 12:35:16 ON 02 SEP 2008

L159 1859 SEA ABB=ON WHITE E7/AU
 L160 1787 SEA ABB=ON REYNOLDS R7/AU
 L161 49 SEA ABB=ON SULING W7/AU
 L162 21361 SEA ABB=ON GRAM(W) (POS OR POSITIVE)
 L163 906 SEA ABB=ON ACTINOBACTER?
 L164 8561 SEA ABB=ON ACTINOMYCET?
 L165 11 SEA ABB=ON ACTINOPLANET?
 L166 5 SEA ABB=ON ACTINOSYNNEMAT?
 L167 0 SEA ABB=ON ARSENICOCC?
 L168 914 SEA ABB=ON CORYNEFORM
 L169 7425 SEA ABB=ON CORYNEBACTER?
 L170 4650 SEA ABB=ON MICROCOCC?
 L171 588 SEA ABB=ON MICROMONOSPOR?
 L172 180 SEA ABB=ON MICROTHRIX
 L173 4304 SEA ABB=ON NOCARDI?
 L174 125 SEA ABB=ON PSEUDONOCARDI?
 L175 106 SEA ABB=ON STREPTOSPORANG?
 L176 63559 SEA ABB=ON BACILLUS OR BACILLALES
 L177 133 SEA ABB=ON ACIDAMINOCOCC?
 L178 243 SEA ABB=ON AEROCOCC?
 L179 23152 SEA ABB=ON CLOSTRIDI?
 L180 4964 SEA ABB=ON EUBACTERI?
 L181 13 SEA ABB=ON HALANAEROBI?
 L182 34 SEA ABB=ON LACHNOSPIR?
 L183 14224 SEA ABB=ON MYCOPLASMA?

```

L184      1 SEA ABB=ON  PARASPOROBACTER?
L185      1191 SEA ABB=ON  PEPTOSTREPTOCOCC?
L186      60675 SEA ABB=ON  STREPTOCOCC?
L187      46717 SEA ABB=ON  MYCOBACTER?
L188      6650 SEA ABB=ON  M TUBERCULOSIS
L189      0 SEA ABB=ON  1404-26-8
L190      1251 SEA ABB=ON  FTSZ

FILE 'STNGUIDE' ENTERED AT 12:35:52 ON 02 SEP 2008

FILE 'HCAPLUS' ENTERED AT 12:36:48 ON 02 SEP 2008
D QUE NOS L47

FILE 'USPATFULL' ENTERED AT 12:36:48 ON 02 SEP 2008
D QUE NOS L90

FILE 'IFIPAT' ENTERED AT 12:36:48 ON 02 SEP 2008
D QUE NOS L157

FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:36:49 ON 02 SEP 2008
L191      6 DUP REM L47 L90 (0 DUPLICATES REMOVED)
        ANSWERS '1-5' FROM FILE HCAPLUS
        ANSWER '6' FROM FILE USPATFULL
        D IBIB ABS HITIND HITSTR 1-6

FILE 'REGISTRY' ENTERED AT 12:37:38 ON 02 SEP 2008
D STAT QUE L7

FILE 'HCAPLUS' ENTERED AT 12:39:08 ON 02 SEP 2008
D QUE NOS L48
D QUE NOS L49
D QUE NOS L51
L192      7 SEA ABB=ON  (L48 OR L49 OR L51) NOT L47

FILE 'USPATFULL' ENTERED AT 12:39:09 ON 02 SEP 2008
D QUE NOS L121
D QUE NOS L122
L193      27 SEA ABB=ON  (L121 OR L122) NOT L90

FILE 'IFIPAT' ENTERED AT 12:39:11 ON 02 SEP 2008
D QUE NOS L158

FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:39:12 ON 02 SEP 2008
L194      33 DUP REM L192 L193 (1 DUPLICATE REMOVED)
        ANSWERS '1-7' FROM FILE HCAPLUS
        ANSWERS '8-33' FROM FILE USPATFULL
        D IBIB ABS HITIND HITSTR 1-7
        D IBIB ABS KWIC HITSTR 8-33
        D IBIB ABS KWIC HITSTR 33

FILE 'REGISTRY' ENTERED AT 12:41:26 ON 02 SEP 2008
D IDE L54 1-

FILE 'HCAPLUS' ENTERED AT 12:41:37 ON 02 SEP 2008
L195      3 SEA ABB=ON  L54
L196      1 SEA ABB=ON  L54 AND (L192 OR L47)

FILE 'HCAPLUS' ENTERED AT 12:42:15 ON 02 SEP 2008
D QUE NOS L196
D SCAN TI L196

```

L197

2 SEA ABB=ON L54 NOT L196
D IBIB ABS HITSTR 1-2
D STAT QUE L7

=>